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CHAPTER 1 
INTRODUCTION 
 
Organophosphorus Insecticides and Their Mechanism of Action 
According to the U.S. Environmental Protection Agency (USEPA), a pesticide is 
“any substance or a mixture of substances intended for preventing, destroying, repelling 
or mitigating any pest”. What makes these compounds uniquely different from other 
toxicants or contaminants is that they are intentionally released into the environment to 
elicit toxicity in certain pests. Pesticides include insecticides, herbicides, fumigants, 
fungicides, repellants, rodenticides and disinfectants. The total expenditure on pesticides 
in 2000 and 2001 exceeded $32.5 billion/year globally and $11 billion/year in the US, 
which accounted for 5 billion pounds of pesticides used worldwide and ~ 1.2 billion 
pounds used in the US annually, respectively (Kiely et al, 2005).  
Unfortunately, a lack of selectivity of pesticides leads to toxicity in non-target 
species. The American Association of Poison Control Centers received 2,155,952 cases 
of human poisoning in the US in 1996, of which, 86,912 cases, comprising 4% of the 
total poisoning cases, occurred as a result of exposure to pesticides (Litovitz et al, 1997). 
According to the World Health Organization, around 3 million people worldwide suffer 
from acute pesticide poisoning annually (Walker and Nidiry, 2002). These pesticide-
related poisonings can occur through occupational exposures, accidental exposure, or  
intentional exposure (i.e., suicide attempts).
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Organophosphorus (OP) insecticides are one of the major chemical classes of 
insecticides used in the world today. The first synthetic OP compound, 
tetraethylpyrophosphate (TEPP) was synthesized in 1854 by Philip de Clermount, but its 
insecticidal properties were not realized until much later (see review by Pope et al, 
2005a). In 1937, a group of German chemists led by Gerhard Schrader at Farbenfabriken 
Bayer AG synthesized the first organophosphorus insecticides. Unfortunately, during this 
World War II era, nerve agents such as tabun, soman and sarin were also synthesized as 
potential chemical warfare agents. The OP insecticides in use today are the fourth 
generation derivatives of these compounds. The first commercially used OP insecticide 
was TEPP (used in the 1930’s). Although effective, TEPP had high non-target species 
toxicity and was chemically unstable in the presence of moisture. This led to the 
development of the prototype OP insecticide parathion (PS) in 1944 and its highly potent 
oxygen analog, paraoxon at a later date. Although both these chemicals possessed 
properties that were considered desirable in an insecticide, such as low volatility, 
environmental persistence and chemical stability in the presence of sunlight and water, 
they showed evidence of marked mammalian toxicity, with a lack of target species 
selectivity. The organochlorine (OC) pesticides of the 1950’s were largely replaced with 
OPs, which was associated with a large number of poisonings of pesticide applicators due 
to the lack of selectivity of the highly toxic OPs compared to the relatively non-toxic and 
more familiar OCs. This led to the search for analogs that had greater selectivity for 
target species and were less toxic to non-target species. Chlorpyrifos (CPF) is one of the 
most extensively used and studied OP insecticides due to the fact that it has relatively low 
mammalian toxicity (Ecobichon, 2001).   
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OP insecticides are among the most commonly used insecticides in the US and 
throughout the rest of the world. OP insecticide use in the US in 2001 totaled 
approximately 73 million pounds and represented 70% of the total insecticides used 
(Kiely et al, 2005). OPs have been used in both human and veterinary medicine, in 
agriculture as well as in industry (Ehrich, 1998). Currently, there exist 38 OP 
anticholinesterases under 10 different chemical classifications that are registered and 
approved for use by the USEPA (Pope, 1999). OP compounds are generally lipophilic 
and can be readily absorbed through the gastrointestinal tract, skin and respiratory tract 
(Atkinson, 1976; Kecik et al, 1993, Fuortes, 2000; Peter and Cherian, 2000). Due to the 
lipophilic nature of these compounds, bioaccumulation occurs in fatty tissues (Kecik et 
al, 1993).  
OP insecticides elicit toxicity by disrupting normal cholinergic neurotransmission, 
which has been diagrammatically represented in Figure 1. Acetylcholine (ACh) is the 
primary neurotransmitter present in the central and peripheral nervous systems of 
cholinergic neurons. Acetylcholine is synthesized in the presynaptic nerve terminal by the 
action of choline acetyltransferase (ChAT; E.C. 2.3.1.6) by utilizing choline and acetyl 
coenzyme A (CoA) as substrates (Lefkowitz et al, 1996).  A vesicular acetylcholine 
transporter (VAChT) transports the newly synthesized ACh into secretory vesicles. 
Action potential-induced depolarization of the pre-synaptic nerve terminal results in the 
release of ACh by exocytosis into the synapse from central nervous system (CNS) 
neurons, all preganglionic autonomic and postganglionic parasympathetic neurons, 
somatic motor neurons and a few postganglionic sympathetic neurons (Moffett et al, 
1993; Nicoll 1995; Lefkowitz et al 1996). Acetylcholine then interacts with the 
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postsynaptic receptors and thereby influences the postsynaptic cell’s function. The ACh 
that is released into the synapse is degraded almost immediately, thereby terminating 
receptor activation, by means of the enzyme acetylcholinesterase (AChE, E.C. 3.1.1.7). 
AChE is one of the most active and efficient of enzymes and is capable of hydrolyzing up 
to 105molecules of ACh per second/enzyme molecule (Hoskins and Ho, 1992; Sultatos 
1994). Acetylcholinesterase hydrolytically cleaves the ester bond of acetylcholine, 
forming choline and acetic acid. The choline that is released is then once again taken 
back into the presynpatic nerve terminal via a high-affinity choline uptake process 
(Happe and Murrin, 1993).  
Cholinergic neurotransmission plays an important role in the normal functioning 
of the heart. Heart rate, contractile force and conduction are controlled by the intrinsic 
cardiac nervous system (Batulevicius et al, 2004). The intrinsic cardiac ganglia, 
comprised of parasympathetic efferent postganglionic neurons, local circuit neurons and 
afferent neurons, are under the control of cholinergic neurotransmission (Darvesh et al, 
1998). Acetylcholine (ACh) activates K+ channels via G-protein-coupled muscarinic 
receptors, culminating in decreased heart rate. Acetylcholine also produces a decrease in 
the pacemaker current in the cells of the sinoatrial node via muscarinic M2 receptor 
activation. The net result of ACh acting directly on the heart is therefore inhibitory 
(Sauviat, 1999). As in other synapses, hydrolysis of ACh is mediated by 
acetylcholinesterase. 
OP insecticides alter cholinergic neurotransmission by inhibiting acetylcholinesterase. 
OPs phosphylate the hydroxyl moiety of a serine residue at the active site of the enzyme, 
thus inactivating its catalytic activity. Interaction between an OP compound and the 
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active site of the AChE enzyme leads to the formation of a transient intermediate 
complex that partially hydrolyzes, resulting in the loss of the “leaving group” and the 
formation of a stable, phosphylated enzyme that (under normal circumstances) is 
reactivated at a very slow rate. Due to the slow rate of spontaneous reactivation, de novo 
synthesis of new enzyme molecules may be required for catalytic recovery, a process that 
can take up to 20-30 days to complete with some OP pesticides. Thus, it is typically 
stated that AChE is “irreversibly” inhibited by OP insecticides. More accurately, the 
phosphylated enzyme can be reactivated, although at a very slow rate (Ecobichon, 2001). 
However, if “aging” of AChE occurs, spontaneous reactivation cannot occur and true 
irreversible inhibition of that enzyme molecule is the result. During the “aging” process, 
dealkylation of the intermediate dialkylphosphylated enzyme occurs by nonenzymatic 
cleavage of one alkyl side-chain of the OP molecule. Recovery of enzyme activity in this 
case relies on synthesis of new enzyme molecules (Sultatos, 1994; Ecobichon, 2001).  
Due to extensive inhibition of AChE by OP insecticides, acetylcholine 
accumulates in the synapse and causes overstimulation of muscarinic and nicotinic 
cholinergic receptors in the central and peripheral nervous systems (Silver, 1974; 
Sultatos, 1994; Pope, 1999). Signs of the ensuing cholinergic toxicity can include 
excessive secretions such as salivation, lacrimation, urination and defecation (SLUD, 
signs of autonomic dysfunction), involuntary movements (e.g., muscle fasciculations, 
tremors, and seizures), bradycardia, miosis, nausea, vomiting, restlessness, ataxia, loss of 
memory, generalized weakness, slurred speech, hypothermia, loss of body weight and 
respiratory dysfunction. Death from OP-induced cholinergic toxicity generally occurs as 
a result of depressed respiratory control centers in the brain, paralysis of the diaphragm  
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Figure 1: A general description of the primary components of and events occurring at the 
cholinergic synapse 
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 and excessive airway secretions (Ecobichon, 2001; Saunders and Harper, 1994; Gupta 
1998; Gordon et al, 1997; Pope et al, 1991; Pope 1999). 
In addition, electrocardiographical (ECG) abnormalities have been found to occur 
in humans with severe OP intoxication, the most common of which are prolongation of 
the Q-Tc interval and ST/T changes (elevated ST segment and inverted T waves) (Karki 
et al, 2004). Another common ECG abnormality that has been found to occur in OP 
poisoning is the torsade de pointes type of polymorphic ventricular tachycardia, which 
has been attributed to the prolonged Q-Tc interval (Saadeh et al, 1997; Ludomirsky et al, 
1982). Although the exact mechanism of cardiotoxicity is still unkown, there have been 
some proposed mechanisms. Peter and Cherian (2000) suggested that OP-induced 
cardiotoxicity may be due to a 1) direct toxic effect on the myocardium, 2) overactivity of 
muscarinic or nicotinic receptors leading to haemodynamic alterations, and 3) 
complications that might arise as a result of high dose atropine therapy. Abraham et al 
(2001) implicated several factors in OP-induced cardiotoxicity, including catecholamine 
overflow, neurogenic effects and direct myocardial damage. Saadeh et al (1997) 
suggested possible mechanisms of cadiotoxicity included sympathetic and 
parasympathetic over-activity, hypoxemia, acidosis, electrolyte imbalance and a direct 
toxic effect of the OP compounds on the myocardium. 
Three primary types of OP insecticides compounds exist, namely, phosphates 
(absence of a sulfur atom), phosphorothioates (containing one sulfur atom) and 
phosphorodithioates (containing 2 sulfur atoms) (WHO, 1986). All OP insecticides that 
are currently in use have four atoms directly attached to the phosphorus atom by three 
single bonds and one double (or coordinate covalent) bond (Chambers, 1992). 
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Chlorpyrifos (CPF) and Parathion (PS), whose structures are depicted in Figures 2 and 3 
respectively, are phosphorothioates. Both CPF and PS are referred to as parent 
compounds in that they both require bioactivation by cytochrome P450 enyzmes to their 
active metabolites, paraoxon (PO) and chlorpyrifos oxon (CPO), respectively. The 
activation step, referred to as oxidative desulfuration, involves enzymatic replacement of 
the double-bonded sulfur by oxygen. The active metabolites (oxons) are about 1,000 
times more potent inhibitors of acetylcholinesterase compared to the parent insecticides 
(Holmstedt, 1963). The structures of CPO and PO are shown in Figures 2 and 3, 
respectively.  
CPF is a broad spectrum OP insecticide which is moderately toxic (oral LD50 ~ 
82-155 mg/kg in rats) (Gaines, 1969), and is widely used, in spite of recent restrictions on 
its use. It is the second most commonly used insecticide in the US (behind malathion), 
with 11-16 million pounds of the active ingredient being used annually in 2001, the latest 
year of use data available (Kiely et al, 2005). Parathion (PS) is a prototype OP that is 
highly toxic (oral LD50 13 mg/kg in rats). Although not used in the US, it is commonly 
used in numerous other countries throughout the world. Most OPs in use today are potent 
inhibitors of AChE and thus can elicit classic signs of cholinergic toxicity as listed above.  
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Chlorpyrifos 
 
Chlorpyrifos oxon 
 
Figure 2: Chemical structures of chlorpyrifos (CPF, O,O’-diethyl-O-(3,5,6-trichloro-2-
pyridyl) phosphorothioate) and chlorpyrifos oxon (CPO, O,O’-diethyl-O-(3,5,6-trichloro-
2-pyridyl) phosphate). 
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Parathion 
 
 
Paraoxon 
 
 
Figure 3: Chemical structures of parathion (PS, O,O’-diethyl-(4-nitrophenyl) 
phosphorothioate)and paraoxon (PO, O,O’-diethyl-(4-nitrophenyl) phosphate) 
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Acetylcholinesterase and Butyrylcholinesterase 
Aldridge and Reiner (1972) operationally classified all esterases into three subsets 
based on their interaction with OP compounds, namely A-esterases, B-esterases and C-
esterases. A-esterases (AE) such as paraoxonase (E.C. 3.1.1.2) can catalyze the 
hydrolysis and detoxification of OPs without being inhibited themselves and are rapidly 
reactivated (Furlong et al 1989; Pond et al, 1996). B-esterases, which include 
acetylcholinesterase (AChE, E.C. 3.1.1.7), butyrylcholinesterase (BChE, E.C. 3.1.1.8) 
and carboxylesterase (CarbE, E.C. 3.1.1.1) stoichiometrically and covalently bind to OPs 
and in the process, become inhibited due to their very slow dephosphylation (Chambers 
et al, 1990). C-esterases (e.g., acetylesterase) do not interact with OP compounds.  
There are two types of cholinesterases in vertebrates, i.e., acetylcholinesterase 
(AChE, acetylcholine acetyl-hydrolase) and butyrylcholinesterase (BChE, acylcholine 
acyl-hydrolase) (Patocka et al, 2004; Dave and Katyare, 2002). These enzymes are 
protein products of two distinct genes (on human chromosomes 7 and 3, respectively). 
The AChE gene is G-C rich, while the BChE gene is A-T rich (Schwarz et al, 1995). 
AChE can exist in multiple forms. The membrane bound is thought to play a prominent 
role in cholinergic synapses throughout the nervous system in regulating cholinergic 
neurotransmission. Soluble forms, as well as monomeric vs. tetrameric, globular and 
assymetric forms of AChE are found in different sites and thought to play different roles.  
AChE, also referred to as “true” cholinesterase, is the main enzyme involved in 
the hydrolysis of the neurotransmitter acetylcholine, and its critical role in cholinergic 
neurotransmission is well understood. In addition to the critical role it plays in 
cholinergic neurotransmission, AChE appears to participate in non-classical functions, 
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which include synaptic development and maintenance, and neurodevelopment via neurite 
outgrowth (Silman and Sussman 2005).  
On the other hand, BChE, also referred to as “pseudo” cholinesterase based on its 
ability to hydrolyze several choline esters, has long been thought to be a vestigial enzyme 
with no known physiological function (Silver, 1974). Since the synthetic substrate of 
BChE, i.e., butyrylcholine (BCh), is not found in living systems, the function of BChE 
has been difficult to determine. For a long time, BChE was of great interest in the field of 
anaesthesiology, wherein its metabolism of the muscle relaxant succinylcholine ensured 
that people receiving this drug did not experience prolonged, life-threatening apnoea 
(Darvesh et al, 2003). This enzyme also gained interest as a scavenger of anti-
cholinesterases such as organophosphates and carbamates. A physiological role for 
BChE, if any, has not been determined. In a 2003 review, Darvesh et al ascribed several 
functions to BChE, including co-regulation of cholinergic neurotransmission, 
neurodevelopment, metabolism of drugs such as heroin, cocaine and succinylcholine, and 
scavenging for natural and synthetic anti-cholinesterases. Additionally, Patocka et al 
(2004) suggested that BChE may also play a role in lipoprotein metabolism, myelin 
maintenance and in the processing of the amyloid precursor protein, thought to play an 
important role in the formation of senile placques. Along with AChE, BChE is found in 
the neurofibrillary plaques and tangles of the Alzheimer’s brain.  
AChE and BChE exhibit 51-54% amino acid identity. In both AChE and BChE, 
the catalytic triad is comprised of serine, histidine and glutamate and is found at the 
bottom of a 20 Å gorge. This gorge is lined by 6 aromatic amino acids in the case of 
BChE, and 14 aromatic amino acids in AChE.  AChE also contains a peripheral anionic 
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binding site which is distinct from its catalytic site. Interaction with this peripheral site 
may influence both substrate and inhibitor binding to the active site. This peripheral 
anionic binding site is absent in BChE. The active site gorge also contains an acyl pocket 
that holds the acyl group of choline esters in place during catalysis. This acyl pocket is 
larger in BChE than in AChE, thus explaining the larger (synthetic) substrates that can be 
hydrolyzed by BChE compared to AChE (Darvesh et al, 2003; Jbilo et al, 1994a; Harel et 
al, 1992).  
While AChE is capable of hydrolyzing only ACh, BChE can hydrolyze both ACh 
(albeit less efficiently than AChE) as well as its own synthetic substrate butyrylcholine (4 
times more rapidly than ACh) (Patocka et al, 2004). Another point of distinction between 
the two enzymes is that AChE displays substrate inhibition, whereas BChE displays 
substrate activation at high concentrations of ACh. As noted before, these differences 
may be based on the presence or absence of the peripheral binding site in the two 
enzymes (Jbilo et al, 1994a). The cumulative evidence suggests that AChE is the primary 
enzyme responsible for hydrolysis of the neurotransmitter ACh, while BChE plays a 
supportive role at high ACh concentrations. ACh levels have been predicted to reach high 
micromolar levels in the vicinity of the synaptic cleft, and the close proximity of glial 
BChE with normal synaptic AChE (which may be inhibited by substrate at high 
concentrations) may facilitate hydrolysis of ACh (Giacobini, 2001). The contribution of  
BChE to cholinergic neurotransmission remains unclear, however.  
 AChE and BChE exist in two molecular forms, namely globular (G1, G2 and G4) 
and asymmetric. The globular forms G1 (monomeric), G2 (dimeric) and G4 (tetrameric), 
are comprised of 1, 2 and 4 catalytic subunits respectively, held together by 
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intermolecular disulfide bonds, and are symmetrical, hydrophilic and soluble. Globular 
forms of AChE and BChE can also exist in asymmetric, amphiphilic membrane-bound 
forms. G2 and G4 globular dimers and tetramers are anchored to the cell membrane by a 
protein anchor known as the proline-rich membrane anchor (PRiMA). Another 
asymmetric collagen-tailed form of AChE and BChE consists of tetramers of catalytic 
subunits that are attached to membranes by a triple helical, non-catalytic collagen anchor 
called collagen Q. One such tetramer is called the A4 form, two such tetramers make up 
the A8 form and three such tetramers comprise the A12 form (Chatonnet and Lockridge, 
1989; Darvesh et al, 2003). Approximately 95% of the cholinesterase activity in human 
plasma is made up of the soluble G4 tetramer of BChE. G1 and G2 forms of BChE in the 
plasma are believed to be degradation products of the G4 form. AChE has also been 
found to exist as a G4 water soluble form in adrenal gland secretions. The asymmetric, 
immobilized A12 collagen-tailed forms of AChE and BChE are localized in synapses and 
motor end plates of skeletal muscles in birds and mammals. Membrane-bound 
amphiphilic globular G2 forms of AChE are found in the plasma membrane of 
erythrocytes. Mammalian brain contains the G4 amphiphilic membrane-bound globular 
forms of AChE and BChE. The heart of some species contains G2 and G4 membrane-
bound amphiphilic globular forms of BChE (Chatonnet and Lockridge, 1989). In adult 
rats, globular G1 and G4 and asymmetric A12 were the major isoforms of AChE in the 
heart, with small amounts of G2 and A8. A certain percentage of the globular isoforms of 
AChE were found to be membrane-bound (Nyquist-Battie et al, 1987).  
The distribution of AChE and BChE is tissue-dependent. AChE and BChE are 
typically both found in blood. In most species, BChE is the predominant cholinesterase in 
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the plasma, while erythrocyte membranes exclusively contain AChE. The liver and heart 
generally contain a high concentration of BChE, while the brain and sketelal muscles 
predominantly express AChE (Jbilo et al, 1994a). The adult rat brain contains ~80% 
AChE and 20% BChE, whereas in humans, ~95% of the total ChE in the brain is AChE, 
with only 5% BChE. AChE in the brain is predominantly located in neurons and axons, 
while BChE is of primarily glial origin, but can be associated with neurons in specific 
nuclei (Ballard et al, 2005; Giacobini, 2004).  
The total ChE of adult hearts of higher vertebrates is made up of around 85% 
BChE and around 15% AChE (Chatonnet and Lockridge, 1989). Although present in 
small amounts, AChE is concentrated in the conducting system of the heart (sinus node, 
atrio-ventricular node and the ventricular conduction tissues), while BChE is 
concentrated in the contractile portions of the atria and ventricles (Chow et al, 2001). The 
relative proportions of AChE and BChE have been found to vary in the heart during post-
natal development. Slavikova and Tucek found that the amount of AChE relative to the 
total ChE in rat heart atrium increased from 6% on postnatal day 1 to 12-15 % in the 
adult (Slavikova and Tucek, 1986). Additionally, it has been observed that in the human 
heart the conducting system predominantly contains BChE in the infant, but mainly 
AChE in the adult (Chow et al, 2001).  
Previous studies suggest discreet association of these two different cholinesterases 
with separate populations of intrinsic cardiac neurons, and their possible selective 
involvement in neurotransmission in the intrinsic cardiac ganglia (Darvesh et al, 1998). In 
the canine right atrial neurons, 4 neuronal populations were present: those containing 
only 1) AChE, 2) only BChE, 3) both AChE and BChE and 4) those containing neither 
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enzyme. The local application of acetylcholine was found to increase the activity of 
intrinsic cardiac neurons, with an even greater increase being observed by local 
application of the non-physiological substrate butyrylcholine. These two substrates were 
found to preferentially affect different populations of intrinsic cardiac neurons, which 
agreed with enzyme kinetic studies showing that canine AChE preferentially hydrolyzed 
ACh, while canine BChE preferentially hydrolyzed BCh. Using AChE-specific and 
BChE-specific inhibitors, and cholinesterase inhibitors inhibiting both enzymes, it was 
found that the activity of neurons in the intrinsic cardiac ganglia were only affected when 
both cholinesterases were inhibited, leading to the conclusion that AChE and BChE 
containing intrinsic cardiac neurons act synergistically to influence the overall tonic 
activity of the intrinsic cardiac ganglia. In a subsequent study using porcine intrinsic 
cardiac neurons which contained AChE and/or BChE, acetylcholine and butyrylcholine 
increased or decreased spontaneous activity of the intrinsic cardiac neurons. Moreover, 
various cholinesterase inhibitors which were used in the study were also found to change 
spontaneous neuronal activity. It was concluded from these studies that inhibition of 
AChE and BChE by cholinesterase inhibitors indirectly affects the porcine intrinsic 
cardiac nervous system (Darvesh et al, 2004). 
Commonly used specific inhibitors of AChE are 1,5-bis 
[allyldimethylammoniumphenyl] pentane-3-dibromide (BW284C51) and Huperzine A, 
while specific inhibitors of BChE include tetraisopropylpyrophosphoramide (iso-OMPA), 
bambuterol and ethopropazine. Iso-OMPA (see Figure 4) is an organophosphorus 
compound that has mainly been used for experimental purposes due to its highly selective 
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inhibition of BChE relative to AChE (Girard et al, 2005; Minic et al, 2003). Iso-OMPA is 
a direct-acting esterase inhibitor, i.e., it does not require metabolic activation.  
Recent studies have evaluated the role of BChE in cholinergic neurotransmission 
in vivo. Studies on the physiological role of BChE have been stimulated by the 
cholinergic hypothesis of Alzheimer’s disease (AD), wherein deficits in learning, 
memory and behavior are believed to be caused in part by decreased levels of 
acetylcholine in selected brain areas. Researchers have suggested that AChE inhibitors 
may be used to intensify the effects of the remaining ACh, thus diminishing the effects of 
cholinergic deficiency, since this was the only enzyme believed to be responsible for the 
hydrolysis of ACh. More recently, however, it was found that BChE did, in fact, play a 
role in the hydrolysis of ACh. Perfusion of a selective BChE inhibitor into the rat brain 
was found to increase extracellular ACh by around 15-fold (Giacobini, 2004). As an 
additional complicating factor, BChE levels in the brain were found to increase in AD 
(for review, see Ballard et al, 2005). These findings increased research into 
butyrylcholinesterase and its possible role in normal physiological as well as 
pathophysiological functions.   
One approach to evaluate the role of BChE was through generation of an AChE-
knockout (-/-, -/+) mouse model. AChE-knockout (-/-) mice expressing normal levels of 
BChE were found to live into adulthood, even though they had weak muscles, could not 
eat solid food and died early from seizures. Three mechanisms were indentified that 
ensured the survival of AChE-knockouts, including 1) a reduction in muscarinic and 
nicotinic receptors, 2) morphological remodeling of the endplate and 3) enhanced 
hydrolysis of ACh by BChE (Li et al, 2003; Adler et al, 2004). AChE (-/-) mice 
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demonstrated a heightened sensitivity to BChE-specific inhibitors such as iso-OMPA and 
bambuterol, suggesting that it was the BChE activity in the knockout mice that facilitated 
their survival, and that a role of BChE (in this model) was to compensate for the function 
of AChE (i.e., hydrolysis of ACh) (Xie et al, 2000; Li et al, 2000). BChE is present in all 
parts of the brain receiving cholinergic signaling in wild types and knockouts. Moreover, 
it was suggested that BChE plays a constitutive rather than a back-up role in the 
hydrolysis of acetylcholine in the normal brain (Mesulam et al, 2002a). Further support 
for this came from the fact that in the absence of AChE, BChE controls the levels of 
extracellular ACh as evidenced by increased hippocampal ACh levels in AChE-knock-
out mice and their regulation by BChE (Hartmann et al, 2007a).   
Measurements of contractility on phrenic nerve-hemidiaphragm preparations from 
AChE (-/-) mice further support the conclusion that BChE functions to hydrolyze 
acetylcholine in these mice (Adler et al, 2004). In a separate study of nerve-evoked 
quantal transmitter release from the hemidiaphragm muscle of the AChE-knockout (-/-) 
mouse, however, it was reported that BChE was not involved in hydrolysis of ACh in the 
AChE-knockout (-/-) mice, since BChE inhibitors did not affect the time course of 
synaptic potentials (Minic et al, 2003). These inhibitors did however, decrease evoked-
quantal transmitter release, suggesting that BChE might be involved in a presynaptic 
modulation of synaptic transmission at mature neuromuscular junctions (Minic et al, 
2003). These investigators hypothesized that BChE inhibition led to diminished rather 
than elevated acetylcholine in the neuromuscular junction (Girard et al, 2005; Girard et 
al, 2007), and measurements of respiratory activity in AChE (-/-) mice agreed with this 
hypothesis (Chatonnet et al, 2003).  
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Recently, BChE homozygous (-/-) and heterozygous (-/+) knockout mice have 
been developed (Li et al, 2006a). BChE (-/-, -/+) knockout, AChE (-/-) knockout and wild 
type mice were treated with AChE-specific inihibitors Huperzine A and donepezil, as 
well as with the OP inhibitors, ecothiophate and chlorpyrifos oxon. After treatment with 
Huperzine A and donepezil, BChE homozygous knockout mice exhibited severe signs of 
toxicity and subsequently died. The BChE heterozygous knockouts exhibited 
intermediate signs of toxicity and survived for a longer time, while the wild type mice 
showed very minor signs of toxicity and recovered after 24 hours. Plasma AChE activity 
was inhibited to the same extent in all 3 groups, whereas plasma BChE activity was 
unaffected. In contrast, AChE (-/-) mice were unaffected by huperzine A and donepezil, 
thereby confirming their specificity for this enzyme. Together, these results suggested 
that the protective effect of BChE in AChE knockouts was not due to inhibitor 
scavenging but transmitter catalysis. When AChE (-/-) mice were treated with 
chlorpryifos oxon, they lost all BChE activity, developed severe signs of cholinergic 
toxicity and died of convulsions, thus demonstrating once again that BChE activity was 
essential for the survival of the AChE (-/-) mouse. From this study, Duysen et al (2007) 
concluded that BChE exerted its protective effect by hydrolyzing excess ACh in 
physiologically relevant regions such as the diaphragm, cardiac muscle and the brain, and 
that BChE functions in cholinergic neurotransmission.  
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Figure 4: Chemical structure of iso-OMPA (tetraisopropylpyrophosphoramide) 
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Muscarinic Cholinergic Receptors 
There are two major subtypes of cholinergic receptors, i.e., nicotinic receptors 
(nAChR) and muscarinic receptors (mAChR). Our studies focused on muscarinic 
receptors. Muscarinic receptors, which are located in both the central and peripheral 
cholinergic nervous systems, mediate the effects of acetylcholine in both locations. Four 
muscarinic receptor subtypes (M1, M2, M3 and M4) have been pharmacologically 
identified (Brown and Taylor, 1996), whereas, using molecular biological techniques, 
five subtypes, designated as M1, M2, M3, M4 and M5 have been identified (Alberts et al, 
1994). These five muscarinic receptors are encoded by 5 distinct genes (Caulfield and 
Birdsall, 1998; Hamilton et al 1998; Eglen et al, 1994). Subtype-specific muscarinic 
receptor antagonists include pirenzipine (M1 receptor selective; Caulfield, 1993; Eglen et 
al, 1994), methoctramine or AF-DX 116 (M2 receptor selective; Eglen et al, 1994), 4-
diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; M3 receptor selective; 
Lazareno et al, 1990; Eglen et al, 1994) and himbacine (M4 receptor selective; Caulfield 
and Brown, 1991; Eglen et al, 1994). Until now, there are no reports on M5-selective 
antagonists or agonists.  
Muscarinic receptors are glycoproteins and belong to the largest superfamily of 
cell-surface receptors, the G protein-coupled receptors. Muscarinic receptors contain 7 
hydrophobic segments that span the phospholipid bilayer and are connected by 3 
extracellular and 3 intracellular loops (Alberts et al, 1994). G proteins, which are located 
on the cytoplasmic face of the plasma membrane, mediate the interaction between the 
receptor and second messenger systems or ion channels. G proteins are so named due to 
their interaction with guanine nucleotides, and are heterotrimeric molecules consisting of 
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α, β and γ subunits (Alberts et al, 1994; Brody, 1994). G proteins, which exist in multiple 
forms, are classified according to their α subunits. There are various subtypes of the α 
subunit (Gα), including Gαs, Gαi, Gαq/11 and Gα12, and these are coupled to various second 
messenger systems (Bourne and Roberts, 1995; Nestler and Duman, 1999). Gαs is 
typically coupled to the stimulation of adenylyl cyclase, Gαi to the inhibition of adenylyl 
cylclase, Gαq to the activation of phospholipase C, and Gα12 to ion channels (Brody, 
1994). The G protein heterotrimer has guanosine 5’-diphosphate (GDP) bound to the Gα 
subunit in the inactive state, i.e., in the absence of a receptor agonist. When an agonsist 
binds to the receptor, guanosine 5’-triphosphate (GTP) displaces GDP from the Gα 
subunit, leading to dissociation of the trimer into Gα and Gβγ subunits. Depending on the 
subtype of the released Gα subunit, selective signaling effects are produced. Once the 
agonist dissociates from the receptor, second messenger signaling mechanism is 
terminated. The activity of the Gα subunit is terminated by its intrinsic GTPase activity, 
which hydrolyses the GTP to GDP, consequently allowing the Gα subunit to re-combine 
with the Gβγ subunits, leading to the re-formation of the heterotrimeric complex (Alberts 
et al, 1994). More recently, cellular signaling roles for the Gβγ subunits Gβγ subunits have 
been identified.  
Stimulation or inhibition of the membrane-bound adenylyl cyclase modulates the 
formation of the second messenger cyclic AMP (cAMP). Cyclic AMP-dependent protein 
kinases (PKA) which are activated by cAMP, and in turn phosphorylate regulatory 
proteins leading to a cascade of downstream signaling events. The effect of cAMP is 
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terminated by the action of phosphodiesterase, which hydrolyzes it to adenosine 5’-
monophosphate. Inhibition of adenylyl cyclase by activation of M2 or M4 receptors 
(coupled to Gαi/o) leads to a decreased production of cAMP and decreased activity of 
PKA, thus altering numerous cellular processes. In some cases, the Gβγ subunit activates 
the inwardly rectifying potassium channel, influencing membrane polarity. Muscarinic 
receptors can be located both presynaptically and postsynaptically. Stimulation of 
presynaptic M2 and M4 muscarinic receptors leads to a decrease in neurotransmitter 
release, thus functioning as autoreceptors (Wessler, 1992; O’Neill and Doukas, 1994). 
Activation of M1, M3 and M5 receptors typically leads to stimulation of phospholipase C 
via Gαq/11. Phospholipase C hydrolyzes phosphotidylinositol bis-phosphate (PIP2) to 
inositol triphosphate (IP3) and diacylglycerol (DAG). DAG activates protein kinase C 
(PKC), while IP3 releases Ca2+ from the endoplasmic reticulum, which in turn activates 
calmodulin. Protein kinase C and calmodulin lead to a series of downstream cellular 
events (Alberts et al, 1994). Through these two basic second messenger pathways, i.e., 
cAMP and IP3/DAG, the muscarinic receptors regulate a diverse range of physiological 
functions.  
Under physiological ionic conditions, muscarinic agonist binding is 
heterogeneous, while antagonist binding is homogeneous (Berrie et al, 1979; Vickroy et 
al, 1984). Cardiac and brain muscarinic receptors exist in multiple agonist binding 
affinity states: super high, high and low (Galper and Smith, 1978; Watson et al, 1986). 
Guanine nucleotides are capable of modulating agonist binding to muscarinic receptors. It 
has been reported that divalent cations such as magnesium are capable of increasing the 
potency of guanine nucleotides, as well as increasing agonist binding in the absence of 
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guanine nucleotides (Wei and Sulakhe, 1980; Sulakhe et al, 1990). The most common 
muscarinic antagonist and agonist used in radioligand binding studies are 
[3H]quinuclidinyl benzilate (QNB) and [3H]oxotremorine methiodide (OXO), 
respectively.  
  In the presence of continuous and excessive stimulation of muscarinic receptors 
by an agonist (acetylcholine), the tissue develops tolerance via modulation of receptor 
density. Reduction in receptor numbers (down-regulation) is a prominent adaptation to 
prolonged agonist exposure. Regulation of G protein-coupled receptors including 
muscarinic receptors involves three steps: desensitization, internalization and down-
regulation. Agonist-bound muscarinic receptors are rapidly phosphorylated by G protein 
coupled receptor kinases: this is the first committed step in receptor desensitization 
(Schlador and Nathanson, 1997; Hamilton et al, 1998). Beta arrestin, a cytoplasmic 
protein, binds to the phosphorylated receptor thus preventing further receptor-G protein 
interaction (Haddad and Rousell, 1998; Lee et al, 2000). These β-arrestins in some 
manner direct phosphorylated receptors to clatharin-coated pits or caveolae, and the 
receptors are subsequently internalized by endocytosis. The internalized receptors can 
return to the surface of the cell membrane after dephosphorylation by receptor 
phosphatases or can be degraded in lysosomes to mediate down-regulation (Logsdon, 
1999). 
While the M1, M2 and M3 subytpes of muscarinic receptors are found in the heart 
of several species including humans, the most predominant is the M2 receptor subtype 
(Dhein et al, 2001; Wang et al, 1999; Sharma et al, 1996). Nishimaru and colleagues 
(2000) suggested that the presence of M2 and M3 receptors in the mouse atrium led to a 
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biphasic response with increasing concentrations of acetylcholine, i.e., a transient 
negative inotropic response (mediated by M2 receptors) followed by a positive inotropic 
response (mediated by M3 receptors), both of which were blocked by atropine. 
Obserhauser et al (2001) demonstrated that in human right atrial appendages, presynaptic 
muscarinic autoreceptors are of the M2 subtype. Other investigators showed that in 
several other species including chicken, rat, rabbit and guinea-pig, the cardiac presynaptic 
muscarinic autoreceptor belonged to either the M1 or M2 subtype (Jeck et al 1988; Bognar 
et al, 1990; Habermeier-Muth et al, 1990). Muscarinic receptors are present in higher 
concentrations in the atria as compared to the ventricles in several species, including rat, 
rabbit, frog and man (Hartzell, 1980; Hancock et al, 1987; Deighton et al, 1990), whereas 
similar densities of muscarinic receptors were found in the two regions in guinea-pig and 
dog (Wei and Sulakhe, 1978). Roskoski Jr. et al (1985) observed regional differences in 
down-regulation in the rat heart, wherein, agonist-induced down-regulation only occurred 
in the right atria, left atria and left ventricle, but not in the right ventricle. 
In the brain, all five subtypes of muscarinic receptors have been found in the 
cortex, hippocampus, thalamus, hypothalamus, striatum, pons and cerebellum. In these 
regions, muscarinic receptors play an important role in such processes as learning and 
memory, body temperature, emotions and involuntary processes such as respiration and 
metabolism (Caulfield, 1993; Stillman et al, 1996). A greater distribution and 
concentration of muscarinic receptor subtypes is present in the brain regions compared to 
peripheral regions such as glands, heart, lung and vasculature (Caulfield, 1993). Tice et al 
(1996), using subtype specific antibodies showed that all five muscarinic receptor 
subtypes were found in all the brain regions examined in the adult rat, but the percentage 
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making up the total was different among regions. The most abundant subtype was m4 in 
the cortex (m4>m1~m2>m3>m5), m2 in the cerebellum (m2>m3>m4=m1=m5), m1 in 
the hippocampus (m1>m4>m2>m3>m5) and m4 in the striatum (m4>m1>m2>m3>m5).  
 
 
Additional Macro-molecular Targets of Organophosphorus Insecticides 
 Although the common mechanism of action for all OPs is through inhibition of 
AChE, there have been reports of differential expression of cholinergic toxicity in the 
presence of similar degrees of AChE inhibition (Chaudhuri et al, 1993; Pope et al., 1995; 
Liu and Pope, 1998). This led to the suggestion that in addition to AChE inhibition, OPs 
produce toxicity by direct or indirect interaction with other macromolecular targets 
(Pope, 1999; Silveira et al, 1990; Ward et al, 1993). Numerous studies indicate that 
inhibit the enzyme BChE, due to which, this enzyme is often used as a biomarker for 
exposure to these pesticides (Thiermann et al, 2007; Casida and Quistad, 2005; Amitai et 
al, 1998). While ~90% of brain cholinesterase (ChE) consists of AChE (Silver, 1974; Li 
et al, 2000; Mortensen et al, 1998), several studies have shown proportionately higher 
levels of BChE in some organs including heart, where BChE makes up about 90% of the 
total cholinesterase activity (Silver, 1974; Li et al, 2000; Slavikova et al, 1982). Due to 
the high density of BChE in the heart, we hypothesized that OPs with selectivity at 
inhibiting this enzyme may have preferential effects on cardiac regulation.  
 There have also been several reports indicating that OPs may directly interact 
with muscarinic receptors (Silveira et al, 1990; Ward and Mundy, 1996; Bomser and 
Casida, 2001). Paraoxon, dichlorvos and tetraethylpyrophosphate inhibited QNB binding 
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in bovine caudate membranes at low nanomolar concentrations (Volpe et al, 1985). Katz 
and Marquis (1989) reported that paraoxon, at concentrations as low as 10-15 M, was 
capable of blocking radioligand binding to M2 and M3 receptors. Bakry et al (1988) 
showed that the organophosphorus compounds echothiophate and VX potently blocked 
the binding of tritiated cis-dioxolane (CD), a high affinity M2-selective agonist, to 
muscarinic receptors. Subsequently, paraoxon, echothiophate and the nerve agents VX, 
soman and tabun were shown to block the in vitro binding of CD to rat cardiac tissues at 
high nanomolar concentrations (Silveira et al, 1990). Jett and colleagues (1991) reported 
that in rat striatal cells, paraoxon displaced CD binding and inhibited the formation of 
cAMP in an atropine-sensitive manner, while the parent insecticide parathion was 180-
fold less potent. Ward et al (1993) observed that paraoxon and malaoxon were more 
potent at blocking CD binding to rat hippocampal and cortical membranes than their 
parent compounds, parathion and malathion.  
 Chlopyrifos oxon was a potent displacer of CD binding and inhibited adenylyl 
cylcase in the rat striatum (Huff et al, 1994). The abilities of paraoxon, malaoxon and 
chlorpyrifos oxon to alter muscarinic receptor-mediated phosphoinositide turnover and 
cAMP formation in rat cortex were examined by Ward and Mundy (1996). All three 
oxons displaced CD binding and inhibited cAMP formation in a concentration-dependent 
manner, with chlorpyrifos oxon being most potent and malaoxon being least potent. All 
of these studies (Jett et al, 1991; Huff et al, 1994; Ward and Mundy, 1996) indicate that 
some OPs can bind directly to M2 receptors and act as agonists in various tissues. The 
binding of the muscarinic agonist [3H]oxotremorine-M was also found to be sensitive to 
low concentrations of some OPs. Paraoxon was a more potent displacer of radiolabeled 
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oxotremorine-M binding to rat brain membranes compared to parathion (Van Den Beukel 
et al, 1997).  
 Howard and Pope (2002) compared the in vitro effects of selected OPs 
(chlorpyrifos, parathion, methyl parathion, and their oxons) on cardiac muscarinic 
receptor binding in neonatal and adult rats. Although all three oxons displaced 
[3H]oxotremorine-M binding from neonatal and adult cardiac muscarinic receptors in a 
concentration-dependent manner, CPO was the most potent and efficacious of the three. 
Surprisingly, MePS displaced [3H]oxotremorine-M from adult but not neonatal cardiac 
muscarinic receptors. While the interaction between CPO and cardiac muscarinic 
receptors appeared to be irreversible, that between MePS and adult cardiac muscarinic 
receptors was not. This finding was similar to the studies by Bomser and Casida (2001), 
who found that CPO bound covalently and irreversibly to the rat cardiac M2 receptor, as 
evidenced by the diethylphosphorylation of the receptors in vitro. All these studies 
suggest that muscarinic receptors, particularly the M2 subtype may be additional sites of 
action for certain OP compounds. Since the heart predominantly contains M2 receptors, 
this organ could be particularly sensitive to these direct receptor effects of OPs. Together, 
all of these studies suggest that the heart may be sensitive to the effects of certain OPs, 
based on high densities of both BChE and M2 receptors in this organ. 
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Age-related Differences in Sensitivity to Organophosphorus Insecticides 
 A topic of major concern for over a decade has been age-related differences in 
sensitivity to pesticides in general, and OPs in particular. A number of studies have 
demonstrated marked differences in sensitivity to OPs during maturation (Atterberry et 
al, 1997; Moser et al, 1998; Pope et al, 1991). In general, immature animals are more 
sensitive than adults to the acute toxicity of OP pesticides. Uncertainty in determination 
of safe exposure levels to pesticides (including OP insecticides) by the USEPA has been 
influenced by the possibility of age-related differences in sensitivity. The Food Quality 
Protection Act of 1996 was passed unanimously by the US Congress, partially based on 
the potential for higher sensitivity of children to pesticides. This Act included the 
requirement of an additional safety factor (up to 10-fold if necessary) to account for 
uncertainty in data relative to childrens protection, as well as an explicit determination 
that tolerances were safe for children (FQPA, 1996).  
Several toxicokinetic and toxicodynamic factors were suggested to play an 
important role in age-related OP toxicity, including nature of the exposure (i.e. acute vs. 
repeated, high level vs. low level), timing of exposure during development relative to 
critical developmental processes and time available for exposure to occur or toxicity to 
develop (Pope, 2001). While several studies have demonstrated marked age-related 
differences in sensitivity to OPs such as chlorpyrifos, parathion and methyl parathion 
(Atterberry et al, 1997; Moser et al, 1998; Pope et al, 1991), most of these studies have 
focused on maturational differences, and very little is known regarding possible 
sensitivity differences with aging. 
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 Karanth and Pope (2000) found that while aged (24 month) Sprague Dawley rats 
exhibited relatively similar acute sensitivity to CPF as compared to adults (3 month) 
based on lethality, they were about 3-fold more sensitive to the acute effects of parathion. 
In the same study, they also evaluated the activity of carboxylesterases (CarbE) and A-
esterases (AE) in the liver, plasma and lung, as well as the in vitro sensitivity of CarbE to 
CPO and PO in different age groups. While aged rats demonstrated similar levels of AE 
in all tissues compared to adults, CarbE levels were similar between adult and aged rats 
only in the liver and lung. In the plasma, however, CarbE levels in aged rats were 50% 
lower than in adults. Moreover, no significant age-related differences were observed in 
the in vitro sensitivity of CarbE to either CPO or PO in any tissue. The acute sensitivity 
to CPF was highly correlated with age-related differences in CarbE and AE activities 
across all three tissues, whereas, only plasma CarbE activity was highly correlated with 
acute sensitivity to PS. Thus, the authors concluded that although both CarbE and AE 
activities were correlated with acute sensitivity to CPF and PS, age-related differences in 
CarbE activity were of more importance in differential toxicity, and that plasma CarbE 
played a crucial role in differential sensitivity to PS between adult and aged rats. Padilla 
et al (2000) arrived at a similar conclusion when they observed that chlorpyrifos elicited a 
toxic response at a 5-fold lower dose in the pre-weanling rat than in the adult rat, whereas 
methamidophos had the same oral maximum tolerated dose in both age-groups of rats. 
Since CPF is detoxified by both CarbE and AE, while methamidophos is not significantly 
detoxified by either enzyme, the authors hypothesized that OP pesticides like CPF, which 
are effectively detoxified by CarbE and/or AE, are more likely to exhibit age-related 
differences in toxicity than OPs that are not detoxified by these enzymes.  
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 Age-related differences in muscarinic receptor density and/or affinity, as well as 
acetylcholinesterase and butyrylcholinesterase activities have been reported in a variety 
of species. These variations in muscarinic receptors or AChE/BChE activity could 
potentially contribute to age-related differences in OP insecticide toxicity. There are 
several conflicting reports on aging-related changes in the functionality and density of 
muscarinic receptors in rats (Dhein et al, 2001). Narayanan and Derby (1983) reported 
that while muscarinic receptor density was higher in the atria of aged rats compared to 
adults, ventricles from both age-groups had similar densities of muscarinic receptors. 
However, they did not observe any age-related change in agonist or antagonist binding 
affinities of atrial or ventricular muscarinic receptors. In contrast, Baker et al (1985) 
reported that with increasing age, the ability of the cardiac muscarinic receptor to form a 
high affinity agonist binding state was reduced. Chevalier et al (1991) reported a 
reduction in cardiac muscarinic receptor density in aged as compared to adult rats.  
Several investigators have reported a reduction in cardiac parasympathetic activity with 
increasing age in humans. This reduced activity has been ascribed to a decrease in the 
density (Brodde et al, 1998) as well as functionality (Brodde et al, 1998; Oberhauser et al, 
2001; Poller et al, 1997) of cardiac muscarinic receptors in the heart of older individuals. 
 A decrease in the densities of muscarinic receptors in the brain of aged as 
compared to adult animals have been reported by several investigators (Tayebati et al, 
2006; Yufu et al, 1994; Araujo et al, 1990; Kadar et al, 1990) using a variety of 
experimental approaches, including radioligand binding methods (Yufu et al, 1994; 
Araujo et al, 1990; Schwarz et al, 1990; Amenta et al, 2006; Amenta et al, 1995), in vitro 
quantitative receptor autoradiography (Tayebati et al, 2006; Kadar et al, 1990) and 
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assessing subtype specific mRNA expression (Lee et al, 1994; Blake et al, 1991). Using 
the radial arm maze, Kadar et al (1990) correlated working memory deficits in 3, 12, 17 
and 24 month-old Wistar rats with an age-related decrease muscarinic receptor density in 
various brain regions.  
 Several reports indicate that basal parasympathetic tone decreases during aging. 
Meyer et al (1985), using a rat atrial mince preparation, reported that choline uptake, 
acetylcholine synthesis and acetyhlcholine release were all decreased in aged rats. 
Kelliher and Conahan (1980) found that the positive inotropic response that is normally 
observed following vagotomy in adult rats was abolished in aged rats. The authors also 
reported that the heart rate response to the muscarinic agonist methacholine was reduced 
in aged compared to adult rats. Kennedy and Seifen (1990) reported that right atrial 
preparations from aged rats were more sensitive to the negative chronotropic action of 
acetylcholine compared to adult rats. However, no age-related difference in sensitivity 
was observed with carbachol, a muscarinic agonist that is resistant to degradation by 
cholinesterases. When the right atrial preparations were pre-treated with 
diisopropylfluorophosphate (DFP), an irreversible OP cholinesterase inhibitor, age-
related differences in responsiveness to acetylcholine were abolished. The authors 
concluded that the increased sensitivity of atria from aged rats to acetylcholine as 
compared to adults occurred as a result of decreased acetylcholinesterase activity. These 
findings agreed with those of Su and Narayanan (1992), who, using isolated, perfused, 
spontaneously-beating rat hearts, found that the greater sensitivity of aged rats to the 
negative chronotropic effects of acetylcholine as compared to adults was diminished in 
the presence of a maximally effective concentration of eserine, a cholinesterase inhibitor. 
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The negative chronotropic and inotropic response to carbachol was also greater in aged 
than in adult rats. Moreover, acetylcholinesterase activities were found to be decreased by 
50-60% in aged atria and ventricles; however, no age-related differences were observed 
in binding of the muscarinic antagonist [3H]QNB in either the atria or ventricles. These 
authors concluded that the enhanced responsiveness of the aging heart to cholinergic 
agonists was at least partly due to an age-related reduction in cardiac acetylcholinesterase 
activity and/or muscarinic receptors.  
 Age-related changes in AChE and/or BChE activities and molecular isoforms 
have been reported in brain of several species including man. Skau and Triplett (1998) 
observed a significant reduction (20-50%) of AChE activity in different brain regions of 
aged (24 months) as compared to adult (6 months) Fischer 344 rats. When the ratio of 
G4/G1 isoforms was evaluated in different brain regions, it was found to be unaltered in 
aged rats, thus indicating that although aged rats exhibit decreased brain AChE levels, 
there does not appear to be any selective reduction of a particular isoform. In contrast, 
Das et al (2001), who evaluated AChE activity in different brain regions of adult (3 
months) and aged (18-22 months) male and female Sprague-Dawley rats, found a 
significant decrease (40-55%) in G4 but not G1 AChE in brain regions of aged male rats. 
Relatively similar differences were observed in adult and aged female rats. Interestingly, 
higher levels of the G4 isoform were observed in female compared to male rats in both 
age-groups. From these studies, the authors concluded that age-related differences in 
AChE were predominantly due to changes in the G4 isoform, and gender-dependent 
differences occur. Atack et al (1986) compared the activities and molecular forms of 
AChE and BChE in different regions of the aged human CNS. AChE activity varied 
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extensively (~50-fold) while BChE activity varied only slightly (3-fold) among the 
different regions studied. Although G4 was the predominant isoform, G1 and G2 
isoforms were also detected in various brain regions. In contrast, the only molecular 
forms of BChE were G4 and G1, and both isoforms were evenly distributed between 
membrane bound and soluble types. The ratio of G4 to G1 isoforms of AChE varied 
widely between different regions, while the G4 to G1 ratio of BChE showed considerably 
less variation.  
 
 
Radiotelemetry and Cardiac Function after Organophosphate Exposure 
Radiotelemetry is considered a humane and efficient method for observing 
physiological parameters in conscious, unrestrained animals (Kramer et al, 2001; Kramer 
et al, 2003). A combination of miniature sensors and transmitters can be used to measure 
physiological parameters (including blood pressure, heart rate, blood flow, 
electrocardiogram [ECG], respiratory rate, body temperature and other biopotentials such 
as EEG and EMG, pH and activity indices), which are then transmitted via a signal to a 
nearby receiver.  It has been found previously that use of non-invasive techniques to 
monitor ECG, such as the use of surface electrodes, required physical restraint with 
potential stressor influence on the test animal, and hence produced artifacts in the results 
obtained including increases in heart rate, body temperature and blood pressure, among 
others. By using radiotelemetric devices, it is possible to monitor several physiological 
parameters in conscious, freely moving animals, in a humane manner. Since no restraints 
are required, there is reduced stress to the animal. Moreover, it is possible to obtain data 
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almost continuously from the animal, with minimal animal handling, which was found to 
reduce variability between animals (Kramer et al, 2003).  
Radiotelemetry has been previously used to evaluate the effects of OP insecticides 
on physiological parameters such as heart rate, body temperature and motor activity in 
the rat model. Gordon (1993) evaluated the acute and delayed effects of 
diisopropylfluorophosphate (DFP) on the above-mentioned parameters using 
radiotelemetry. In this study, these parameters were continuously monitored for 96 hour 
after subcutaneous treatment of Long-Evans rats with DFP (0, 0.1 or 1 mg/kg). The 
reduction in core body temperature in rats treated with 1 mg/kg DFP peaked by 5 hours 
post-treatment and recovered to control values by 17 hours after treatment. Although 
motor activity and heart rate were affected during the first 24 hours (motor activity 
decreased; heart rate initially increased, then decreased), core body temperature was 
significantly elevated during the 24-96 hour recovery phase. The 0.1 mg/kg DFP group 
displayed a hyperthermic response throughout. It has long been known that OP toxicity is 
associated with hypothermia in rats. This was the first report of a delayed hyperthermic 
response (preceded by hypothermia) following OP exposure. Rapid blockade of this 
hyperthermic response was achieved by administration of sodium salicylate, an 
antipyretic drug that acts through inhibition of cyclooxygenase activity (Gordon, 1996). 
This finding corroborates many observations of fever in humans acutely exposed to OP 
pesticides (Namba et al, 1971; Hirshberg and Lerman, 1984; Hantson et al, 1996).  
Gordon et al (1997) evaluated the thermoregulatory effects of orally administered 
chlorpyrifos (0, 10, 50 or 80 mg/kg) in male and female Long-Evans rats using 
radiotelemetry. Following treatment with CPF, both male and female rats exhibited a 
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significant hypothermic response that lasted ~16 hours and a delayed hyperthermia which 
persisted during the diurnal phase for 1-2 days after CPF exposure. Female rats were 
significantly more sensitive to CPF, exhibiting a significant hypothermic response at 
doses which did not produce hypothermia in male rats. Similar to DFP, the CPF-induced 
hyperthermia was blocked by administration of sodium salicylate. Castrated male rats 
were significantly more sensitive to the hypothermic and hyperthermic effects of CPF 
compared to sham operated controls, whereas, ovariectomized female rats displayed 
similar sensitivity to CPF compared to sham operated controls. Hence, the authors 
concluded that testicular function plays an important role in gender-dependent differences 
in sensitivity to CPF. In a subsequent study, Gordon and Yang (2000a) reported that 
vasodilatation of the tail skin is an important mechanism by which core body temperature 
decreases during the acute hypothermic stage of CPF exposure, and that these 
hypothermic and vasodilatory responses to CPF are mediated via a cholinergic 
muscarinic pathway in the CNS. A radiotelemetric probe was used to non-invasively 
monitor the tail skin temperature of rats (Gordon et al, 2002).  
Radiotelemetric techniques were also used by Gordon and Padnos (2000b) to 
monitor systolic, diastolic and mean blood pressure, pulse pressure (systolic-diastolic), 
heart rate, core body temperature and motor activity in rats treated with various doses of 
CPF. The highest dose of CPF led to an increase in blood pressure within 2 hours of 
treatment, which persisted throughout the night and into the next day, a slight decrease in 
heart rate, hypothermia followed by hyperthermia, elevated pulse pressure and decreased 
motor activity. The authors concluded that the increase in blood pressure without a 
corresponding increase in heart rate could be due to CPF-induced increase in total 
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peripheral resistance and an alteration of the baroreflex control of blood pressure. They 
concluded that although the initial effects of CPF on blood pressure could be explained 
by cholinergic stimulation of the central nervous system, persistent pressor response 
probably involved neurohumoral pathways.  
 
 
Specific Aims of Project 
In this study, we proposed to evaluate further the role of BChE in the regulation 
of cardiac function. The effects of tetraisopropylpyrophosphoramide (iso-OMPA), an OP 
with high selectivity towards BChE, on cardiac function were evaluated using 
radiotelemetry. We also proposed to compare cardiac function in adult and aged rats 
following exposure to the common OPs chlorpyrifos (CPF) and parathion (PS). 
Chlorpyrifos has relative selectivity for inhibiting BChE while parathion has relative 
selectivity for inhibiting AChE. Thus, if BChE plays a role in cardiac function, 
chlorpyrifos may alter heart function at dosages below those leading to acute 
neurotoxicity mediated by AChE inhibition. Our studies also evaluated in vitro tissue- 
and age-related differences in sensitivity of cholinesterases and muscarinic receptors to 
chlorpyrifos oxon (CPO) and paraoxon (PO) in heart and brain of adult and aged rats.  
Based on previous publications and our preliminary findings, we hypothesized 
that: 1) selective inhibition of cardiac BChE would disrupt heart function, 2) the relative 
selectivity of chlorpyrifos for inhibiting BChE would make this insecticide more 
effective than parathion at disrupting cardiac function, and 3) the greater sensitivity of 
heart BChE in aged rats to inhibition by CPO would make aged rats more sensitive than 
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adults to cardiotoxicity of chlorpyrifos. We hypothesized that BChE plays a role in 
cardiac function and that selective effects of chlorpyrifos and parathion on AChE, BChE 
and muscarinic receptors would lead to OP- and age-related differences in toxicity. The 
specific aims of this project were as follows:  
 
Specific Aim 1:  To compare the in vitro sensitivity of AChE, BChE and muscarinic 
receptor agonist binding in brain and heart of adult and aged rats to CPO and PO.  
Specific Aim 2: To assess the dose-related effects of a BChE-selective OP 
(tetraisopropylpyrophosphoramide, iso-OMPA) on cardiac function.  
Specific Aim 3: To compare dose- and age-related effects of chlorpyrifos (CPF) on 
AChE, BChE, muscarinic receptor agonist binding and cardiac function in adult 
(3 months) and aged (18 months) rats.  
Specific Aim 4: To compare dose- and age-related effects of parathion (PS) on AChE, 
BChE, muscarinic receptor agonist binding and cardiac function in adult (3 
months) and aged (18 months) rats.  
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CHAPTER 2 
METHODS 
 
Chemicals 
Chlorpyrifos (CPF, O,O’-diethyl-O-(3,5,6-trichloro-2-pyridinyl) 
 phosphorothioate, 99% purity), chlorpyrifos oxon (CPO, O,O’-diethyl-O-(3,5,6- 
trichloro-2-pyridinyl) phosphate, 99.1% purity), parathion (PS, O,O’-diethyl-O-(4-
nitrophenyl)  phosphorothioate, 99% purity) and paraoxon (PO, O,O’-diethyl-O-(4-
nitrophenyl) phosphate, 99.1% purity) were obtained from Chem Service (West Chester, 
PA) and were maintained dessicated under nitrogen at 4 ºC. 10 mM stock solutions of all 
Organophosphorus toxicants were prepared in 100% dry ethanol and stored under 
nitrogen in dessicators at -80°C until the day of assay. Dry ethanol (100%) was prepared 
using sodium sulfate.  
Acetylcholine iodide (acetyl-3H; specific activity 76.0 mCi/mmol), oxotremorine-
M acetate (methyl-3H; specific activity 75.8 Ci/mmol) and quinuclidinyl benzilate (L-
benzilic-4,4’-3H; specific activity 52.0 mCi/mmol) were purchased from Perkin Elmer 
(Boston, MA).  
HEPES (N-[2-hydroxyethyl]piperazine-N’-[2-ethane sulfonic acid]), Tris (Tris 
[hydroxymethyl] aminomethane), EDTA (ethylenediaminetetraacetic acid), PEI 
(polyethylenimine, 50% w/v), absolute ethyl alcohol, sodium hydroxide, hydrochloric 
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acid, sodium chloride, sodium sulfate, potassium phosphate (monobasic), potassium 
phosphate (dibasic), atropine sulfate, acetylcholine iodide, triton X-100, chloroacetic 
acid, BW284C51 (1,5-bis [allyldimethylammoniumphenyl] pentane-3-dibromide), iso-
OMPA (tetraisopropylpyrophosphoramide), BSA (bovine serum albumin), Folin and 
Ciocalteu’s Phenol reagent, sodium potassium tartarate, cupric sulfate, PPO (2,5-
diphenyloxazole), POPOP (1,4-bis[5-phenyl-2-oxazolyl]benzene), Heparin, p-nitrophenyl 
acetate and glutaraldehyde solution (25% in water) were purchased from Sigma Chemical 
Company (St. Louis, MO). Isoamyl alcohol, toluene and acetone were obtained from 
Fisher Scientific Company (Houston, TX). Sodium carbonate was purchased from JT 
Baker Chemical Company (Phillipsburg, NJ). All chemicals used in experiments were 
reagent grade.   
Haemo-Sol Non-Sudsing enzymatic detergent was purchased from Haemo-Sol 
Inc. (Baltimore, MD).  
Acetylcholinesterase (Type V-S) purified from electric eel was obtained from 
Sigma Chemical Company in the form of a lyophilized powder (1070 units per mg 
protein) and was resuspended in 50 mM potassium phosphate buffer (pH 7.0) at 50 units 
per ml.   
 
 
Animals 
All animals used throughout the experiments were adult (3 months-old) or aged 
(18 months-old) male, Sprague-Dawley rats purchased from Harlan Sprague Dawley 
(Indianapolis, IN). Adult male rats were housed individually in plastic cages and were 
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allowed 7 days to acclimate prior to the start of any studies. To obtain aging rats, six 
month-old, male Sprague-Dawley rats were housed 2/cage for 1 year, and were used at 18 
months of age. They were also housed individually for at least 7 days prior to any studies. 
All animals were maintained under a 12-h light/dark cycle and were provided ad libitum 
food and tap water. All procedures involving animals followed established protocols as 
described in the NIH/NRC “Guide for the Care and Use of Laboratory Animals” and 
were approved by the Institutional Laboratory Animal Care and Use Committee 
(IACUC) of Oklahoma State University.   
 
 
In Vitro Studies 
 
Tissue Collection and Preparation 
The adult and aged animals were sacrificed by partial asphyxiation followed by 
decapitation, following which the cortex and heart were collected. The cerebral cortex 
was dissected on ice, according to the method of Glowinski and Iversen (1966), while the 
heart was collected as described previously (Howard and Pope, 2002). Briefly, after the 
heart was removed from the thoracic cavity, it was cleared of connective tissue and blood 
vessels. Subsequently, it was rinsed in a buffer containing 10 mM Tris HCl and 1 mM 
EDTA (pH 7.4) and the whole heart was minced and stored at -70 ºC, until time of assay. 
The tissues were prepared depending on the biochemical assay to be performed: tissue 
homogenates were used for the cholinesterase assays, while membrane preparations were 
used for receptors binding assays. On the day of the (cholinesterase) assay, the thawed 
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cortex was homogenized on ice (1:20 in 50 mM Potassium phosphate buffer, pH 7) for 20 
seconds at 25000 rpm using a Polytron PT 3000 homogenizer (Brinkmann Instruments, 
Westerbury, NY). Similarly, after rinsing the thawed heart tissue in ice-cold 0.9% saline 
and blotting it dry, it was homogenized (1:20 in 50 mM Potassium phosphate buffer, pH 
7) twice for 30 seconds, with a 30 seconds pause in between. These crude tissue 
homogenates were used for the cholinesterase assays. The cardiac and cortical 
membranes (for the M2 receptor binding assay) were prepared as described previously 
(Howard and Pope, 2002; Liu et al, 1999). In brief, after the cortex was homogenized 
(1:20 w/v in 5mM Hepes, pH 7.4) on ice as described above, the homogenate was 
centrifuged at 48000g for 10 minutes. The P1 pellet obtained was then re-homogenized 
and re-centrifuged to obtain the P2 pellet, which was then diluted in the original volume 
of buffer and homogenized prior to the start of the assay. The heart tissue was 
homogenized (1:15, w/v in 5 mM Hepes, pH 7.4) four times, for 30 seconds each, 
pausing for 1 minute between the homogenizations. This cardiac homogenate was then 
centrifuged for 10 minutes at 1000g at 4ºC, following which, the supernatant was re-
centrifuged at 40,000g for 45 minutes. The pellet thus formed was resuspended in the 
original volume of buffer by 10 strokes of a Dounce homogenizer, just before the assay.  
 
 
Cholinesterase Assays 
AChE, BChE and total ChE (AChE + BChE) activity was measured in the 
cortical and cardiac homogenates by the radiometric method of Johnson and Russell 
(1975) using 1 mM final concentration of tritiated Acetylcholine iodide as the substrate. 
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To estimate the levels of AChE and BChE in the adult and aged cortex and heart, as well 
as to ascertain the specificity and selectivity of the specific inhibitors for their respective 
cholinesterases, cardiac and cortical tissue homogenates were incubated with increasing 
concentrations of either iso-OMPA or BW at 37°C for 15 minutes, before assessing the 
residual ChE activity. For total ChE (AChE + BChE) activity, the tissue homogenate was 
pre-incubated in potassium phosphate buffer (no inhibitor), prior to performing the assay.  
Tissue homogenates that had been pre-incubated with 10 µM iso-OMPA (to obtain AChE 
activity only) or 10 µM BW (to obtain BChE activity only) were incubated at 37°C for 30 
minutes in the presence of either vehicle (0.1% ethanol), CPO (100 pM to 300 nM) or PO 
(300 pM to 10 µM), prior to measuring the residual ChE activity. 
Preliminary assays were carried out to determine incubation times that resulted in 
linear rates of substrate hydrolysis. Cholinesterase assays were carried out in 7 ml 
scintillation vials at room temperature. The reaction mixture consisted of 60 µl of 1% 
Triton X-100 (in 50 mM potassium phosphate buffer, pH 7.0), 20 µl of tissue 
homogenate and 20 µl of radiolabeled substrate ([3H]Acetylcholine iodide) in 50 mM 
potassium phosphate buffer, pH 7.0. In order to determine non-enzymatic hydrolysis of 
substrate, blanks containing buffer only (no tissue) were included. Twenty µl of electric 
eel (50 units/ml in 50 mM potassium phosphate buffer, pH 7.0) was added in lieu of the 
tissue sample to determine total hydrolysis of radioactive substrate. The radiolabeled 
substrate was added to the reaction vials at staggered (10 seconds) intervals to start the 
incubation and reactions were terminated by staggered addition of 100 µl of ChE “stop” 
solution. Once the reactions had been stopped, 5 ml of organic scintillation cocktail was 
added to each vial. The vials were capped and vortexed for  5-10 seconds and were then 
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counted in a Wallac Liquid Scintillation Counter (Model 1049 DSA, PerkinElmer, Inc., 
Boston, MA).  
 
 
Preparation of [3H]Acetylcholine Iodide Substrate 
The radiolabeled substrate was prepared by suspending 1 mCi of acetylcholine 
iodide [acetyl-3H] in 2 ml of 50 mM potassium phosphate buffer, pH 7.0. This stock 
solution was subsequently stored at -70°C. Twenty ml of 5 mM working solution of 
substrate was prepared by adding 150 µl of stock radioligand solution to 10 ml of 
9.90132 mM unlabeled acetylcholine iodide and making up the volume to 20 ml by 
adding 9.85 ml of 50 mM potassium phosphate buffer, pH 7.0. Aliquots were made in 
800 µl volumes and stored at -70°C until day of assay. 
 
 
Preparation of Cholinesterase Stop Solution 
The cholinesterase stop solution was prepared by adding 9.45 grams of 
chloroacetic acid, 2 grams of sodium hydroxide and 11.6 grams of sodium chloride to 
100 ml of deionized water. This solution was then stored at 4 °C and aliquots of 20 ml 
were made for use. 
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Preparation of Organic Scintillation Cocktail 
Organic scintillation cocktail for the cholinesterase assay consisted of 0.5% (w/v) 
2,5-diphenyloxazole (PPO), 0.03% (w/v) 1,4-bis[5-phenyl-2-oxazolyl]benzene (POPOP) 
and 10% (v/v) isoamyl alcohol in toluene. To make four liters of cocktail, 20 grams of 
PPO, 1.2 grams of POPOP and 400 ml of isoamyl alcohol were added to 3600 ml of 
toluene. This mixture was then stirred overnight with a magnetic stirrer and stored at 
room temperature.  
 
 
Oxotremorine-M Displacement Assays 
Muscarinic receptor binding assay was carried out according to the modified 
version of Silveira et al (1990), as described previously (Howard and Pope, 2002).  
Membranes (280-310 µl/reaction) were incubated at 21ºC for 90 minutes in the presence 
of [3H]Oxotremorine-M acetate (1 nM final concentration) and either vehicle (0.1% 
ethanol) or one of a range of OP (CPO or PO) concentrations (100 pM to 10µM). 
Atropine (10µl final concentration) was used to determine non-specific binding. 
[3H]OXO was prepared in 5 mM Hepes, whereas the OP toxicants were prepared in 1% 
ethanol (0.1% ethanol final concentration). The entire reaction up until the incubation 
step was carried out on ice. At the end of the incubation period, the reaction was 
terminated by vacuum filtration over GF/B filter paper (Brandel Inc., Gaithersburg, MD) 
saturated with ice-cold 0.05% polyethylenimine. Subsequently, the filter disks were 
immersed overnight in scintillation cocktail (Fisher Scientific, Pittsburgh, PA) prior to 
counting. Specific binding was calculated as the difference in total and non-specific 
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binding, which correspond to the reactions without and with atropine, respectively. 
Protein content was determined according to Lowry et al., 1951. 
 
 
Tissue Protein Content Estimation 
The protein content of tissue homogenates and membrane preps was determined 
by the method of Lowry et al, 1951, by using Bovine serum albumin (BSA) as the 
standard. One ml aliquots of BSA (1 mg/ml in deionized water) were prepared in advance 
and stored at -70°C. A standard curve consisting of 0, 10, 25, 50, 75 and 100 mg BSA per 
reaction was performed for each assay. For the standard curve, reactions contained BSA 
and the same volume of 5 mM Hepes (pH 7.4) or 50 mM potassium phosphate buffer (pH 
7.0) as that used in the tissue samples for the unknowns. The amount of tissue used for 
the assay depended on the dilution and was adjusted in such a way that the protein 
content would fall within the range of the standard curve. Reactions for tissue samples 
were run in duplicate. The volume was adjusted to 200 µl for both the standard reactions 
as well as the tissue samples using deionized water. Two ml of “Reagent 1” was added to 
each tube, vortexed and was incubated for ten minutes at room temperature. 
Subsequently, 200 µl of “Reaction 2” was added, vortexed and tubes were then incubated 
for another 30 minutes at room temperature. The absorbance was then read using a 
Beckman General Purpose UV-Vis Spectrophotometer (Beckman-Coulter, Fullerton, 
CA) at a wavelength of 720 nM. The protein content of the samples was estimated from 
the absorbance values of the standard curve.   
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Preparation of Reagents 1 and 2 for Protein Assay 
Both reagents 1 and 2 were prepared just immediately before performing the 
assay. Reagent 1 was prepared by combining 1 part of 0.5% copper sulfate, 1 part of 1% 
sodium potassium tartarate and 100 parts of 2% sodium carbonate in 0.1 N sodium 
hydroxide. Stock solutions of sodium carbonate, copper sulfate and sodium potassium 
tartarate were prepared in advance in deionized water. The sodium carbonate solution 
was stored at room temperature, while the copper sulfate and sodium potassium tartarate 
solutions were stored at 4 °C. Reagent 2 was prepared by mixing equal parts of Folin and 
Ciocalteu’s Phenol Reagent and deionized water.   
 
 
In Vivo Studies 
 
Dose-Determination Studies 
The goal of the first part of the project was to arrive at appropriate dosages of iso-
OMPA, chlorpyrifos (CPF) parathion (PS) to be used in subsequent in vivo studies. Since 
the Maximum Tolerated Dose (MTD) of CPF and PS had already been evaluated in adult 
and aged rats in the past, we established treatment regimens based on this prior 
knowledge. Adult and aged rats were treated with CPF (MTD: 280 mg/kg in both age-
groups) @ 0.1xMTD (28 mg/kg), 0.5xMTD (140 mg/kg) and 1xMTD (280 mg/kg), 
which served as the low, medium and high dose-groups in both ages, respectively. 
Similarly, based on the known MTD’s of PS in adult (18 mg/kg) and aged (6 mg/kg) rats, 
low (0.5xMTD; adult: 9 mg/kg, aged: 3 mg/kg), medium (0.75xMTD; adult: 13.5 mg/kg, 
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aged: 4.5 mg/kg) and high (1xMTD; adult:18 mg/kg, aged: 6 mg/kg) doses were decided 
upon. Chlorpyrifos and parathion were prepared in peanut oil and administered 
subcutaneously at 2 ml/kg body weight. In all cases, peanut oil served as the vehicle for 
the control groups.  
Since iso-OMPA had never been used in vivo in our lab prior to this, a dose-
determination study was performed to arrive at doses of iso-OMPA that would selectively 
inhibit cardiac BChE in the absence of central cholinesterase inhibition. Iso-OMPA was 
dissolved in 0.9% saline (1 ml/kg) and rats were treated with either vehicle (normal 
saline) or one of a range of doses of iso-OMPA (1.25, 2.5, 5, 15, 25, 50 and 100 mg/kg) 
subcutaneously. Body weight and functional signs were observed before treatment and at 
the end of the study (24 hours post-treatment), when rats were sacrificed.  
 
 
Treatment of Animals 
Rats were treated with iso-OMPA at 0, 1.25 or 5 mg/kg, sc (n=6-10/group) and 
were sacrificed 24 and 96 hours post-treatment. For the CPF and PS studies, adult 
(n=4/group) and aged (n=4-5/group) rats were treated at the doses metioned above and 
were sacrificed 96 hours later by partial asphyxiation (using CO2) followed by 
decapitation. Body weight and functional signs of toxicity were monitored every 24 hours 
until the end of the study. In all cases, for treatment, rats were placed in a restrainer, the 
skin behind the site of telemetric device placement was lifted and the OP was injected 
subcutaneously using a 1 cc syringe attached to a 21 guage needle, taking care not to hit 
the telemetric implant.  
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Observation of Functional Signs of Cholinergic Toxicity 
Twenty four, forty eight, seventy two and ninety six hours post-treatment with 
either CPF or PS, adult and aged rats were weighed and graded for functional signs of 
cholinergic toxicity as noted by salivation, lacrimation, urination and defecation (SLUD) 
and involuntary movements, according to a modified method of Moser et al. (1988). All 
scoring of functional signs was performed in “blind”. Involunatry movements were 
scored as follows: 1: repetitive movements of mouth and jaws; 2: normal quivering of 
vibrissae, head and limbs, 3: mild, fine tremor that would usually be observed in the head 
and forelimbs; 4: severe, whole body tremors. SLUD signs were scored as follows: 1: 
none; 2: slight (one symptom or multiple mild symptoms); 3: moderate (multiple 
moderate symptoms); 4: severe (multiple severe symptoms).  
 
 
Preparation of CTA-F40 Transmitters for Surgical Implantation 
A CTA-F40 telemetric transmitter device was used for implantation in rats. In 
order to prepare the transmitter for surgical implantation, using a sharp sterile blade, 
about 2-2.5 cm of the silicone tubing was cut off from the tip of one biopotential lead, so 
as to expose the helix of stainless steel wire inside. The tubing was cut by applying light 
pressure and rotating the lead. The silicone tubing was then removed and cut in half. One 
half was then placed over the tip of the lead, leaving some part extending over the wire, 
and at least 1-1.5 cm of the wire being exposed. Using 4-0 non-absorbable silk suture, the 
tubing was held in place by tightly applying knots. The distal part of the exposed lead 
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was also tightly secured using 4-0 non-absorbable silk. The purpose of securing the 
silicone tubing over the helix of wire was to prevent the sharp end of the proximal portion 
of the lead from causing injury to the animals tissues, and to prevent moisture ingress via 
the distal part of the exposed lead. The same process was repeated for the other lead. 
Figure 5 represents an image of the prepared transmitter that is ready for surgical 
implantation in rats.  
 
 
Surgical Implantation of CTA-F40 Telemetric Device 
Adult and aged rats were anesthesized using a mixture of ketamine and xylazine 
(0.67 ml/kg body weight, i.p.)  by means of a 1 ml syringe with a 26 guage needle. This 
ketamine/xylazine solution was prepared by adding 1 ml of a 100 mg/ml solution of 
xylazine to 10 ml of 100 mg/ml ketamine solution. If anethesia was not achieved within 
10-15 minutes, an additional injection of 25% of the original dose was given. The depth 
of anesthesia was assessed by evaluating the animals reaction to tail-pinch test.  
The rat was prepped for surgery by shaving the hair above the scapula, from the 
base of the neck to midway down the back using hair clippers. The areas of lead 
placement, i.e., right shoulder and left xiphoid space were also shaved. The shaved areas 
were made aseptic by swabbing with 70% ethanol. The rat was placed in sternal 
recumbancy on a sterile drape and another surgical drape was used to cover the animal, 
leaving a small window with which to work. An incision was made along the dorsal 
midline, parallel to the long axis of the body, immediately caudal to the scapula. The 
incision should be large enough to accommodate the implant device body. Using artery 
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forceps or blunt-tipped dissecting scissors, a pouch was formed by separating the skin 
from the underlying subcutaneous tissue.  The pouch was made just slightly larger than 
the device body, which would allow it to lie within the pouch without producing 
excessive tension on the overlying skin. The skin incision was then covered with sterile 
gauze and the rats was turned onto its back. Subsequently, skin incisions (~ 3 cm in 
length) were made in the regions of the right shoulder for the negative lead, and left of 
the xyphoid space, caudal to the ribcage for the positive lead. Using artery forceps, the 
skin was separated from underlying tissue so as to provide a greater surface area for 
suturing. The skin incisions (for lead placement) were then covered using sterile gauze 
and the animal was once again placed with its dorsal side up. The implant device body 
was then placed in the pouch with the suture rib side up (Figure 6). Using a trocar placed 
inside a plastic sleeve, a subcutaneous tunnel was formed from the dorsal incision to the 
lead incision. Subsequently, the trocar was removed, leaving the plastic sleeve in place. 
The negative lead was then passed through the sleeve to the site of lead incision, after 
which, the sleeve was removed. This process was repeated for the positive lead as well. 
Figure 7 represents an image of the positive and negative leads in place. After placing the 
lead in its approximate position, the excess lead was coiled up and placed beneath the 
implant device body. The dorsal skin incision was closed using 2-0 non-absorbable silk 
sutures, in a simple interrupted pattern. While suturing the skin, the needle was passed 
through one edge of the incision, then through the suture rib of the device and finally 
through the other edge before tying a knot, as can be seen in Figure 8. Once the dorsal 
skin incision was closed, the animal was placed on its back and the forelimbs were held 
down (by applying a tape) so as to have clearer access to the surgical site. The muscle 
 52 
fibers at the site of lead placement were bluntly dissected so as to provide a shallow area 
in which the lead was to be placed. Care was taken to ensure that the tip of the lead lay 
straight and flat. The exposed part of the lead or helix of wire was held in place by 
suturing the muscle tissue up over the lead using 3-0 non-absorbable silk suture (Figure 
9). This was done to allow the muscle tissue to grow into the lead, so as to obtain a clear 
telemetric signal in the absence of any extraneous noise. In order to do this, the needle 
was passed through the muscle tissue on one side of the helix of wire, passed over the 
lead, and another bite was taken on the other side of the lead. The two ends of the suture 
were pulled together, which resulted in the helix of the lead being embedded in the 
muscle tissue, and a knot was tied off. This process was repeated for the other lead as 
well. Finally, skin incisions (for lead placement) were closed using 9 mm EZ wound clips 
(Braintree Scientific Inc., MA), removing as much dead space as possible (Figure 10). 
All skin incisions were cleaned using Betadine®, after which an antibiotic ointment was 
applied topically. 
For recovery, the rat was placed in a warm environment, and additional warmth 
was provided using a light source. The animals recovery was monitored until the rat was 
fully awake. Childrens ibuprofen (2 ml) was added to the drinking water to alleviate pain, 
and rats were allowed access to this for up to upto 3 days after surgery. The rats were 
given 7 days to recover from the surgery before they were used in any study. 
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Explantation of the CTA-F40 Transmitter 
Once the study was completed, rats were sacrificed by partial asphyxiation (by 
CO2) followed by decapitation. Subsequently, the sites of lead implantation were opened 
by cutting the skin just below the wound clips. The sutures securing the muscle around 
the leads were removed and the muscle was dissected so as to expose and free the leads 
from surrounding tissue. The rat was then placed in sternal recumbancy and the sutures at 
the site of device body placement were carefully cut one by one, so as to separate the skin 
from the suture ribs of the device body. The skin incision was then opened and the device 
body was freed from adjacent tissue and fascia. Subsequently, the device was removed 
from the subcutaneous pouch and the leads were carefully pulled out of the sites of 
placement (via the subcutaneous tunnels) taking care not to stretch the leads.  
 
 
Sterilization of the CTA-F40 Transmitter Post-Surgery 
After explantation of the transmitter from the animal, care was taken to ensure that 
the suture ties around each biopotential lead were intact, in order to prevent moisture 
ingress. If not, they were tied off using 4-0 non-absorbable silk suture. Subsequently, the 
transmitters were rinsed under running tap water to remove as much blood and tissue as 
possible, taking special care to clean the suture ribs. A three-step process was adopted for 
sterilization of these biopotential transmitters.  
1. Enzymatic detergent: Haemo-Sol N. S. (Haemo-Sol, Inc), a non-sudsing, 
proteolytic powdered detergent was used to remove blood and tissue debris from 
the implant post-explantation. 5 grams of the powder was mixed with 1 liter of 
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cold water. The device was soaked in this solution for a minimum of 4 hours. If 
blood or tissue was found to persist, additional soaking in the detergent was 
carried out (upto a maximum of 72 hours). Thereafter, it was cleaned by rinsing 
under running tap water.  
2. Chemical Sterilant: Since the DSI transmitters are heat sensitive, cold sterilization 
was performed by using a chemical sterilant such as Glutaraldehyde. 25% 
Glutaraldehyde was purchased from Sigma Chemical Company and was diluted 
to a 2% solution using autoclaved water, by adding 80 ml of 25% Glutaraldeyhde 
to 920 ml sterile, autoclaved water. The transmitter was completely immersed in 
2% Glutaraldehyde for upto 24 hours.  
3. Sterile Saline: Sterile saline was prepared by adding 9 grams of Sodium Chloride 
to 1 liter of water and then autoclaving it. The chemically sterilized transmitters 
were immersed in sterile saline so as to remove all traces of 2% Glutaraldehyde 
before implantation in the animal. For temporary storage (<48 hours) of the 
transmitters, until surgical implantation, the transmitters were left in the sterile 
saline. If use was not immediate, they were allowed to air dry and were then 
stored in a safe, dry place.   
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Acquisition of Telemetric Data 
For telemetric data collection, a Chronic Use TA11CTA-F40 implant, PhysioTel 
Receiver Model RPC-1 and DataQuest ART (Advanced Research Technology) Version 
4.0 software were used (DSI, St. Paul, MN). At the beginning of each new study, a 
configuration was established, which included configuration settings, name and the folder 
in which the data would be stored. For each configuration, eight unique animal IDs were 
created and subsequently, each transmitter was configured to a specific receiver  by 
entering the manufacturers specified calibrations into the configuration window. After 
post-surgical recovery, baseline telemetric data (heart rate, body temperature and physical 
activity) were collected from rats for 24 hours prior to treatment. Thereafter, telemetric 
data was acquired every 24 hours for upto 96 hours post-treatment. In order to collect 
biopotential data from the rat, the transmitter had to be switched on. In order to turn the 
transmitter to the “On” operational mode, an AM radio was tuned to the low AM band 
and held close to the rat with the implanted device. Thereafter, a strong magnet was 
passed over the device body by moving it within about 1 inch from the rats back. When 
the transmitter was turned on, an audible tone was heard on the radio. The transmitter 
was turned on about 15 minutes prior to data collection. The rats were then placed in their 
home cages, which were placed on top of the receivers and the Acquisition program 
(DataQuest ART 4.0) was set up to collect data  by continuous sampling. At the end of 
the study, the transmitter was turned off in a similar manner as described above. When 
the transmitters were in the “off” mode, no tone could be heard from the radio.  
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Telemetric Data Analysis 
Once the study had been completed, parametric data (heart rate, body temperature 
and physical activity) that had been collected and saved by the acquisition program was 
exported into a Microsoft Excel spreadsheet by the Analysis program of the Dataquest 
ART software. Since data was collected in 10 second intervals, each cell in the Excel 
sheet represented that parameter over 10 seconds. For heart rate and body temperature, 
360 consecutive cells were averaged to obtain an hourly estimate. For physical activity, 
360 cells were summed to obtain total activity in one hour. This process was carried out 
for the entire 120 hours (24 hours pre-treatment and 96 hours post-treatment) of the 
study. Subsequently, the hourly estimates for each parameter (for each animal) were 
combined into 8 hour diurnal (10:30 to 18:30 hours) and nocturnal (20:30 to 04:30 hours) 
intervals. For heart rate and body temperature, hourly data was averaged over these 
diurnal and nocturnal intervals, whereas physical activity was summed over these 
intervals. Subsequently, for each diurnal and nocturnal time point, average and standard 
error were determined, based on the number of animals per treatment group.  
 
 57 
  
  
 
 
 
 
 
 
Figure 5: CTA-F40 transmitter prepared for surgical implantation in rats. 
 
 
 
Transmitter device body 
Positive biopotential lead 
Negative biopotential 
lead Helix of wire 
Tip cover 
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Figure 6: Placement of transmitter device body in dorsal subcutaneous pouch, suture-side 
up. 
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Figure 7: Placement of positive lead in the left xiphoid space, just caudal to the rib cage 
and negative lead in the region of the right shoulder.  
Positive lead 
Negative lead 
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Figure 8: Suturing of dorsal skin incision through suture ribs of telemetric implant device 
body. 
Suture ribs 
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Figure 9: Suturing of the muscle up and over the exposed helix of wire of biopotential 
lead. 
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Figure 10: Closing of ventral skin incisions using skin staples. 
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Figure 11: Placement of rats in their home cages on top of receivers subsequent to 
surgery.  
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Biochemical Assays 
 
Tissue Collection and Preparation 
Rats were sacrificed 24 hours after treatment with iso-OMPA and 96 hours after 
treatment with CPF or PS by partial asphyxiation (in a CO2 chamber) followed by 
decapitation. Subsequently, brain cortex, atria, ventricles and diaphragm were collected 
as described previously. Trunk blood was collected for plasma in heparinized vials (20 µl 
heparin-10,000 units/ml) and centrifuged at 12,000 rpm for 10 minutes. The supernatant 
plasma was then transferred to fresh eppendorf tubes and stored along with the other 
tissues at -70 ºC until day of assay. AChE, BChE and Lowry protein assays were 
performed on all tissues (except plasma); muscarinic receptor binding assays were 
performed on cortex, atria and ventricles; and the carboxylesterase (CarbE) assay was 
performed on cortex, atria, ventricles and plasma. On the day of assay, tissues were 
thawed, weighed and diluted (cortex 1:20; atria 1:15; ventricles 1:15; diaphragm 1:10; 
plasma 1:3) in 5 mM Hepes, pH 7.4 in 7 ml polycarbonate centrifuge tubes on ice. 
Tissues were then homogenized (cortex: 20 seconds; atria, ventricles: 30 seconds 4 times, 
with a 1 minute pause in between; diaphragm: 30 seconds twice with a 30 second pause 
in between) on ice at 28,000 rpm using a Polytron PT 3000 homogenizer (Brinkmann 
Instruments, Westerbury, NY). Aliquots (0.5-1 ml) of these crude tissue homogenates 
were separated for AChE, BChE, CarbE and protein assays, while the remaining 
homogenate was used to obtain  membranes, as described previously. 
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Acetylcholinesterase and Butyrylcholinesterase Assays 
AChE and BChE activities were evaluated in aliquoted tissue homogenates or 
diluted plasma samples as described previously in the In Vitro Studies sections. In brief, 
tissue homogenates were pre-incubated with either 10 µM iso-OMPA (to obtain AChE 
activity) or 10 µM BW (to obtain BChE activity) at 37°C for 15 minutes. Subsequently, 
20 µl of tissue sample was taken in duplicate to measure the residual ChE activity. 
Protein content was estimated as described previously in the In Vitro Studies section.  
 
 
Muscarinic Receptor Binding Assays 
Cardiac (atrial and ventricular) and cortical membranes were prepared as 
described in the In Vitro Studies section. Muscarinic receptor binding was evaluated by 
following a modified version of Silveira et al (1990), as described previously (Howard 
and Pope, 2002).  Membranes (280-310 µl/reaction) were incubated at 21ºC for 90 
minutes in the presence of either a non-selective muscarinic agonist, [3H]oxotremorine-M 
acetate (OXO, 1 nM final concentration) or a non-selective muscarinic antagonist, 
[3H]Quinuclidinyl benzilate (QNB, 1 nM final concentration). In both cases, atropine 
(10µl final concentration) was used to determine non-specific binding. Muscarinic 
receptor agonist and antagonist binding were evaluated as described previously in the In 
Vitro Studies section. Protein content was estimated as described previously in the In 
Vitro Studies section. 
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Carboxylesterase Assay 
The carboxylesterase activity in tissue samples was estimated according to the 
method of Clement and Erhardt, 1990. 10 µl of aliquoted tissue homogenate or diluted 
plasma sample was added in duplicate to 980 µl of 0.1 M Tris-HCl buffer (pH 7.8) 
containing 2 mM EDTA and this mixture was pre-incubated at 37 °C for 5 minutes. The 
substrate, 50 mM p-nitrophenyl acetate (p-NPA), was freshly prepared in acetone on the 
day of the assay. The reaction was initiated by adding 10 µl of substrate (p-NPA, final 
concentration 0.5 mM) to the tubes in a staggered fashion and further incubating for a 
pre-determined amount of time at 37°C. Preliminary assays were carried out to determine 
incubation times that resulted in linear rates of substrate hydrolysis. The absorbance was 
then read at 405 nm in the same staggered manner against a reagent blank that contained 
only buffer and substrate (no tissue). A p-NPA standard curve was used to calculate the 
specific activity of CarbE. Protein content was estimated as described previously in the In 
Vitro Studies section.   
 
 
Data Analyses 
 
In Vitro Studies 
Each assay was repeated three independent times to allow generation of mean and 
standard error bars for each data point. IC50 values were estimated by sigmoidal dose-
response analysis using GraphPad Prism 4 software (Graphpad Software, San Diego, 
CA, USA, www.Graphpad.com).   Assessment of the 95% confidence interval around the 
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IC50 was used to estimate significant differences in sensitivity of AChE, BChE or OXO 
binding to PO and CPO, as well as age-related differences in sensitivity to these OPs. 
GraphPad Prism  software was used to perform all data analyses and p<0.05 was 
considered to be statistically significant. Variability about the mean was calculated and 
reported as standard error (SE). The great majority of publications in toxicology-related 
journals present standard error and not standard deviation.  
 
 
 
In vivo Studies: iso-OMPA 
For the dose-determination study, enzyme assays were analyzed using one-way 
ANOVA, followed by Tukey’s post hoc test. Heart rate and body temperature data were 
averaged over diurnal or nocturnal intervals and were expressed in terms of mean ± 
standard error (SE). The total physical activity over a diurnal or nocturnal interval was 
averaged and was expressed as mean ± SE. Data were analyzed using SAS statistical 
software and GraphPad Prism software. Diurnal and nocturnal data were analyzed 
individually using one-way repeated measures ANOVA (with time being the repeated 
factor), followed by multiple comparison tests with a Bonferoni adjustment factor. Heart 
rate, which was expressed in 4 hourly intervals (up to 48 hours post-treatment) was 
analyzed using one way repeated measures ANOVA, with time being the repeated factor, 
followed by Tukey’s post hoc test. Biochemical assays (acetylcholinesterase, 
butyrylcholinesterase, carboxylesterase and muscarinic agonist binding) were analyzed 
using two-way ANOVA (treatment: control, low, high; time-points: 24 hours, 96 hours), 
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followed by a Tukey’s post hoc test. In all cases, p<0.05 was considered to be statistically 
significant.  
 
 
In vivo Studies: CPF and PS 
Heart rate and body temperature data were averaged over diurnal or nocturnal 
intervals and were expressed in terms of mean ± standard error (SE). The total physical 
activity over a diurnal or nocturnal interval was averaged and was expressed as mean ± 
SE. Data were analyzed using SAS statistical software. Diurnal and nocturnal data were 
analyzed individually using one-way repeated measures ANOVA (with time being the 
repeated factor), followed by multiple comparison tests with a Bonferoni adjustment 
factor. In all cases, analysis was adjusted for weight as a time-dependent covariate. Body 
weight data, expressed in terms of percent of day 0, were represented as mean ± SE, and 
were analyzed using one-way repeated measures ANOVA, followed by multiple 
comparison tests with a Bonferoni adjustment factor. SLUD and IM data were reported as 
median ± interquartile range (IQR) and were analyzed using MANOVA. In all cases, 
p<0.05 was considered to be statistically significant. Acetylcholinesterase, 
butyrylcholinesterase and carboxylesterase activities were reported as mean ± SE. 
Muscarinic receptor agonist, [3H]Oxotremorine-M and antagonist [3H]Quinuclidinyl 
benzilate binding values were also represented as mean ± SE. For the CPF and PS adult 
vs aged study, these data were analyzed using two-way ANOVA (age: adult vs aged; 
treatment: control, low, medium, high), followed by a Tukey’s post hoc test. GraphPad 
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Prism  software was used to perform all data analyses and p<0.05 was considered to be 
statistically significant.   
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CHAPTER 3 
RESULTS 
 
Distribution of Cholinesterases in Cortex & Heart of Adult and Aged rats 
 The distribution of AChE and BChE in the heart and brain of adult and aged rats 
was evaluated using the AChE-specific inhibitor BW284C51 (BW), and the BChE-
specific inhibitor iso-OMPA. Figures 12-15 show the titration of AChE & BChE in adult 
heart (Figure 12), aged heart (Figure 13), adult cortex (Figure 14) and aged cortex (Figure 
15), using the selective inhibitors BW & iso-OMPA. The IC50 values of BW against 
AChE activity in heart from adult and aged heart (0.129 µM and 2.67 µM respectively) 
were approximately 10 to 100-fold higher than in adult and aged cortex (30.19 nM and 
48.57 nM respectively). On the other hand, the IC50 values for iso-OMPA against BChE 
in adult and aged heart (0.19 µM and 0.17 µM respectively) were about 10 fold lower 
than in adult and aged cortex (4.39 µM and 1.61 µM respectively).  
Table 1 shows the AChE & BChE content in adult & aged rat heart and cortex. In 
the cortex, the predominant cholinesterase is AChE, with much lower levels of BChE. In 
the heart however, BChE was the predominant cholinesterase, with AChE being present 
to a much lesser extent. No age-related difference was observed in the relative 
composition of the two cholinesterases making up the total cholinesterase activity in 
either of these tissues, however. 
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Figure 12:  In vitro inhibition of AChE and BChE using BW284C51 and iso-OMPA in 
adult rat cardiac tissue homogenates (n=3 per group). Cardiac tissue homogenates from 
adult rats were incubated with iso-OMPA or BW (at the concentrations noted) at 37°C 
for 15 minutes, before assessing the residual ChE activity, as described previously. Data 
(mean ± standard error) represent AChE (triangle) or BChE (square) activity as percent 
of control (i.e., activity in the absence of either inhibitor). 
 72 
-9 -8 -7 -6 -5 -4 -3
0
25
50
75
100
125
Iso-OMPA
BW
log [inhibitor, M]
Ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
 
(%
 
Co
n
tr
o
l)
 
Figure 13:  In vitro inhibition of AChE and BChE using BW284C51 and iso-OMPA in 
aged rat cardiac tissue homogenates (n=3 per group). Cardiac tissue homogenates from 
aged rats were incubated with iso-OMPA or BW (at the concentrations noted) at 37°C for 
15 minutes, before assessing the residual ChE activity, as described previously. Data 
(mean ± standard error) represent AChE (triangle) or BChE (square) activity as percent 
of control (i.e., activity in the absence of either inhibitor).  
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Figure 14:  In vitro inhibition of AChE and BChE using BW284C51 and iso-OMPA in 
adult rat cortical tissue homogenates (n=3 per group). Cortical tissue homogenates from 
adult rats were incubated with iso-OMPA or BW (at the concentrations noted) at 37°C 
for 15 minutes, before assessing the residual ChE activity, as described previously. Data 
(mean ± standard error) represent AChE (triangle) or BChE (square) activity as percent 
of control (i.e., activity in the absence of either inhibitor). 
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Figure 15:  In vitro inhibition of AChE and BChE using BW284C51 and iso-OMPA in 
aged rat cortical tissue homogenates (n=3 per group). Cortical tissue homogenates from 
aged rats were incubated with iso-OMPA or BW (at the concentrations noted) at 37°C for 
15 minutes, before assessing the residual ChE activity, as described previously. Data 
(mean ± standard error) represent AChE (triangle) or BChE (square) activity as percent 
of control (i.e., activity in the absence of either inhibitor). 
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Table 1. Distribution of AChE and BChE activity in the cortex and heart of adult and 
aged rats 
Cortex Heart  
Adult Aged Adult Aged 
AChE (% Total ChE) 90.27 ± 3.72 83.35 ± 4.15 13.86 ± 6.02 14.23 ± 1.18 
BChE (% Total ChE) 8.85 ± 2.71 14.17 ± 3.46 91.59 ± 2.52 82.46 ± 5.07 
 
Cardiac and cortical tissue homogenates were incubated with of iso-OMPA (10 µM) or 
BW (10 µM) at 37°C for 15 minutes, before assessing the residual ChE activity, as 
described in the Methods section. For total cholinesterase activity, the tissue homogenate 
was pre-incubated in potassium phosphate buffer only (i.e., no inhibitor), prior to 
performing the assay. Data (mean ± standard error) represent AChE or BChE activity as 
percent of total ChE activity. 
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In vitro inhibition of Cholinesterases (Acetylcholinesterase & Butyrylcholinesterase) 
in Adult and Aged Heart & Cortex by Chlorpyrifos Oxon and Paraoxon 
The in vitro potencies of chlorpyrifos oxon (CPO) and paraoxon (PO) on cardiac 
and cortical acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) were 
evaluated in crude tissue homogenates from adult and aged rats. Figures 16-23 represent 
the in vitro inhibition of AChE and BChE activity in adult and aged heart and cortex by 
CPO (Figures 16-19) and PO (Figures 20-23). The IC50 values for CPO and PO against 
both cholinesterase activities in the heart and cortex are shown in Tables 2 and 3, 
respectively. In the heart, CPO was significantly less potent against AChE (4 to 11-fold) 
than BChE. While there was no age-related difference in sensitivity of AChE to CPO, 
BChE in the heart from aged rats was significantly more sensitive to CPO than BChE in 
heart of adult rats (~ 2.5 fold). Similarly, CPO was significantly less potent at inhibiting 
cortical AChE (4 to 10-fold) than BChE in brain (cortex) of both age groups. Although 
BChE in the cortex of aged rats appeared about 2-fold more sensitive to the effect of CPO 
than BChE in the cortex of adult rats, this difference was not statistically significant.  
In contrast, PO was a more potent inhibitor of heart AChE than BChE in both age 
groups, with relatively similar differences also being noted in the brain. Furthermore, 
there was no apparent age-related difference in sensitivity of AChE or BChE to PO in 
either tissue.  
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Figure 16: In vitro inhibition of AChE and BChE from adult heart (n=3 per group) using 
chlorpyrifos oxon. Cardiac tissue homogenates from adult rats were pre-incubated with 
either 10 µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were 
incubated at 37°C for 30 minutes in the presence of CPO at the concentrations noted, 
prior to measuring the residual ChE activity as described previously. Data (mean ± 
standard error) represent AChE (triangle with dotted line) or BChE (open circle with 
solid line) activity in terms of percent of control. 
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Figure 17: In vitro inhibition of AChE and BChE from aged heart (n=3 per group) using 
chlorpyrifos oxon. Cardiac tissue homogenates from aged rats were pre-incubated with 
either 10 µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were 
incubated at 37°C for 30 minutes in the presence of CPO at the concentrations noted, 
prior to measuring the residual ChE activity as described previously. Data (mean ± 
standard error) represent AChE (triangle with dotted line) or BChE (open circle with 
solid line) activity in terms of percent of control. 
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Figure 18: In vitro inhibition of AChE and BChE from adult cortex (n=3 per group) using 
chlorpyrifos oxon. Cortical tissue homogenates from adult rats were pre-incubated with 
either 10 µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were 
incubated at 37°C for 30 minutes in the presence of CPO at the concentrations noted, 
prior to measuring the residual ChE activity as described previously. Data (mean ± 
standard error) represent AChE (triangle with dotted line) or BChE (open circle with 
solid line) activity in terms of percent of control. 
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Figure 19: In vitro inhibition of AChE and BChE from aged cortex (n=3 per group) using 
chlorpyrifos oxon. Cortical tissue homogenates from aged rats were pre-incubated with 
either 10 µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were 
incubated at 37°C for 30 minutes in the presence of CPO at the concentrations noted, 
prior to measuring the residual ChE activity as described previously. Data (mean ± 
standard error) represent AChE (triangle with dotted line) or BChE (open circle with 
solid line) activity in terms of percent of control. 
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Figure 20: In vitro inhibition of AChE and BChE from adult heart (n=3 per group) using 
paraoxon. Cardiac tissue homogenates from adult rats were pre-incubated with either 10 
µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were incubated 
at 37°C for 30 minutes in the presence of PO at the concentrations noted, prior to 
measuring the residual ChE activity as described previously. Data (mean ± standard 
error) represent AChE (triangle with dotted line) or BChE (open circle with solid line) 
activity in terms of percent of control. 
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Figure 21: In vitro inhibition of AChE and BChE from aged heart (n=3 per group) using 
paraoxon. Cardiac tissue homogenates from aged rats were pre-incubated with either 10 
µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were incubated 
at 37°C for 30 minutes in the presence of PO at the concentrations noted, prior to 
measuring the residual ChE activity as described previously. Data (mean ± standard 
error) represent AChE (triangle with dotted line) or BChE (open circle with solid line) 
activity in terms of percent of control. 
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Figure 22: In vitro inhibition of AChE and BChE from adult cortex (n=3 per group) using 
paraoxon. Cortical tissue homogenates from adult rats were pre-incubated with either 10 
µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were incubated 
at 37°C for 30 minutes in the presence of PO at the concentrations noted, prior to 
measuring the residual ChE activity as described previously. Data (mean ± standard 
error) represent AChE (triangle with dotted line) or BChE (open circle with solid line) 
activity in terms of percent of control. 
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Figure 23: In vitro inhibition of AChE and BChE from aged cortex (n=3 per group) using 
paraoxon. Cortical tissue homogenates from aged rats were pre-incubated with either 10 
µM iso-OMPA or 10 µM BW at 37°C for 15 minutes. Subsequently, they were incubated 
at 37°C for 30 minutes in the presence of PO at the concentrations noted, prior to 
measuring the residual ChE activity as described previously. Data (mean ± standard 
error) represent AChE (triangle with dotted line) or BChE (open circle with solid line) 
activity in terms of percent of control. 
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Table 2. IC50 values of chlorpyrifos oxon and paraoxon against AChE and BChE activity 
in adult and aged rat heart 
Adult Aged  
AChE BChE AChE BChE 
CPO 31.53 nM# 8.47 nM 35.46 nM# 3.27 nM* 
PO 25.3 nM 42.8 nM 23.5 nM 40.4 nM 
 
Cardiac tissue homogenates were pre-incubated with either 10 µM iso-OMPA or 10 µM 
BW at 37°C for 15 minutes. Thereafter, they were incubated at 37°C for 30 minutes in 
the presence of either CPO (30 pM to 3 µM) or PO (100 pM to 10 µM), prior to 
measuring the residual ChE activity as described previously. Data represents the mean 
IC50 for each inhibitor against each enzyme from three separate experiments. The pound 
signs represents values significantly different from BChE in the same age-group, while 
asterisks represent values significantly different from BChE in the adult (P<0.05).  
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Table 3. IC50 of chlorpyrifos oxon and paraoxon against AChE and BChE activity in 
adult and aged cortex  
Adult Aged  
AChE BChE AChE BChE 
CPO 6.64 nM# 1.58 nM 7.21 nM# 0.69 nM 
PO 18.7 nM 28.5 nM 19.5 nM 32.1 nM 
 
Cortical tissue homogenates were pre-incubated with either 10 µM iso-OMPA or 10 µM 
BW at 37°C for 15 minutes. Subsequently, they were incubated at 37°C for 30 minutes in 
the presence of either CPO (30 pM to 3 µM) or PO (100 pM to 10 µM), prior to 
measuring the residual ChE activity as described previously. Data represents the mean 
IC50 for each inhibitor against each enzyme from three separate experiments. Pound signs 
represent values significantly different from BChE in the same age-group (P<0.05).  
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In Vitro Displacement of [3H]Oxotremorine-M Binding by CPO and PO  
in Adult and Aged Heart and Cortex 
The abilities of chlorpyrifos oxon (CPO) and paraoxon to displace 
[3H]Oxotremorine-M ([3H]OXO) binding were evaluated in adult and aged cardiac and 
cortical membranes. Figures 24-27 show the displacement of [3H]OXO in heart and 
cortex from adult & aged rats by CPO (Figures 24 and 25) and PO (Figures 26 and 27). 
The IC50 and maximum percent displacement for each OP are summarized in Table 4. 
Both CPO and PO displaced [3H]OXO binding in heart and cortex of adult and aged rats. 
Of the two, CPO was the more potent displacer of [3H]OXO in the heart and cortex of 
both age-groups. Similarly, PO also potently displaced [3H]OXO from adult and aged 
cardiac and cortical membranes. Both OPs appeared to have similar efficacies in 
displacing [3H]OXO binding in heart and cortex of the two age-groups. No age-related 
difference was observed in displacement of [3H]OXO binding in either tissue.  
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Figure 24. In vitro displacement of [3H]OXO by chlorpyrifos oxon in adult and aged 
heart (n=3 per group). Cardiac membranes from adult (square) and aged (triangle) rats 
were incubated at 21ºC for 90 minutes in the presence of 1 nM [3H]OXO and CPO at the 
concentrations noted. Atropine (10 µM) was used in paired tubes to block specific 
binding, which was calculated as the binding between tubes incubated in the presence and 
absence of atropine. Data (mean ± standard error) represent specific binding in terms of 
percent of control. 
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Figure 25. In vitro displacement of [3H]OXO by chlorpyrifos oxon in adult and aged 
cortex (n=3 per group). Cortical membranes from adult (square) and aged (triangle) rats 
were incubated at 21ºC for 90 minutes in the presence of 1 nM [3H]OXO and CPO at the 
concentrations noted. Atropine (10 µM) was used in paired tubes to block specific 
binding, which was calculated as the binding between tubes incubated in the presence and 
absence of atropine. Data (mean ± standard error) represent specific binding in terms of 
percent of control. 
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Figure 26. In vitro displacement of [3H]OXO by paraoxon in adult and aged heart (n=3 
per group). Cardiac membranes from adult (square) and aged (triangle) rats were 
incubated at 21ºC for 90 minutes in the presence of 1 nM [3H]OXO and PO at the 
concentrations noted. Atropine (10 µM) was used in paired tubes to block specific 
binding, which was calculated as the binding between tubes incubated in the presence and 
absence of atropine. Data (mean ± standard error) represent specific binding in terms of 
percent of control. 
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Figure 27. In vitro displacement of [3H]OXO by paraoxon in adult and aged cortex (n=3 
per group). Cortical membranes from adult (square) and aged (triangle) rats were 
incubated at 21ºC for 90 minutes in the presence of 1 nM [3H]OXO and PO at the 
concentrations noted. Atropine (10 µM) was used in paired tubes to block specific 
binding, which was calculated as the binding between tubes incubated in the presence and 
absence of atropine. Data (mean ± standard error) represent specific binding in terms of 
percent of control. 
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Table 4. In vitro displacement of [3H]Oxotremorine-M binding in adult and aged rat heart 
and cortex using chlorpyrifos oxon and paraoxon  
CPO PO  
IC50 Maximum 
displacement 
IC50 Maximum 
displacement 
Adult Heart 6.4 nM 50.27 ± 3.13% 17.9 nM 54.5 ± 1.28% 
Aged Heart 9.7 nM 39.38 ± 3.47% 33.1 nM 58.39 ± 3.51% 
Adult Cortex 7.3 nM 50.83 ± 2.04% 39.1 nM 55.02 ± 4.51% 
Aged Cortex 17.3 nM 49.1 ± 2.75% 43.9 nM 48.22 ± 2.75% 
 
Cardiac and cortical membranes (n=3/group) were incubated at 21ºC for 90 minutes in 
the presence of 1 nM [3H]Oxotremorine-M acetate and one of a range of OP (CPO or PO) 
concentrations as described in the Methods section. Atropine (10 µM) was used in paired 
tubes to block specific binding, which was calculated as the binding between tubes 
incubated in the presence and absence of atropine. Data represent the mean IC50 value 
and percent maximum displacement (mean ± S.E.) of [3H]OXO from three individual 
experiments.  
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Effects of Various Doses of iso-OMPA on Acetylcholinesterase, 
Butyrylcholinesterase and Carboxylesterase from Atria, Ventricles and Cortex 
In order to determine doses of iso-OMPA that would selectively inhibit only 
cardiac BChE in the absence of central AChE inhibition, a dose-determination study was 
performed in vivo, using various doses of iso-OMPA (1.25 to 100 mg/kg, sc). In addition 
to AChE and BChE activity, carboxylesterase (CarbE) activity was also evaluated, since 
iso-OMPA is a potent inhibitor of this enzyme. Figures 28-36 show the dose-related 
effects of iso-OMPA on AChE, BChE and CarbE in atria (Figures 28-30), ventricles  
(Figures 31-33) and cortex (Figures 34-36).  
 Iso-OMPA elicited a dose-dependent inhibition of BChE activity in the atria, 
ventricles and brain, with a maximal selective inhibition of ~85%. Higher doses of iso-
OMPA led to non-specific inhibition of AChE activity. From this study, it was 
determined that 1.25 and 5 mg/kg of iso-OMPA, which selectively inhibited 60-65% and 
75-80% cardiac (atrial & ventricular) BChE respectively, did not inhibit AChE activity in 
either any tissue. Of these two dosages, 5 mg/kg elicited significant inhibition of CarbE 
(10-60%) activity. We therefore selected these two dosages for subsequent studies.  
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Figure 28: The effects of various doses of iso-OMPA on acetylcholinesterase activity in 
atrium. Rats (n=3-7/dose group) were treated subcutaneously with iso-OMPA at the 
doses indicated and sacrificed 24 hours later. Atrial tissue homogenates were pre-
incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. The highest doses of iso-OMPA (50 and 100 
mg/kg) inhibited AChE activity in the atria. Data (mean ± standard error) represent AChE 
activity in terms of percent of control. The asterisk, pound, dollar, a, and b signs represent 
values that are significantly different from control, 1.25, 2.5, 5 and 25 mg/kg dose-
groups, respectively. 
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Figure 29: The effects of various doses of iso-OMPA on butyrylcholinesterase activity in 
atrium. Rats (n=3-7/dose group) were treated subcutaneously with iso-OMPA at the 
doses indicated and sacrificed 24 hours later. Atrial tissue homogenates were pre-
incubated with 10 µM BW284C51 at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. A dose-dependent inhibition of BChE was observed 
with the lower doses, with maximal BChE inhibition plateauing at ~85% in rats treated 
with > 5 mg/kg of iso-OMPA. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and the 1.25 mg/kg dose group, respectively. 
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Figure 30: The effects of various doses of iso-OMPA on carboxylesterase activity in 
atrium. Rats (n=3-7/dose group) were treated subcutaneously with iso-OMPA at the 
doses indicated and sacrificed 24 hours later. Atrial tissue homogenates were incubated at 
37°C in the presence of the substrate p-nitrophenyl acetate to assess CarbE activity. Iso-
OMPA produced a dose-dependent inhibition of CarbE activity in the atria. Data (mean ± 
standard error) represent CarbE activity in terms of percent of control. The asterisk, 
pound, and dollar signs represent values that are significantly different from control, 1.25 
and 2.5 mg/kg dose group, respectively. 
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Figure 31: The effects of various doses of iso-OMPA on acetylcholinesterase activity in 
ventricular tissue homogenates. Rats (n=3-7/dose group) were treated subcutaneously 
with iso-OMPA at the doses indicated and sacrificed 24 hours later. Ventricular tissue 
homogenates were pre-incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to 
measuring the residual ChE activity as described previously. No significant inhibition of 
AChE was obtained with any of the dose groups. Data (mean ± standard error) represent 
AChE activity in terms of percent of control.  
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Figure 32: The effects of various doses of iso-OMPA on butyrylcholinesterase activity in 
ventricular tissue homogenates. Rats (n=3-7/dose group) were treated subcutaneously 
with iso-OMPA at the doses indicated and sacrificed 24 hours later. Ventricular tissue 
homogenates were pre-incubated with 10 µM BW284C51 at 37°C for 15 minutes prior to 
measuring the residual ChE activity as described previously. Iso-OMPA produced a dose-
dependent inhibition of BChE activity in the ventricles. Data (mean ± standard error) 
represent BChE activity in terms of percent of control. The asterisk and pound signs 
represent values that are significantly different from control and the 1.25 mg/kg dose 
group, respectively. 
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Figure 33: The effects of various doses of iso-OMPA on carboxylesterase activity in 
ventricular tissue homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA 
(sc) at the doses indicated and sacrificed 24 hours later. Ventricular tissue homogenates 
were incubated at 37°C in the presence of the substrate p-nitrophenyl acetate to assess 
CarbE activity. Iso-OMPA produced a dose-dependent inhibition of CarbE activity in the 
ventricles. Data (mean ± standard error) represent CarbE activity in terms of percent of 
control. The asterisk, pound, dollar, a, and b signs represent values that are significantly 
different from control, 1.25, 2.5, 5 and 25 mg/kg dose-groups, respectively. 
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Figure 34: The effects of various doses of iso-OMPA on acetylcholinesterase activity in 
cortical tissue homogenates. Rats (n=3-7/dose group) were treated subcutaneously with 
iso-OMPA at the doses indicated and sacrificed 24 hours later. Cortical tissue 
homogenates were pre-incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to 
measuring the residual ChE activity as described previously. No significant inhibition of 
AChE was obtained with any of the dose groups. Data (mean ± standard error) represent 
AChE activity in terms of percent of control.  
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Figure 35: The effects of various doses of iso-OMPA on BChE activity in cortical tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 hours later. Cortical tissue homogenates were pre-incubated 
with 10 µM BW at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. The lower doses of iso-OMPA (1,25, 2.5 and 5 mg/kg) did not 
cause significant inhibition of cortical BChE, while the higher doses (≥15 mg/kg) 
produced a dose-dependent inhibition of BChE activity in the cortex. Data (mean ± 
standard error) represent BChE activity in terms of percent of control. The asterisk, 
pound, dollar, and a signs represent values that are significantly different from control, 
1.25, 2.5 and 5 mg/kg dose-groups, respectively. 
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Figure 36: The effects of various doses of iso-OMPA on carboxylesterase activity in 
cortical tissue homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at 
the doses indicated and sacrificed 24 hours later. Cortical tissue homogenates were 
incubated at 37°C in the presence of the substrate p-nitrophenyl acetate to assess CarbE 
activity. Iso-OMPA produced a dose-dependent inhibition of CarbE activity in the cortex 
with doses ≥ 5 mg/kg. Data (mean ± standard error) represent CarbE activity in terms of 
percent of control. The asterisk, pound and dollar signs represent values that are 
significantly different from control, 1.25 and 2.5 mg/kg dose groups, respectively. 
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Effects of iso-OMPA on Heart Rate, Body Temperature and Physical Activity 
 In Adult Male Sprague-Dawley Rats 
The effects of iso-OMPA on heart rate, body temperature and physical activity 
were evaluated upto 96 hours post-treatment. From the dose-determination studies, 1.25 
and 5 mg/kg were selected as the low and high dose groups, respectively. Neither of the 
two doses of iso-OMPA produced any effect on body weight or functional signs of 
toxicity (data not shown).  
The low and high doses of iso-OMPA produced a decrease in heart rate (Figures 
37-39) at 24 hours post-treatment, with recovery occuring thereafter. The magnitude of 
the heart rate decrease was greater in the low dose than the high dose group. Compared to 
their baseline (pre-treatment) values, diurnal heart rate was significantly reduced towards 
the end of the study in the high dose group (84 hours post-treatment), low dose group 
(108 hours post-treatment), and interestingly, also in the control group. On the other 
hand, heart rate was significantly reduced at 24 (low and high dose groups) and 48 (low 
dose group) hours post-treatment, with subsequent recovery occurring thereafter. Since 
most of the effects of iso-OMPA on heart rate seemed to occur upto 48 hours post-
treatment, heart rate was grouped into 4 hourly intervals and evaluated upto 48 hours 
post-treatment (Figure 40). The low and high doses of iso-OMPA produced a decrease in 
heart rate 16-20 hours post-treatment, with subsequent recovery occuring thereafter. 
Although there appeared to be a reduction of heart rate 36-40 hours post-treatment in the 
low and high dose-groups, it was not statistically significant.  
Neither dose of iso-OMPA produced any effect on body temperature (Figures 41-
43) at any of the time points examined. Physical activity (Figures 44-46) was only 
 104 
significantly reduced in the low dose group of iso-OMPA at 72 hours post-treatment (in 
the nocturnal phase), with subsequent recovery occurring to pre-treatment values.  
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Figure 37:  The effects of various doses of iso-OMPA on heart rate in adult rats. Rats 
(n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and sacrificed 
24 or 96 hours later. This figure shows 24 hour baseline (pre-treatment) heart rate with 
the following 96 hours post-treatment data. The data (mean ± standard error) represent 
heart rate averaged over 8 hour diurnal and nocturnal intervals. The low and high doses 
of iso-OMPA elicited decreases in heart rate at 24 hours post-treatment, with subsequent 
recovery. The asterisk and pound signs represent values that are significantly different 
from control, and 1.25 mg/kg dose groups at the same time point, respectively.
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Figure 38:  The effects of various doses of iso-OMPA on heart rate in adult rats during 
the diurnal (light) periods. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at 
the doses indicated and sacrificed 24 or 96 hours later. This figure shows baseline (pre-
treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents heart rate averaged over subsequent 8-hour diurnal intervals. The low 
and high doses of iso-OMPA produced a decrease in heart rate at 108 and 84 hours post-
treatment, respectively. a, b, and c represent values that are significantly different from 
the same dose at 12, 36 and 60 hours, respectively. Note that controls also exhibited a  
time-dependent reduction in diurnal heart rate. 
 107 
0 24 48 72 96 120 144
370
380
390
400
410
420
430
440
Control
Low dose (1.25 mg/kg)
High dose (5 mg/kg)Treatment
a
a
a
Time (Hours)
H
ea
rt
 
Ra
te
 
(B
ea
ts
 
Pe
r 
 
M
in
u
te
)
 
Figure 39:  The effects of various doses of iso-OMPA on heart rate in adult rats during 
the nocturnal (dark) periods. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at 
the doses indicated and sacrificed 24 or 96 hours later. This figure shows 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents heart rate averaged over subsequent 8-hour nocturnal intervals. 
The low and high doses of iso-OMPA produced a decrease in heart rate at 24 hours post-
treatment. a represents values that are significantly different from the same dose at 24 
hours.
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Figure 40:  The effects of various doses of iso-OMPA on heart rate in adult rats. Rats 
(n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and sacrificed 
24 or 96 hours later. This figure shows 24 hour baseline (pre-treatment) data followed by 
48 hours post-treatment data. The data (mean ± standard error) represent heart rate 
averaged over 4 hourly intervals. The low and high doses of iso-OMPA produced a 
decrease in heart rate 16-20 hours post-treatment, with subsequent recovery occuring. 
The asterisk and pound signs represent values that are significantly different from 
control, and 1.25 mg/kg dose groups at the same time point, respectively.
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Figure 41:  The effects of various doses of iso-OMPA on body temperature in adult rats. 
Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and 
sacrificed 24 or 96 hours later. This figure shows 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
body temperature averaged over diurnal and nocturnal intervals (8 hours). Body  
temperature was not significantly affected by iso-OMPA.
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Figure 42:  The effects of various doses of iso-OMPA on body temperature in adult rats 
during the diurnal (light) periods. Rats (n=3-7/dose group) were treated with iso-OMPA 
(sc) at the doses indicated and sacrificed 24 or 96 hours later. This figure shows 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents body temperature averaged over 8 hour diurnal intervals. Body 
temperature was not significantly affected by iso-OMPA.
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Figure 43:  The effects of various doses of iso-OMPA on body temperature in adult rats 
during the nocturnal (dark) periods. Rats (n=3-7/dose group) were treated with iso-
OMPA (sc) at the doses indicated and sacrificed 24 or 96 hours later. This figure shows 
24 hour baseline (pre-treatment) data followed by 96 hours post-treatment data. The data 
(mean ± standard error) represents body temperature averaged over 8 hour nocturnal 
intervals. Body temperature was not significantly affected by iso-OMPA.
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Figure 44:  The effects of various doses of iso-OMPA on physical activity in adult rats. 
Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and 
sacrificed 24 or 96 hours later. This figure shows 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
physical activity averaged over 8 hour diurnal and nocturnal intervals. Physical activity 
was not significantly affected by iso-OMPA. 
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Figure 45:  The effects of various doses of iso-OMPA on physical activity in adult rats 
during the diurnal (light) periods. Rats (n=3-7/dose group) were treated with iso-OMPA 
(sc) at the doses indicated and sacrificed 24 or 96 hours later. This figure shows 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents physical activity averaged over 8 hour diurnal intervals.  
Physical activity was not significantly affected by iso-OMPA.
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Figure 46:  The effects of various doses of iso-OMPA on physical activity in adult rats 
during the nocturnal (dark) periods. Rats (n=3-7/dose group) were treated with iso-
OMPA (sc) at the doses indicated and sacrificed 24 or 96 hours later. This figure shows 
24 hour baseline (pre-treatment) data followed by 96 hours post-treatment data. The data 
(mean ± standard error) represents physical activity averaged over 8 hour nocturnal 
intervals. Physical activity was reduced by the low dose of iso-OMPA 72 hours post-
treatment. a, and d represent values that are significantly different from the same dose at 
24 and 96 hours, respectively. 
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In vitro Inhibition of Butyrylcholinesterase and Displacement of [3H]Oxotremorine 
Binding by iso-OMPA in Adult Heart 
The ability of iso-OMPA to inhibit BChE and displace [3H]OXO binding in vitro 
was evaluated in adult rat heart. Figure 47 represents the in vitro inhibition of BChE and 
displacement of [3H]OXO binding in cardiac tissue preps from adult rats. In addition to 
inhibiting BChE, iso-OMPA was found to be capable of displacing [3H]OXO binding in 
the heart. Iso-OMPA was approximately three orders of magnitude more potent at 
inhibiting BChE (IC50: 188 nM) than displacing [3H]OXO binding (IC50: 116 µM).  This 
indicates that at low concentrations, iso-OMPA inhibits BChE, and as the concentration 
of iso-OMPA increases, it recruits an additional mechanism of action, via direct binding 
to muscarinic receptors.  
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Figure 47: In vitro inhibition of butyrylcholinesterase and displacement of 
[3H]Oxotremorine-M in adult rat heart. For the BChE assay, cardiac tissue homogenates 
were incubated with iso-OMPA at the concentrations noted at 37°C for 15 minutes, prior 
to measuring the residual ChE activity as described previously. For the [3H]OXO 
displacement assay, cardiac membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Oxotremorine-M and iso-OMPA at the concentrations noted. 
Atropine (10 µM) was used in paired tubes to block specific binding, which was 
calculated as the binding between tubes incubated in the presence and absence of 
atropine. Data (mean ± standard error) represent BChE activity (triangle with dotted line) 
or [3H]OXO (square with solid line) in terms of percent of control. 
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Total Cholinesterase, Acetylcholinesterase, Butyrylcholinesterase and 
Carboxylesterase Activities in Atria, Ventricles, Cortex  
and Plasma of Adult Rats 
The levels of total ChE, AChE, BChE and CarbE in the atria, ventricles, cortex 
and plasma of adult rats were evaluated using the AChE-specific inhibitor BW284C51, 
the BChE-specific inhibitor iso-OMPA, and the CarbE substrate, p-nitrophenyl acetate. 
Table 5 shows the total ChE, AChE, BChE and CarbE content in the atria, ventricles, 
cortex and plasma of adult rats. 
In agreement with our earlier observations, the total cholinesterase activity in the 
cortex is comprised of 90% AChE and 10% BChE. The total ChE in the ventricles is 
made up of ~90% BChE and 10% AChE, while in the atria, 80% BChE and 20% AChE 
make up the total ChE. Atria contains ~2.5-fold more cholinesterase activity (4 times 
more AChE activity and 2 times more BChE activity), and 1.5-fold more 
carboxylesterase activity than the ventricles. Plasma was found to be comprised of ~70% 
AChE and ~30% BChE. Plasma had the most cholinesterase and carboxylesterase 
activites, followed by the cortex, atria and ventricles (plasma>cortex>atria>ventricles). 
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Table 5. Total cholinesterase, acetylcholinesterase, butyrylcholinesterase and 
carboxylesterase activities in atria, ventricles, cortex and plasma of adult, male Sprague-
Dawley rats. 
 Total ChE AChE BChE CarbE 
Ventricles 8.54  ±  0.45 0.89  ±  0.09 7.83  ±  0.36 68.03  ±  3.7 
Atria 19.67  ±  1.08 3.99  ±  0.39 16.92  ±  1.01 90.66  ±  4.02 
Cortex 28.45  ±  2.35 26.59  ±  2.39 1.29  ±   0.13 108.36  ±  3.12 
Plasma 246.04  ±  11.49 170.76   ±  10.37 79.33  ±  5.65 1806.70  ±  99.18 
 
Atrial, ventricular and cortical tissue homogenates were incubated with 10 µM of iso-
OMPA or BW at 37°C for 15 minutes, before assessing the residual ChE activity, to 
obtain AChE and BChE activities, respectively. For total ChE activity, the tissue 
homogenates were pre-incubated in buffer (no inhibitor), prior to performing the assay. 
Carboxylesterase activity was assessed following incubation of the tissue homogenates at 
37°C in the presence of the substrate p-nitrophenyl acetate. Data (mean ± standard error) 
represent enzyme activities in terms of nmol of substrate hydrolyzed/mg protein/minute 
or nmol of substrate hydrolyzed/ml plasma/minute. 
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Effects of iso-OMPA on Acetylcholinesterase, Butyrylcholinesterase, 
Carboxylesterase and Muscarinic Receptor Binding in Ventricles, Atria, Cortex and 
Plasma 24 and 96 Hours Post-Treatment 
The effects of iso-OMPA on AChE, BChE, CarbE and muscarinic receptor 
binding were evaluated at 24 and 96 hours post-treatment.  In addition to the atria, 
ventricles and cortex, which were assessed during the dose-determination studies, plasma 
was also included in this study, since it has been found to contain significant amounts of 
BChE and CarbE, both of which are inhibited by iso-OMPA.  
 Iso-OMPA produced a dose-dependent inhibition of BChE (Figures 48, 52, 56 
and 59) and CarbE (Figures 50, 54, 58 and 61) in all of the tissues investigated. Iso-
OMPA inhibited ~60% (low dose) to 80% (high dose) BChE activity in the atria, 
ventricles and plasma at the 24 hour time point, with enzyme recovery occurring by the 
96 hour time point. In the cortex, only the high dose produced a significant inhibition of 
BChE at the 24 hour time point, with enzyme recovery occuring by the 96 hour time 
point. The amount of CarbE inhibited by iso-OMPA at the 24 hour time point ranged 
from ~10% (atria and ventricles) to 30% (plasma) for the low dose, and 10% (cortex) to 
~40% (atria, ventricles and plasma) for the high dose. The amount of CarbE inhibited 
remained approximately the same by 96 hours post-treatment for all tissues, except the 
ventricles, wherein the high dose of iso-OMPA caused further inhibition of CarbE.  
 Neither of the two doses of iso-OMPA used in the study produced any inhibition 
of AChE (Figures 49, 53, 57 and 60) at the 24 and 96 hour time points, thereby 
confirming their selectivity for BChE. However, in the atria, the high dose of iso-OMPA 
had significantly higher levels of AChE at the 24 hour time point. Similarly, the low dose 
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of iso-OMPA also had elevated levels of AChE in the cortex at the 24 and 96 hour time 
points.  
 Muscarinic receptor binding (Figures 51 and 55) was evaluated by using the 
agonist [3H]Oxotremorine-M. Muscarinic receptors were significantly downregulated 
(~25%) by the high dose of iso-OMPA in the ventricles at 24 hours, with recovery 
occurring by 96 hours post-treatment. Approximately 20% downregulation of muscarinic 
receptors occurred in the low and high dose groups of iso-OMPA in the atria at 24 hours 
post-treatment, which persisted until 96 hours.  
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Figure 48: The effects of iso-OMPA on butyrylcholinesterase activity in ventricular 
tissue homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the 
doses indicated and sacrificed 24 or 96 hours later. Ventricular tissue homogenates were 
pre-incubated with 10 µM BW284C51 at 37°C for 15 minutes prior to measuring the 
residual ChE activity as described previously. Iso-OMPA produced a dose-dependent 
inhibition of BChE activity in the ventricles at 24 hours with apparent enzyme recovery 
occurring by 96 hours post-treatment. Data (mean ± standard error) represent BChE 
activity in terms of percent of control. The asterisks and pound represent values that are 
significantly different from control and 1.25 mg/kg dose groups at the same time point, 
respectively, while the dollar sign represents values that are significantly different from 
the same dose at the 24 hour time point.  
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Figure 49: The effects of iso-OMPA on acetylcholinesterase activity in ventricular tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Ventricular tissue homogenates were pre-
incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. Iso-OMPA did not inhibit AChE at any of the doses 
at the 24 or 96 hour time point. Data (mean ± standard error) represent AChE activity in 
terms of percent of control.  
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Figure 50: The effects of iso-OMPA on carboxylesterase activity in ventricular tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Ventricular tissue homogenates were 
incubated at 37°C in the presence of the substrate p-nitrophenyl acetate to assess CarbE 
activity. Iso-OMPA produced a dose-related inhibition of CarbE activity in the ventricles 
at the 24 and 96 hour time points, with further enzyme inhibition occurring in the high 
dose group at the 96 hour time point. Data (mean ± standard error) represent CarbE 
activity in terms of percent of control. The asterisk and pound signs represent values that 
are significantly different from control and 1.25 mg/kg dose groups at the same time 
point, respectively, while the dollar sign represents values that are significantly different 
from the same dose at the 24 hour time point.  
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Figure 51: The effects of iso-OMPA on muscarinic receptor binding in ventricular 
membranes. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Membranes were incubated at 21ºC for 90 
minutes in the presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine 
(to determine specific binding). Data (mean ± standard error) represent specific binding 
in terms of percent of control. Iso-OMPA produced a downregulation of muscarinic 
receptors in the high dose-group at 24 hours post-treatment, with apparent recovery to 
control values by 96 hours. Data (mean ± standard error) represent [3H]OXO binding in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 1.25 mg/kg dose groups at the same time point, 
respectively.  
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Figure 52: The effects of iso-OMPA on butyrylcholinesterase activity in atrial tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Atrial tissue homogenates were pre-
incubated with 10 µM BW284C51 at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. Iso-OMPA produced a dose-dependent inhibition 
of BChE activity in the atria at 24 hours with apparent enzyme recovery occurring by 96 
hours post-treatment. Data (mean ± standard error) represent BChE activity in terms of 
percent of control. The asterisk and pound signs represent values that are significantly 
different from control and 1.25 mg/kg dose groups at the same time point, respectively, 
while the dollar sign represents values that are significantly different from the same dose 
at the 24 hour time point.  
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Figure 53: The effects of iso-OMPA on acetylcholinesterase activity in atrial tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Atrial tissue homogenates were pre-
incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. Iso-OMPA did not inhibit AChE at any of the doses 
at the 24 or 96 hour time point. In fact, the AChE activity in the high dose group was 
found to be significantly higher than the control at the 24 hour time point. Data (mean ± 
standard error) represent AChE activity in terms of percent of control. Asterisks represent 
values that are significantly different from control at the same time point. 
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Figure 54: The effects of iso-OMPA on carboxylesterase activity in atrial tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Atrial tissue homogenates were incubated at 
37°C in the presence of the substrate p-nitrophenyl acetate to assess CarbE activity. Iso-
OMPA produced a dose-dependent inhibition of CarbE activity in the ventricles at the 24 
and 96 hour time points, with relatively similar amounts of enzyme being inhibited at the 
2 time points. Data (mean ± standard error) represent CarbE activity in terms of percent 
of control. The asterisk and pound signs represent values that are significantly different 
from control and 1.25 mg/kg dose groups at the same time point.  
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Figure 55: The effects of iso-OMPA on muscarinic receptor binding in atrial membranes. 
Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and 
sacrificed 24 or 96 hours later. Membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to determine 
specific binding). Data (mean ± standard error) represent specific binding in terms of 
percent of control. Iso-OMPA produced a downregulation of muscarinic receptors in the 
low and high dose-group at both, the 24 and 96 hour time points. Data (mean ± standard 
error) represent [3H]OXO binding in terms of percent of control. Asterisks represent 
values that are significantly different from control at the same time point.  
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Figure 56: The effects of iso-OMPA on butyrylcholinesterase activity in cortical tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Cortical tissue homogenates were pre-
incubated with 10 µM BW284C51 at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. Iso-OMPA produced a significant inhibition of 
BChE activity in the cortex at 24 and 96 hours, with apparent enzyme recovery occurring 
by 96 hours post-treatment. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 1.25 mg/kg dose groups at the same time point, 
respectively, while the dollar sign represents values that are significantly different from 
the same dose at the 24 hour time point. 
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Figure 57: The effects of iso-OMPA on acetylcholinesterase activity in cortical tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Cortical tissue homogenates were pre-
incubated with 10 µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual 
ChE activity as described previously. Iso-OMPA did not inhibit AChE at any of the doses 
at the 24 or 96 hour time point. However, the AChE activity in the low dose group was 
found to be significantly higher than the control at the 24 and 96 hour time points. Data 
(mean ± standard error) represent AChE activity in terms of percent of control. The 
asterisk and pound signs represent values that are significantly different from control and 
1.25 mg/kg dose groups at the same time point.  
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Figure 58: The effects of iso-OMPA on carboxylesterase activity in cortical tissue 
homogenates. Rats (n=3-7/dose group) were treated with iso-OMPA (sc) at the doses 
indicated and sacrificed 24 or 96 hours later. Cortical tissue homogenates were incubated 
at 37°C in the presence of the substrate p-nitrophenyl acetate to assess CarbE activity. 
Iso-OMPA significantly inhibited CarbE activity in the high dose group at the 24 and 96 
hour time points, with relatively similar amounts of enzyme being inhibited at the 2 time 
points. Data (mean ± standard error) represent CarbE activity in terms of percent of 
control. The asterisk and pound signs represent values that are significantly different 
from control and 1.25 mg/kg dose groups at the same time point. 
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Figure 59: The effects of iso-OMPA on butyrylcholinesterase activity in plasma. Rats 
(n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and sacrificed 
24 or 96 hours later. Diluted plasma samples were pre-incubated with 10 µM BW284C51 
at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. Iso-OMPA produced a significant inhibition of BChE activity in the plasma 
at 24 hours, with apparent enzyme recovery occurring by 96 hours post-treatment. Data 
(mean ± standard error) represent BChE activity in terms of percent of control. The 
asterisk and pound signs represent values that are significantly different from control and 
1.25 mg/kg dose groups at the same time point, respectively, while the dollar sign 
represents values that are significantly different from the same dose at the 24 hour time 
point.
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Figure 60: The effects of iso-OMPA on acetylcholinesterase activity in plasma. Rats 
(n=3-7/dose group) were treated with iso-OMPA (sc) at the doses indicated and sacrificed 
24 or 96 hours later. Diluted plasma samples were pre-incubated with 10 µM iso-OMPA 
at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. Iso-OMPA did not inhibit AChE at either dose or at either the 24 or 96 hour 
time point. Data (mean ± standard error) represent AChE activity in terms of percent of 
control.  
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Figure 61: The effects of iso-OMPA on carboxylesterase activity in plasma. Rats (n=3-
7/dose group) were treated with iso-OMPA (sc) at the doses indicated and sacrificed 24 
or 96 hours later. Diluted plasma samples were incubated at 37°C in the presence of the 
substrate p-nitrophenyl acetate to assess CarbE activity. Iso-OMPA produced a dose-
dependent inhibition of CarbE activity in the plasma at the 24 and 96 hour time points. 
Data (mean ± standard error) represent CarbE activity in terms of percent of control. The 
asterisk and pound signs represent values that are significantly different from control and 
1.25 mg/kg dose groups at the same time point, respectively.  
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Effects of Acute Chlorpyrifos or Parathion Exposure on Body Weight, Involuntary 
Movements and SLUD Signs in Adult and Aged Rats 
The effects of acute CPF and PS exposure on body weight, involuntary 
movements and SLUD (i.e., salivation, lacrimation, urination and defecation) were 
evaluated in adult and aged rats. For the CPF study, adult and aged rats were treated with 
vehicle (peanut oil), 0.1 x MTD (low dose), 0.5 x MTD (medium dose) and 1 x MTD 
(high dose), while for the PS study, rats of the two age-groups were treated with vehicle 
(peanut oil), 0.5 x MTD (low dose), 0.75 x MTD (medium dose) and 1 x MTD (high 
dose). Functional signs of toxicity (IM and SLUD) and body weight were monitored 
every 24 hours following CPF or PS exposure.  
Figures 62 and 63 show changes in body weight  following CPF exposure in adult 
and aged rats, respectively. CPF produced a dose-dependent decrease in body weight, 
which persisted until the end of the study in the medium and high dose groups of adult 
and aged rats. In adult rats, the decrease in body weight (15% reduction compared to day 
0) peaked 48 hours after treatment in the medium and high dose-groups, after which it 
stayed at that level in the high dose, and showed a trend towards recovery in the medium 
dose, until the end of the study. In aged rats, body weight reduction peaked at 24 hours 
(5% reduction compared to day 0) in the medium dose group, after which it showed a 
trend towards recovery. In the high dose group, body weight decrease reached a 
maximum (10% reduction compared to day 0) by 72 hours post-treatment, and this 
persisted until the end of the study.  
Figures 64 and 65 represent changes in body weight  following PS exposure in 
adult and aged rats, respectively. PS produced a dose-dependent decrease in body weight, 
 136 
which persisted until the end of the study in the medium and high dose groups of adult 
and aged rats. In adult rats, the decrease in body weight peaked 48 hours after treatment 
in the medium dose-group and 72 hours after treatment in the high dose-group, and this 
persisted until the end of the study. In aged rats, body weight decrease peaked at 48 hours 
in the medium dose group and at 72 hours in the medium dose group, and body weight 
stayed at these levels until the end of the study in both dose groups.  
Tables 6-9 show the functional signs of toxicity [involuntary movements (IM) and 
SLUD signs (i.e., salivation, lacrimation, urination and defecation)] after acute exposure 
to CPF in adult and aged rats. Although CPF produced some signs of toxicity (mainly 
IM) in the high dose group of adult and aged rats, there was no significant difference.  
Figures 66, 67, 68 and 69 show the functional signs of toxicity (IM and SLUD) in 
adult and aged rats after acute exposure to PS. In adult rats, the high dose of PS produced 
IM and SLUD signs 24 hours after treatment, which peaked by 72 hours, and these 
effects persisted until the end of the study. Involuntary movements had a slightly delayed 
onset (48 hours post-treatment) in the high dose group of aged rats, after which it peaked 
by 72 hours. SLUD signs were observed in the high dose group of adult rats 24 hours 
after treatment, and these effects start to diminish by 72 hours post-treatment. 
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Figure 62: The effects of various doses of CPF on body weight in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. Rats were weighed before treatment and every 24 hours after 
treatment. CPF produced a dose-dependent decrease in body weight, which remained 
lower than control values by the end of the study in the medium and high dose groups. 
Data (mean ± standard error) represent body weight in terms of percent of Day 0. The 
asterisk, pound and dollar signs represent values that are significantly different from 
control, 28 mg/kg and 140 mg/kg dose groups at the same time point, respectively.  
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Figure 63: The effects of various doses of CPF on body weight in aged rats. Rats (n=4-
5/dose group) were treated subcutaneously with CPF at the doses indicated and sacrificed 
96 hours later. Rats were weighed before treatment and every 24 hours after treatment. 
CPF produced a dose-dependent decrease in body weight, which remained lower than 
control values by the end of the study in the medium and high dose groups. Data (mean ± 
standard error) represent body weight in terms of percent of Day 0. The asterisk, pound 
and dollar signs represent values that are significantly different from control, 28 mg/kg 
and 140 mg/kg dose groups at the same time point, respectively.  
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Figure 64: The effects of various doses of PS on body weight in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with PS at the doses indicated and 
sacrificed 96 hours later. Rats were weighed before treatment and every 24 hours after 
treatment. PS produced a dose-dependent decrease in body weight, which remained lower 
than control values by the end of the study in the medium and high dose groups. Data 
(mean ± standard error) represent body weight in terms of percent of Day 0. The asterisk, 
pound and dollar signs represent values that are significantly different from control, 9 
mg/kg and 13.5 mg/kg dose groups at the same time point, respectively.  
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Figure 65: The effects of various doses of PS on body weight in aged rats. Rats (n=5/dose 
group) were treated subcutaneously with PS at the doses indicated and sacrificed 96 
hours later. Rats were weighed before treatment and every 24 hours after treatment. PS 
produced a dose-dependent decrease in body weight, which remained lower than control 
values by the end of the study in the medium and high dose groups. Data (mean ± 
standard error) represent body weight in terms of percent of Day 0. The asterisk, pound 
and dollar signs represent values that are significantly different from control, 3 mg/kg and 
4.5 mg/kg dose groups at the same time point, respectively. 
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Table 6. Involuntary movement scores for adult rats following acute exposure to 
chlorpyrifos. 
Time After Treatment  
24 hours 48 hours 72 hours 96 hours 
Control 
 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
Low Dose 
(28 mg/kg) 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
Medium Dose 
(140 mg/kg) 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
C 
P 
F 
 
D 
O 
S 
E 
S 
High Dose 
(280 mg/kg) 
2  ±  0 2  ±  0.25 2  ±  0.25 2  ±  0.25 
 
Rats (n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. Involuntary movements were evaluated every 24 hours after 
treatment. Data (median ± interquartile range) represent IM scores.  
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Table 7. SLUD scores (i.e., salivation, lacrimation, urination and defecation) in adult rats 
following acute exposure to chlorpyrifos. 
Time After Treatment  
24 hours 48 hours 72 hours 96 hours 
Control 
 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
Low Dose 
(28 mg/kg) 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
Medium Dose 
(140 mg/kg) 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
C 
P 
F 
 
D 
O 
S 
E 
S 
High Dose 
(280 mg/kg) 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
 
Rats (n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. SLUD signs were evaluated every 24 hours after treatment. 
Data (median ± interquartile range) represent SLUD scores.  
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Table 8: Involuntary movement scores for aged rats following acute exposure to 
chlorpyrifos. 
Time After Treatment  
24 hours 48 hours 72 hours 96 hours 
Control 
 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
Low Dose 
(28 mg/kg) 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
Medium Dose 
(140 mg/kg) 
2  ±  0 2  ±  0 2  ±  0 2  ±  0 
C 
P 
F 
 
D 
O 
S 
E 
S 
High Dose 
(280 mg/kg) 
2  ±  0.25 2  ±  0.125 2  ±  0 2  ±  0 
 
Rats (n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. Involuntary movements were evaluated every 24 hours after 
treatment. Data (median ± interquartile range) represent IM scores.  
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Table 9: SLUD scores (i.e., salivation, lacrimation, urination and defecation) in aged rats 
following acute exposure to chlorpyrifos. 
Time After Treatment  
24 hours 48 hours 72 hours 96 hours 
Control 
 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
Low Dose 
(28 mg/kg) 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
Medium Dose 
(140 mg/kg) 
1  ±  0 1  ±  0 1  ±  0 1  ±  0 
C 
P 
F 
 
D 
O 
S 
E 
S 
High Dose 
(280 mg/kg) 
1  ±  0.5 1  ±  0 1  ±  0 1  ±  0 
 
Rats (n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. SLUD signs were evaluated every 24 hours after treatment. 
Data (median ± interquartile range) represent SLUD scores.  
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Figure 66: Involuntary movement scores for adult rats following acute exposure to 
parathion. Rats (n=4/dose group) were treated subcutaneously with PS at the doses 
indicated and sacrificed 96 hours later. Involuntary movements were evaluated every 24 
hours after treatment. The high dose of PS showed an increase in IM which persisted 
until the end of the study. Data (median ± interquartile range) represent IM scores. The 
asterisk, pound and dollar signs represent values that are significantly different from 
control, 9 mg/kg and 13.5 mg/kg dose groups at the same time point, respectively.  
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Figure 67: SLUD scores (i.e., salivation, lacrimation, urination and defecation) in adult 
rats following acute exposure to parathion. Rats (n=4/dose group) were treated 
subcutaneously with PS at the doses indicated and sacrificed 96 hours later. SLUD signs 
were evaluated every 24 hours after treatment. The high dose of PS showed an increase in 
SLUD signs which persisted until the end of the study. Data (median ± interquartile 
range) represent SLUD scores. The asterisk, pound and dollar signs represent values that 
are significantly different from control, 9 mg/kg and 13.5 mg/kg dose groups at the same 
time point, respectively.  
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Figure 68: Involuntary movement scores for aged rats following acute exposure to 
parathion. Rats (n=4/dose group) were treated subcutaneously with PS at the doses 
indicated and sacrificed 96 hours later. Involuntary movements were evaluated every 24 
hours after treatment. The high dose of PS showed an increase in IM which persisted 
until the end of the study. Data (median ± interquartile range) represent IM scores.  The 
asterisk, pound and dollar signs represent values that are significantly different from 
control, 3 mg/kg and 4.5 mg/kg dose groups at the same time point, respectively.  
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Figure 69: SLUD scores (i.e., salivation, lacrimation, urination and defecation) in aged 
rats following acute exposure to parathion. Rats (n=4/dose group) were treated 
subcutaneously with PS at the doses indicated and sacrificed 96 hours later. SLUD signs 
were evaluated every 24 hours after treatment. The high dose of PS showed an increase in 
SLUD signs which started subsiding 72 hours after treatment. Data (median ± 
interquartile range) represent SLUD scores. The asterisk, pound and dollar signs 
represent values that are significantly different from control, 3 mg/kg and 4.5 mg/kg dose 
groups at the same time point, respectively. 
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Effects of Chlorpyrifos on Heart Rate, Body Temperature and Physical Activity in  
Adult and Aged Rats 
Basal heart rate in aged rats was considerably (~50 beats per minute) lower than 
that of adult rats. CPF produced a dose-dependent decrease in heart rate in the medium 
and high dose-groups of adult and aged rats. Figures 70-72 show the effects of the 
various doses of CPF on heart rate in adult rats. CPF caused a slight but significant 
decrease in heart rate in the medium dose group, which persisted until the end of the 
study. In the high dose group, the heart rate was briefly elevated, after which it was 
substantially decreased, and remained depressed until the end of the observation period. 
Figures 73-75 show the effects of the various doses of CPF on heart rate in aged rats. 
CPF produced a diurnal increase in heart rate in all treatment groups in the first 12 hours 
post-treatment, following which the heart rate showed a persistent decrease until the end 
of the study in the medium and high dose-groups.  
CPF produced a dose-dependent decrease in body temperature in the medium and 
high dose-groups of adult and aged rats. Figures 76-78 show the effects of the various 
doses of CPF on body temperature in adult rats. The decrease in body temperature in the 
medium and high dose-groups predominantly occurred during the nocturnal phase and 
peaked 24 (medium dose group) to 48 (high dose group) hours post-treatment. This 
parameter recovered to baseline (pre-treatment) values by the end of the study in both 
dose groups. Figures 79-81 show the effects of the various doses of CPF on body 
temperature in aged rats. CPF produced a dose-dependent decrease in body temperature 
(which was evident in the diurnal and nocturnal phase) in the medium and high dose-
 150 
groups, which peaked 24 hours post-treatment. Although body temperature showed a 
trend towards recovery in both dose groups, it was still lower than the baseline values.  
CPF elicited a dose-related effect on physical activity in the medium and high 
dose-groups of adult and aged rats. Figures 82-84 illustrate the effects of the various 
doses of CPF on physical activity in adult rats. CPF produced a dose-related decrease in 
physical activity which peaked 24 hours after treatment in the low, medium and high 
dose-groups. By 60 hours post-treatment, CPF treatment was associated with a diurnal 
increase in physical activity in the medium and high dose groups, which recovered to 
baseline values by the end of the study. Figures 85-87 show the effects of the various 
doses of CPF on physical activity in aged rats. During the diurnal phase, CPF produced a 
decrease in physical activity in the low dose-group 36 hours after treatment, and an 
increase in the high dose-group 60 and 84 hours post-treatment. Although the high dose 
of CPF did not produce any decrease in physical activity in the diurnal phase, during the 
nocturnal phase, physical activity was initially depressed (peaking by 24 hours after 
treatment) and then elevated above pre-treatment values by the end of the study. 
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Figure 70:  The effects of various doses of CPF on heart rate in adult rats. Rats (n=4/dose 
group) were treated subcutaneously with CPF at the doses indicated and sacrificed 96 
hours later. The graph represents 24 hour baseline (pre-treatment) data followed by 96 
hours post-treatment data. The data (mean ± standard error) represent heart rate averaged 
over 8 hour diurnal and nocturnal intervals. The medium dose of CPF caused a slight but 
sustained decrease in heart rate, while the high dose produced an initial increase followed 
by a persistent decrease in heart rate. The asterisk, pound and dollar signs represent 
values that are significantly different from control, 28 and 140 mg/kg dose groups at the 
same time point, respectively. 
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Figure 71:  The effects of various doses of CPF on heart rate in adult rats during the 
diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with CPF at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represent heart rate averaged over 8 hour diurnal intervals. CPF produced a dose-
dependent decrease in heart rate. The high dose of CPF produced an initial increase 
followed by a persistent decrease in heart rate. a, b, and c represent values that are 
significantly different from the same dose at 12, 36 and 60 hours, respectively. 
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 Figure 72:  The effects of various doses of CPF on heart rate in adult rats during the 
nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with CPF at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represent heart rate averaged over 8 hour nocturnal intervals. CPF produced a dose-
dependent decrease in heart rate. Both the medium and high dose of CPF produced a 
decrease in heart rate, which persisted until the end of the study. a, b, and c represent 
values that are significantly different from the same dose at 24, 48 and 72 hours, 
respectively. 
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 Figure 73:  The effects of various doses of CPF on heart rate in aged rats. Rats (n=4-
5/treatment group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
heart rate averaged over 8 hour diurnal and nocturnal intervals. CPF produced a dose-
dependent decrease in heart rate, which persisted until the end of the study in the medium 
and high dose-groups. The asterisk, pound and dollar signs represent values that are 
significantly different from control, 28 and 140 mg/kg dose groups at the same time 
point, respectively.  
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Figure 74:  The effects of various doses of CPF on heart rate in aged rats during the 
diurnal (light) periods. Rats (n=4-5/dose group) were treated subcutaneously with CPF at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represent heart rate averaged over 8 hour diurnal intervals. CPF produced a diurnal 
increase in heart rate in all the dose-groups 12 hours after treatment, with apparent 
recovery to pre-treatment levels by the end of the study. a, b, and c represent values that 
are significantly different from the same dose at 12, 36 and 60 hours, respectively.  
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Figure 75:  The effects of various doses of CPF on heart rate in aged rats during the 
nocturnal (dark) periods. Rats (n=4-5/dose group) were treated subcutaneously with CPF 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represent heart rate averaged over 8 hour nocturnal intervals. CPF produced a dose-
dependent decrease in heart rate in the medium and high dose-groups, which persisted 
until the end of the study. a, b, and c represent values that are significantly different from 
the same dose at 24, 48 and 72 hours, respectively.  
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 Figure 76:  The effects of various doses of CPF on body temperature in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
body temperature averaged over 8 hour diurnal and nocturnal intervals. CPF produced a 
dose-dependent decrease in body temperature. The body temperature recovered to control 
values by the end of the study in all three dose-groups. The asterisk, pound and dollar 
signs represent values that are significantly different from control, 28 and 140 mg/kg 
dose groups at the same time point, respectively. 
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 Figure 77:  The effects of various doses of CPF on body temperature in adult rats during 
the diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with CPF 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represent body temperature averaged over 8 hour diurnal intervals. CPF produced a 
significant decrease in body temperature during the diurnal phase, that peaked by 12 
hours (low dose group) and 36 hours (high dose group) post-treatment. a, and b represent 
values that are significantly different from the same dose at 12 and 36 hours, respectively. 
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 Figure 78:  The effects of various doses of CPF on body temperature in adult rats during 
the nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represent body temperature averaged over 8 hour nocturnal intervals. CPF 
produced a dose-dependent decrease in body temperature which peaked at 48 hours post-
treatment and recovered to baseline values by the end of the study. a, b, and c represent 
values that are significantly different from the same dose at 24, 48 and 72 hours, 
respectively. 
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Figure 79:  The effects of various doses of CPF on body temperature in aged rats. Rats 
(n=4-5/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represents 
body temperature averaged over 8 hour diurnal and nocturnal intervals. CPF produced a 
significant decrease in body temperature, which peaked 24 hours post-treatment and 
started recovering to control values thereafter. The asterisk, pound and dollar signs 
represent values that are significantly different from control, 28 and 140 mg/kg dose 
groups at the same time point, respectively.  
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Figure 80:  The effects of various doses of CPF on body temperature in aged rats during 
the diurnal (light) periods. Rats (n=4-5/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents body temperature averaged over 8 hour diurnal intervals. CPF 
produced a decrease in body temperature in the high dose-group 36 hours after treatment, 
with apparent recovery to pre-treatment levels by the end of the study. a, b, c, and d 
represent values that are significantly different from the same dose at 12, 36, 60 and 84 
hours, respectively.  
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Figure 81:  The effects of various doses of CPF on body temperature in aged rats during 
the nocturnal (dark) periods. Rats (n=4-5/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents body temperature averaged over 8 hour nocturnal intervals. 
CPF produced a dose-dependent decrease in body temperature in the medium and high 
dose-groups, which persisted until the end of the study. a, b, c, and d represent values that 
are significantly different from the same dose at 24, 48, 72 and 96 hours, respectively.  
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Figure 82:  The effects of various doses of CPF on physical activity in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represents 
physical activity averaged over 8 hour diurnal and nocturnal intervals. CPF produced a 
dose-dependent decrease in physical activity, which recovered to control values by the 
end of the study in all dose-groups. Asterisks represent values that are significantly 
different from the control group at the same time point.  
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 Figure 83:  The effects of various doses of CPF on physical activity in adult rats during 
the diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with CPF 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents physical activity averaged over 8 hour diurnal intervals. CPF produced a 
diurnal increase in physical activity in the medium and high dose groups 60 hours post-
treatment, which recovered to pre-treatment levels by the end of the study. a, b, and c 
represent values that are significantly different from the same dose at 12, 36 and 60 
hours, respectively.  
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 Figure 84:  The effects of various doses of CPF on physical activity in adult rats during 
the nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents physical activity averaged over 8 hour nocturnal intervals. CPF 
produced a dose-dependent decrease in physical activity which peaked 24 hours post-
treatment in all 3 dose groups and recovered to baseline values by the end of the study. a, 
b, c, and d represent values that are significantly different from the same dose at 24, 48, 
72 and 96 hours, respectively.  
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Figure 85:  The effects of various doses of CPF on physical activity in aged rats. Rats 
(n=4-5/dose group) were treated subcutaneously with CPF at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represents 
physical activity averaged over 8 hour diurnal and nocturnal intervals. CPF produced a 
significant decrease in physical activity in the high dose-group, which peaked 24 hours 
post-treatment and started increasing above control values by 60 hours post-treatment. 
The asterisk, pound and dollar signs represent values that are significantly different from 
control, 28 and 140 mg/kg dose groups at the same time point, respectively.  
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 Figure 86:  The effects of various doses of CPF on physical activity in aged rats during 
the diurnal (light) periods. Rats (n=4-5/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents physical activity averaged over 8 hour diurnal intervals. CPF 
produced a decrease in physical activity in the low dose-group 36 hours after treatment, 
and a diurnal increase in physical activity in the high dose-group 60 and 84 hours post-
treatment. a, b, c, and d represent values that are significantly different from the same 
dose at 12, 36, 60 and 84 hours, respectively.  
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 Figure 87:  The effects of various doses of CPF on physical activity in aged rats during 
the nocturnal (dark) periods. Rats (n=4-5/dose group) were treated subcutaneously with 
CPF at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour 
baseline (pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± 
standard error) represents physical activity averaged over 8 hour nocturnal intervals. The 
physical activity in the high dose-group was initially depressed and then elevated above 
pre-treatment (baseline) values by the end of the study. a, b, c, and d represent values that 
are significantly different from the same dose at 24, 48, 72 and 96 hours, respectively.  
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Effects of Parathion on Heart Rate, Body Temperature and Physical Activity in  
Adult and Aged Rats 
PS produced a dose-dependent decrease in heart rate in the medium and high 
dose-groups of adult and aged rats. Figures 88-90 represent the effects of the various 
doses of PS on heart rate in adult rats. PS produced a brief diurnal (12 hours post-
treatment) increase in heart rate in the medium dose group, followed by a prolonged 
decrease, with a trend towards recovery by the end of the study. Relative to the control 
group, the high dose of PS caused an increase in heart rate 12 hours post-treatment, 
followed by a significant and prolonged decrease in heart rate, which persisted until the 
end of the study. Figures 91-93 represent the effects of the various doses of PS on heart 
rate in aged rats. In the medium dose group of aged rats, PS produced an initial diurnal 
increase (12 hours post-treatment) in heart rate, followed by a decrease and a subsequent 
trend towards recovery (by the end of the study). In the high dose group, an initial 
decrease in heart rate (24 hours post-treatment) was followed by a brief period of increase 
(48 hours after treatment), after which the heart rate continued to decrease significantly 
until the end of the study (72 hours post-treatment onwards). This transient increase in 
heart rate response was absent in adult rats and in other treatment groups of aged rats.  
 PS produced a dose-dependent decrease in body temperature in the medium and 
high dose-groups of adult and aged rats. Figures 94-96 represent the effects of the various 
doses of PS on body temperature in adult rats. PS produced a dose-dependent decrease in 
body temperature in the medium and high dose-groups, which peaked 24 hours after 
treatment. By the end of the study, body temperature recovered to pre-treatment values in 
the medium dose-group and remained depressed in the high dose-group. Figures 97-99 
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represent the effects of the various doses of PS on body temperature in aged rats. Similar 
to the observation in adult rats, PS produced a dose-dependent decrease in body 
temperature (which peaked at 24 hours post-treatment in the high dose group and at 36 
hours post-treatment in the medium dose-group). By the end of the study, the body 
temperature in the medium dose group had recovered to baseline values, while it 
remained depressed in the high dose group. 
  PS produced a dose-dependent effect on physical activity in adult and aged rats. 
Figures 100-102 represent the effects of the various doses of PS on physical activity in 
adult rats. PS produced a dose-dependent decrease in physical activity, which peaked 24 
hours post-treatment in the low, medium and high dose groups. By the end of the study, 
physical activity in the low dose group recovered to baseline values, while in the medium 
and high dose-groups, it remained depressed. Figures 103-105 represent the effects of the 
various doses of PS on physical activity in aged rats. PS produced a dose-dependent 
decrease in physical activity in the low, medium and high dose-groups, which peaked at 
24 hours post-treatment. In the nocturnal phase, physical activity recovered to baseline 
values in all 3 treatment groups by the end of the study. Interestingly, in the diurnal 
phase, PS produced an increase in physical activity around 60 hours post-treatment in the 
medium and high dose-groups, which persisted until the end of the study. 
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Figure 88:  The effects of various doses of PS on heart rate in adult rats. Rats (n=4/dose 
group) were treated subcutaneously with PS at the doses indicated and sacrificed 96 
hours later. The graph represents 24 hour baseline (pre-treatment) data followed by 96 
hours post-treatment data. The data (mean ± standard error) represent heart rate averaged 
over 8 hour diurnal and nocturnal intervals. The medium and high dose-groups of PS 
caused an initial increase followed by a prolonged decrease in heart rate, which remained 
depressed in the high dose-group and recovered to control values in the medium dose-
group by the end of the study. The asterisk, pound and dollar signs represent values that 
are significantly different from control, 9 and 13.5 mg/kg dose groups at the same time 
point, respectively.  
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 Figure 89:  The effects of various doses of PS on heart rate in adult rats during the 
diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with PS at the 
doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline (pre-
treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents heart rate averaged over 8 hour diurnal intervals. PS produced an initial 
increase followed by a decrease in heart rate in the medium dose-group and a persistent 
decrease in the high dose-group. a, and b represent values that are significantly different 
from the same dose at 12 and 36 hours, respectively.  
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Figure 90:  The effects of various doses of PS on heart rate in adult rats during the 
nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents heart rate averaged over 8 hour nocturnal intervals. PS produced a dose-
dependent decrease in heart rate in the medium and high dose-groups, which persisted 
until the end of the study. a, b, c, and d represent values that are significantly different 
from the same dose at 24, 48, 72 and 96 hours, respectively.  
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Figure 91:  The effects of various doses of PS on heart rate in aged rats. Rats (n=5/dose 
group) were treated subcutaneously with PS at the doses indicated and sacrificed 96 
hours later. The graph represents 24 hour baseline (pre-treatment) data followed by 96 
hours post-treatment data. The data (mean ± standard error) represent heart rate averaged 
over 8 hour diurnal and nocturnal intervals. PS produced a significant and persistent 
decrease in heart rate in the medium and high dose-groups. The asterisk, pound and dollar 
signs represent values that are significantly different from control, 3 and 4.5 mg/kg dose 
groups at the same time point, respectively.  
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Figure 92:  The effects of various doses of PS on heart rate in aged rats during the diurnal 
(light) periods. Rats (n=5/dose group) were treated subcutaneously with PS at the doses 
indicated and sacrificed 96 hours later. The graph represents 24 hour baseline (pre-
treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents heart rate averaged over 8 hour diurnal intervals. PS produced an initial 
increase followed by a decrease and a trend towards recovery in heart rate in the medium 
dose-group, and a persistent decrease in the high dose-group. a, b, c, and d represent 
values that are significantly different from the same dose at 12, 36, 60 and 84 hours, 
respectively.  
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Figure 93: The effects of various doses of PS on heart rate in aged rats during the 
nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents heart rate averaged over 8 hour nocturnal intervals. PS produced a dose-
dependent decrease in heart rate. The medium dose group showed a trend towards 
recovery 96 hours post-treatment, while in the high dose group, an initial decrease was 
followed by a brief period of increase (48 hours after treatment), after which the heart 
rate continued to decrease significantly until the end of the study. a, b, c, and d represent 
values that are significantly different from the same dose at 24, 48, 72 and 96 hours, 
respectively.  
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 Figure 94:  The effects of various doses of PS on body temperature in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with PS at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represents 
body temperature averaged over 8 hour diurnal and nocturnal intervals. PS produced a 
dose-dependent decrease in body temperature, which recovered to control values in the 
medium dose-group, and remained depressed in the high dose-group by the end of the 
study. The asterisk, pound and dollar signs represent values that are significantly different 
from control, 9 and 13.5 mg/kg dose groups at the same time point, respectively.  
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Figure 95:  The effects of various doses of PS on body temperature in adult rats during 
the diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents body temperature averaged over 8 hour diurnal intervals. PS produced a 
diurnal decrease in body temperature in the high dose-group which peaked 36 hours post-
treatment and remained depressed until the end of the study. a, b, and c represent values 
that are significantly different from the same dose at 12, 36 and 60 hours respectively.  
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 Figure 96: The effects of various doses of PS on body temperature in adult rats during 
the nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents body temperature averaged over 8 hour nocturnal intervals. PS produced 
a dose-dependent decrease in body temperature in the medium and high dose-groups, 
which recovered to pre-treatment values in the medium dose-group and persisted until the 
end of the study in the high dose-group. a, and b represent values that are significantly 
different from the same dose at 24 and 48 hours, respectively.  
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Figure 97:  The effects of various doses of PS on body temperature in aged rats. Rats 
(n=5/dose group) were treated subcutaneously with PS at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
body temperature averaged over 8 hour diurnal and nocturnal intervals. PS produced a 
significant and persistent decrease in body temperature in the high dose-group. The 
asterisk, pound and dollar signs represent values that are significantly different from 
control, 3 and 4.5 mg/kg dose groups at the same time point, respectively.  
 181 
0 24 48 72 96 120
33.0
33.5
34.0
34.5
35.0
35.5
36.0
36.5
Control
Low Dose (3 mg/kg)
Medium Dose (4.5 mg/kg)
High Dose (6 mg/kg)
Treatment
ab ab ab
ab
c
c
Time (Hours)
B
o
dy
 
Te
m
pe
ra
tu
re
 
(°C
)
 Figure 98:  The effects of various doses of PS on body temperature in aged rats during 
the diurnal (light) periods. Rats (n=5/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents body temperature averaged over 8 hour diurnal intervals. PS produced a 
decrease in body temperature followed by a trend towards recovery in the medium dose-
group, and a persistent decrease in the high dose-group. a, b, and c represent values that 
are significantly different from the same dose at 12, 36 and 60 hours, respectively.  
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Figure 99: The effects of various doses of PS on body temperature in aged rats during the 
nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents body temperature averaged over 8 hour nocturnal intervals. PS produced 
a dose-dependent decrease in body temperature. By the end of the study, the body 
temperature in the medium dose group had recovered to baseline values, while it 
remained depressed in the high dose group. a, and b represent values that are significantly 
different from the same dose at 24 and 48 hours, respectively.  
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Figure 100:  The effects of various doses of PS on physical activity in adult rats. Rats 
(n=4/dose group) were treated subcutaneously with PS at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represents 
physical activity averaged over 8 hour diurnal and nocturnal intervals. PS produced a 
dose-dependent decrease in physical activity in the medium and high dose-groups, which 
peaked at 24 hours post-treatment, and started recovering thereafter. The asterisk and 
pound signs represent values that are significantly different from control and 9 mg/kg 
dose groups at the same time point, respectively.  
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Figure 101:  The effects of various doses of PS on physical activity in adult rats during 
the diurnal (light) periods. Rats (n=4/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents physical activity averaged over 8 hour diurnal intervals. PS produced a 
diurnal decrease in physical activity in the medium and high dose-group, which peaked 
36 hours post-treatment and recovered to baseline values thereafter. a, b, and c represent 
values that are significantly different from the same dose at 12, 36 and 60 hours, 
respectively.  
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 Figure 102: The effects of various doses of PS on physical activity in adult rats during 
the nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents physical activity averaged over 8 hour nocturnal intervals. PS produced 
a dose-dependent decrease in nocturnal physical activity, which peaked 24 hours after 
treatment. The physical activity in the low dose-group recovered to baseline values, while 
in the medium and high dose-groups, it remained depressed until the end of the study. a, 
b, and c represent values that are significantly different from the same dose at 24, 48 and 
72 hours, respectively.  
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Figure 103:  The effects of various doses of PS on physical activity in aged rats. Rats 
(n=5/dose group) were treated subcutaneously with PS at the doses indicated and 
sacrificed 96 hours later. The graph represents 24 hour baseline (pre-treatment) data 
followed by 96 hours post-treatment data. The data (mean ± standard error) represent 
physical activity averaged over 8 hour diurnal and nocturnal intervals. PS produced a 
decrease in physical activity in the high dose-group, followed by an increase 96 hours 
post-treatment in the medium and high dose-groups. The asterisk and pound signs 
represent values that are significantly different from control and 3 mg/kg dose groups at 
the same time point, respectively.  
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 Figure 104:  The effects of various doses of PS on physical activity in aged rats during 
the diurnal (light) periods. Rats (n=5/dose group) were treated subcutaneously with PS at 
the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents physical activity averaged over 8 hour diurnal intervals. PS produced a 
diurnal increase in physical activity around 60 hours post-treatment in the medium and 
high dose-groups, which persisted until the end of the study. a, b, c, and d represent 
values that are significantly different from the same dose at 12, 36, 60 and 84 hours, 
respectively.  
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 Figure 105: The effects of various doses of PS on physical activity in aged rats during 
the nocturnal (dark) periods. Rats (n=4/dose group) were treated subcutaneously with PS 
at the doses indicated and sacrificed 96 hours later. The graph represents 24 hour baseline 
(pre-treatment) data followed by 96 hours post-treatment data. The data (mean ± standard 
error) represents body physical activity averaged over 8 hour nocturnal intervals. PS 
produced a dose-dependent decrease in physical activity in all 3 dose-groups, which 
peaked at 24 hours post-treatment, with a subsequent trend towards recovery until the end 
of the study. a, b, and c represent values that are significantly different from the same 
dose at 24, 48 and 72 hours, respectively.  
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Total Cholinesterase, Acetylcholinesterase, Butyrylcholinesterase and 
Carboxylesterase Activities in Atria, Ventricles, Cortex, Plasma  
and Diaphragm of Adult and Aged Rats 
The levels of total ChE, AChE, BChE and CarbE in the atria, ventricles, cortex, 
plasma and diaphragm of adult (3 months) and aged (18 moths) rats were evaluated using 
the AChE-specific inhibitor BW284C51, the BChE-specific inhibitor iso-OMPA, and the 
CarbE substrate, p-nitrophenyl acetate. Table 5 summarizes these values in adult atria, 
ventricles, cortex and plasma. Information on these values in aged rats was lacking, 
however. In order to assess the effects of the various doses of CPF and PS on these 
enzymes in adult and aged rats, it was critical to evaluate the normal levels of these 
enzymes in tissues from these two age-groups. Figures 106-110 show the comparative 
ChE, AChE, BChE and CarbE content in the ventricles, atria, cortex, plasma and 
diaphragm, respectively, in adult and aged rats.  
The ventricles of adult and aged rats contain approximately 10% AChE and 90% 
BChE. In both adult and aged rats, atria are comprised of 80% BChE and ~20% AChE, 
while the cortex has ~90% AChE and 10% BChE. The plasma in both ages was made up 
of ~70% AChE and 30% BChE, while the diaphragm in adult and aged rats contains 90% 
AChE and 10% BChE. Although the ventricles and cortex in aged rats appear to contain 
less amounts total ChE, AChE, BChE and CarbE as compared to adults, this difference 
was not significant. The atria and diaphragm in adult and aged rats contain essentially the 
same amount of each enzyme. In contrast, plasma in aged rats has ~1.5-fold higher levels 
of total ChE, AChE and BChE, and 35% lower CarbE activity than aged rats. Since both 
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AChE and BChE levels in the plasma increase during aging, the ratio of AChE:BChE 
remains the same as in adults.  
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Figure 106: Total cholinesterase, acetylcholinesterase, butyrylcholinesterase and 
carboxylesterase activities in the ventricles of adult and aged rats. Ventricular tissue 
homogenates were incubated with 10 µM of iso-OMPA or BW at 37°C for 15 minutes, 
before assessing the residual ChE activity, to obtain AChE and BChE activities, 
respectively. For total ChE activity, the tissue homogenates were pre-incubated in buffer 
(no inhibitor), prior to performing the assay. Carboxylesterase activity was assessed 
following incubation of the tissue homogenates at 37°C in the presence of the substrate p-
nitrophenyl acetate. Data (mean ± standard error) represent enzyme activities in terms of  
nmol of substrate hydrolyzed/mg protein/minute.
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Figure 107: Total cholinesterase, acetylcholinesterase, butyrylcholinesterase and 
carboxylesterase activities in the atria of adult and aged rats. Atrial tissue homogenates 
were incubated with 10 µM of iso-OMPA or BW at 37°C for 15 minutes, before 
assessing the residual ChE activity, to obtain AChE and BChE activities, respectively. 
For total ChE activity, the tissue homogenates were pre-incubated in buffer (no inhibitor), 
prior to performing the assay. Carboxylesterase activity was assessed following 
incubation of the tissue homogenates at 37°C in the presence of the substrate p-
nitrophenyl acetate. Data (mean ± standard error) represent enzyme activities in terms of  
nmol of substrate hydrolyzed/mg protein/minute.
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Figure 108: Total cholinesterase, acetylcholinesterase, butyrylcholinesterase and 
carboxylesterase activities in the cortex of adult and aged rats. Cortical tissue 
homogenates were incubated with 10 µM of iso-OMPA or BW at 37°C for 15 minutes, 
before assessing the residual ChE activity, to obtain AChE and BChE activities, 
respectively. For total ChE activity, the tissue homogenates were pre-incubated in buffer 
(no inhibitor), prior to performing the assay. Carboxylesterase activity was assessed 
following incubation of the tissue homogenates at 37°C in the presence of the substrate p-
nitrophenyl acetate. Data (mean ± standard error) represent enzyme activities in terms of  
nmol of substrate hydrolyzed/mg protein/minute.
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Figure 109: Total cholinesterase, acetylcholinesterase, butyrylcholinesterase and 
carboxylesterase activities in the plasma of adult and aged rats. Diluted plasma samples 
were incubated with 10 µM of iso-OMPA or BW at 37°C for 15 minutes, before 
assessing the residual ChE activity, to obtain AChE and BChE activities, respectively. 
For total ChE activity, the diluted plasma samples were pre-incubated in buffer (no 
inhibitor), prior to performing the assay. Carboxylesterase activity was assessed 
following incubation of the diluted plasma samples at 37°C in the presence of the 
substrate p-nitrophenyl acetate. Data (mean ± standard error) represent enzyme activities 
in terms of nmol of substrate hydrolyzed/ml plasma/minute. Asterisks represent values 
that are significantly different from adults.  
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Figure 110: Total cholinesterase, acetylcholinesterase and butyrylcholinesterase activities 
in the diaphragm of adult and aged rats. Diaphragm tissue homogenates were incubated 
with 10 µM of iso-OMPA or BW at 37°C for 15 minutes, before assessing the residual 
ChE activity, to obtain AChE and BChE activities, respectively. For total ChE activity, 
the tissue homogenates were pre-incubated in buffer (no inhibitor), prior to performing 
the assay. Data (mean ± standard error) represent enzyme activities in terms of nmol of 
substrate hydrolyzed/mg protein/minute. 
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Effects of Chlorpyrifos on Acetylcholinesterase, Butyrylcholinesterase, 
Carboxylesterase and Muscarinic Receptor Binding in Ventricles, Atria,  
Cortex, Plasma and Diaphragm of Adult and Aged Rats 
The effects of CPF on AChE, BChE, CarbE, muscarinic receptor agonist and 
antagonist binding were evaluated in adult and aged rats. The tissues examined were 
atria, ventricles, cortex, plasma and diaphragm. CPF produced a dose-dependent 
inhibition of AChE (Figures 111, 116, 121, 126 and 129) and BChE (Figures 112, 117, 
122, 127 and 130) in all of the tissues examined in adult and aged rats. In general, the 
same dose of CPF inhibited BChE to a greater extent (~2 to 2.5 fold) than AChE, and this 
was especially obvious with the low (28 mg/kg) and medium (140 mg/kg) dose groups of 
CPF. AChE and BChE in the ventricles were inhibited to a greater extent than in the atria, 
with all doses of CPF. In the atria, both AChE and BChE were inhibited to a greater 
extent in aged than in adult rats by the same dose of CPF (evident with the low dose of 
CPF). Similarly, AChE and BChE in the plasma and diaphragm of aged rats were also 
inhibited to a greater extent in aged as compared to adult rats. In the ventricles and 
cortex, both enzymes were inhibited to a similar degree by the same dose of CPF in both 
age-groups. The maximum amount of enzyme inhibited by the highest dose of CPF was 
~85-90% for AChE and 90-95% for BChE.  
Carboxylesterase was also inhibited in a dose-dependent manner by CPF (Figures 
113, 118, 123 and 128) in adult and aged rats. The amount of CarbE inhibited ranged 
from 35% (low dose) to 80% (high dose). Other than the ventricles, there did not appear 
to be any age-related difference in the amount of CarbE inhibited by a certain dose of 
CPF. The highest dose of CPF inhibited a maximum of ~80% of the total CarbE activity 
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in a tissue, with the exception of the cortex, which had ~40% residual enzyme after 
treatment with 280 mg/kg CPF.  
Muscarinic receptor binding was also evaluated through the use of a radiolabeled 
agonist  ([3H]OXO) (Figures 114, 119 and 124) and antagonist ([3H]QNB) (Figures 115, 
120 and 125). Muscarinic antagonist binding was found to be reduced by ~20% in adult 
ventricles (Figure 115) in the group treated with the high dose of CPF. A similar 
reduction in [3H]QNB binding was observed in the cortex (Figure 125), wherein ~20% of 
the receptors were downregulated in the medium and high dose groups of adults, and in 
the high dose group of aged rats. Muscarinic agonist binding was also reduced in the 
cortex (Figure 124) to a similar extent (~25%) in the high dose groups of adult and aged 
rats. A more robust decrease in [3H]OXO binding was observed in the atria (Figure 119), 
wherein ~50% reduction in receptor binding was noted in the high dose group of adult 
and aged rats.  
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Figure 111: The effects of CPF on acetylcholinesterase activity in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular tissue homogenates were pre-incubated with 10 
µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of AChE activity in the 
ventricles of adult and aged rats. Data (mean ± standard error) represent AChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively.  
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Figure 112: The effects of CPF on butyrylcholinesterase activity in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular tissue homogenates were pre-incubated with 10 
µM BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of BChE activity in the 
ventricles of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively. 
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Figure 113: The effects of CPF on carboxylesterase activity in ventricles from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Ventricular tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. CPF produced a 
dose-dependent inhibition of CarbE activity in the ventricles of adult and aged rats, with 
slightly more CarbE being inhibited by the high dose of CPF in aged than adult rats. Data 
(mean ± standard error) represent CarbE activity in terms of percent of control. Asterisks 
represent values that are significantly different from control, while the plus sign 
represents values that are significantly different from the same dose in adult rats.
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Figure 114: The effects of CPF on muscarinic agonist binding in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular membranes were incubated at 21ºC for 90 
minutes in the presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine 
(to determine specific binding). CPF did not affect muscarinic receptor binding in adult 
or aged rats at any of the doses used. Data (mean ± standard error) represent specific 
binding in terms of percent of control.  
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Figure 115: The effects of CPF on muscarinic antagonist binding in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular membranes were incubated at 21ºC for 90 
minutes in the presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM 
atropine (to determine specific binding). CPF significantly downregulated muscarinic 
receptors in the high dose group of adult rats. Data (mean ± standard error) represent 
specific binding in terms of percent of control. The asterisk, pound and dollar signs 
represent values that are significantly different from control, 28 mg/kg and 140 mg/kg 
dose groups, respectively. 
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Figure 116: The effects of CPF on acetylcholinesterase activity in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were pre-incubated with 10 µM iso-
OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. CPF produced a dose-dependent inhibition of AChE activity in the atria of 
adult and aged rats. AChE in aged rats was inhibited to a significantly greater extent by 
the low dose of CPF than AChE in adults. Data (mean ± standard error) represent AChE 
activity in terms of percent of control. The asterisk and pound signs represent values that 
are significantly different from control and 28 mg/kg dose groups, respectively, while the 
plus sign represents values that are significantly different from the same dose group in 
adults.  
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Figure 117: The effects of CPF on butyrylcholinesterase activity in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of BChE activity in the 
atria of adult and aged rats. BChE in aged rats was inhibited to a significantly greater 
extent by the low dose of CPF than BChE in adults. Data (mean ± standard error) 
represent BChE activity in terms of percent of control. The asterisk and pound signs 
represent values that are significantly different from control and 28 mg/kg dose groups, 
respectively, while the plus sign represents values that are significantly different from the 
same dose group in adults. 
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Figure 118: The effects of CPF on carboxylesterase activity in atria from adult and aged 
rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. CPF produced a 
dose-dependent inhibition of CarbE activity in the atria of adult and aged rats. Data 
(mean ± standard error) represent CarbE activity in terms of percent of control. The 
asterisk and pound signs represent values that are significantly different from control and 
28 mg/kg dose groups, respectively. 
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Figure 119: The effects of CPF on muscarinic agonist binding in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to determine 
specific binding). The high dose of CPF produced a significant downregulation of 
muscarinic receptors in adult and aged rats. Data (mean ± standard error) represent 
specific binding in terms of percent of control. Asterisks represent values that are 
significantly different from control. 
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Figure 120: The effects of CPF on muscarinic antagonist binding in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM atropine (to 
determine specific binding). CPF did not affect muscarinic receptor binding in adult or 
aged rats at any of the doses used.  Data (mean ± standard error) represent specific 
binding in terms of percent of control.  
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Figure 121: The effects of CPF on acetylcholinesterase activity in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were pre-incubated with 10 µM 
iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of AChE activity in the 
cortex of adult and aged rats. Data (mean ± standard error) represent AChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively.  
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Figure 122: The effects of CPF on butyrylcholinesterase activity in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of BChE activity in the 
cortex of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively.
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Figure 123: The effects of CPF on carboxylesterase activity in cortex from adult and aged 
rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. CPF produced a 
dose-dependent inhibition of CarbE activity in the cortex of adult and aged rats. Data 
(mean ± standard error) represent CarbE activity in terms of percent of control. The 
asterisk, pound and dollar signs represent values that are significantly different from 
control, 28 mg/kg and 140 mg/kg dose groups, respectively. 
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Figure 124: The effects of CPF on muscarinic agonist binding in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical membranes were incubated at 21ºC for 90 minutes in 
the presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to 
determine specific binding). The high dose of CPF produced a significant downregulation 
of muscarinic receptors in adult and aged rats. Data (mean ± standard error) represent 
specific binding in terms of percent of control. Asterisks represent values that are 
significantly different from control. 
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Figure 125: The effects of CPF on muscarinic antagonist binding in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical membranes were incubated at 21ºC for 90 minutes in 
the presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM atropine (to 
determine specific binding). CPF produced a significant downregulation of muscarinic 
receptors in the low and high dose-groups of adult rats, and in the high dose-group of 
aged rats. Data (mean ± standard error) represent specific binding in terms of percent of 
control. The asterisk and pound signs represent values that are significantly different 
from control and 28 mg/kg dose group, respectively. 
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Figure 126: The effects of CPF on acetylcholinesterase activity in plasma from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Diluted plasma samples were pre-incubated with 10 µM iso-
OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. CPF produced a dose-dependent inhibition of AChE activity in the plasma of 
adult and aged rats. Data (mean ± standard error) represent AChE activity in terms of 
percent of control. The asterisk and pound signs represent values that are significantly 
different from control and 28 mg/kg dose groups, respectively. 
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Figure 127: The effects of CPF on butyrylcholinesterase activity in plasma from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Diluted plasma samples were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of BChE activity in the 
plasma of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively.
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Figure 128: The effects of CPF on carboxylesterase activity in plasma from adult and 
aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated and 
sacrificed 96 hours later. Diluted plasma samples were incubated at 37°C in the presence 
of the substrate p-nitrophenyl acetate to assess CarbE activity. CPF produced a dose-
dependent inhibition of CarbE activity in the plasma of adult and aged rats. CarbE in 
aged rats was inhibited to a significantly greater extent by the low dose of CPF than 
CarbE in adults. Data (mean ± standard error) represent CarbE activity in terms of 
percent of control. The asterisk and pound signs represent values that are significantly 
different from control and 28 mg/kg dose groups, respectively, while the plus sign 
represents values that are significantly different from the same dose group in adults.
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Figure 129: The effects of CPF on acetylcholinesterase activity in diaphragm from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Diaphragm tissue homogenates were pre-incubated with 10 
µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of AChE activity in the 
diaphragm of adult and aged rats. Data (mean ± standard error) represent AChE activity 
in terms of percent of control. The asterisk, pound and dollar signs represent values that 
are significantly different from control, 28 mg/kg and 140 mg/kg dose groups, 
respectively. 
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Figure 130: The effects of CPF on butyrylcholinesterase activity in diaphragm from adult 
and aged rats. Rats (n=4-5/dose group) were treated with CPF (sc) at the doses indicated 
and sacrificed 96 hours later. Diaphragm tissue homogenates were pre-incubated with 10 
µM BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. CPF produced a dose-dependent inhibition of BChE activity in the 
diaphragm of adult and aged rats. Data (mean ± standard error) represent BChE activity 
in terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and 28 mg/kg dose groups, respectively. 
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Effects of Parathion on Acetylcholinesterase, Butyrylcholinesterase, 
Carboxylesterase and Muscarinic Receptor Binding in Ventricles, Atria,  
Cortex, Plasma and Diaphragm of Adult and Aged Rats 
The effects of PS on AChE, BChE, CarbE, muscarinic receptor agonist and 
antagonist binding were evaluated in the atria, ventricles, cortex, diaphragm and plasma 
of adult and aged rats. PS produced a dose-dependent inhibition of AChE (Figures 131, 
136, 141, 146 and 149) and BChE (Figures 132, 137, 142, 147 and 150) in all of the 
tissues examined in adult and aged rats. In general, the same dose of PS was found to 
inhibit AChE to a greater extent (~1.5 fold) than BChE, and this was especially obvious 
with the low (adult: 9 mg/kg; aged: 3 mg/kg) and medium (adult: 13.5 mg/kg; aged: 4.5 
mg/kg) dose groups. All the doses of PS used in the study inhibited AChE and BChE to a 
greater extent in the ventricles as compared to the atria. In the atria, both AChE and 
BChE were inhibited to a greater extent in aged than in adult rats by the same dose of PS, 
as was seen with the low dose of PS. Although not significant, BChE in the plasma of 
aged rats appeared to be inhibited to a greater degree than in adult rats. No such age-
related difference was observed for plasma AChE activity. The maximum amount of 
enzyme inhibited by the highest dose of PS was ~90-95% for AChE and 70-75% for 
BChE.  
Carboxylesterase was also inhibited in a dose-dependent manner by PS (Figures 
133, 138, 143 and 148) in adult and aged rats. There did not appear to be any age-related 
difference in the amount of CarbE inhibited by any dose of PS. The highest dose of PS 
inhibited a maximum of ~70% of the total CarbE activity in any of the tissues examined, 
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with the exception of the cortex, which had ~50% residual enzyme after treatment with 
the highest dose of PS.  
Muscarinic receptor binding was also evaluated through the use of a radiolabeled 
agonist ([3H]OXO) (Figures 134, 139 and 144) and antagonist ([3H]QNB) (Figure 135, 
140 and 145). Muscarinic antagonist binding in the cortex (Figure 145) was found to be 
reduced by ~25% in aged rats in the group treated with the high dose of PS. Conversely, 
an increase in [3H]QNB binding was observed in the ventricles (Figure 135), wherein 
~30% of the receptors were upregulated in the high dose group of aged rats. Muscarinic 
agonist binding in the ventricles (Figure 134) was reduced by ~25% in the medium and 
high dose groups of adults. A similar downregulation of receptors (20%) in the atria 
(Figure 139) was observed in the low dose of adult rats and high dose of aged rats, with a 
more robust decrease being observed in the medium and high dose groups of adult rats, 
wherein ~35-40% of the receptors were downregulated. Muscarinic receptors were also 
found to be downregulated in the cortex (Figure 144), wherein, [3H]OXO binding  in the 
cortex of aged rats was reduced by ~45% in the high dose group.   
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Figure 131: The effects of PS on acetylcholinesterase activity in ventricles from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Ventricular tissue homogenates were pre-incubated with 10 µM 
iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of AChE activity in the 
ventricles of adult and aged rats. Data (mean ± standard error) represent AChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from the control and low (adult: 9 mg/kg; aged: 3 mg/kg) dose 
groups, respectively. 
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Figure 132: The effects of PS on butyrylcholinesterase activity in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular tissue homogenates were pre-incubated with 10 
µM BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of BChE activity in the 
ventricles of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk, pound and dollar signs represent values that are 
significantly different from control, low (adult: 9 mg/kg; aged: 3 mg/kg) and medium 
(adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively.  
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Figure 133: The effects of PS on carboxylesterase activity in ventricles from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Ventricular tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. All three doses of 
PS inhibited ~60% of CarbE activity in the ventricles of adult and aged rats. Data (mean 
± standard error) represent CarbE activity in terms of percent of control. Asterisks 
represent values that are significantly different from control. 
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Figure 134: The effects of PS on muscarinic agonist binding in ventricles from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Ventricular membranes were incubated at 21ºC for 90 minutes 
in the presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to 
determine specific binding). PS produced a significant downregulation of muscarinic 
receptors in the medium and high dose groups of adult, but not aged rats. Data (mean ± 
standard error) represent specific binding in terms of percent of control. The asterisk and 
pound signs represent values that are significantly different from the control and low 
(adult: 9 mg/kg; aged: 3 mg/kg) dose groups, respectively.  
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Figure 135: The effects of PS on muscarinic antagonist binding in ventricles from adult 
and aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated 
and sacrificed 96 hours later. Ventricular membranes were incubated at 21ºC for 90 
minutes in the presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM 
atropine (to determine specific binding). PS caused a significant (30%) upregulation of 
muscarinic receptors in the high dose group of aged rats. Data (mean ± standard error) 
represent specific binding in terms of percent of control. The asterisk and pound signs 
represent values that are significantly different from the control and low (adult: 9 mg/kg; 
aged: 3 mg/kg) dose groups, respectively. 
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Figure 136: The effects of PS on acetylcholinesterase activity in atria from adult and aged 
rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were pre-incubated with 10 µM iso-
OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. PS produced a dose-dependent inhibition of AChE activity in the atria of 
adult and aged rats. AChE in aged rats was inhibited to a significantly greater extent by 
the low dose of PS than AChE in adults. Data (mean ± standard error) represent AChE 
activity in terms of percent of control. The asterisk, pound and dollar signs represent 
values that are significantly different from control, low (adult: 9 mg/kg; aged: 3 mg/kg) 
and medium (adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively, while the 
plus sign represents values that are significantly different from the same dose group in 
adults.  
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Figure 137: The effects of PS on butyrylcholinesterase activity in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of BChE activity in the 
atria of adult and aged rats. BChE in aged rats was inhibited to a significantly greater 
extent by the low dose of PS than BChE in adults. Data (mean ± standard error) represent 
BChE activity in terms of percent of control. The asterisk, pound and dollar signs 
represent values that are significantly different from control, low (adult: 9 mg/kg; aged: 3 
mg/kg) and medium (adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively, 
while the plus sign represents values that are significantly different from the same dose 
group in adults.  
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Figure 138: The effects of PS on carboxylesterase activity in atria from adult and aged 
rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. PS produced a 
dose-dependent inhibition of CarbE activity in the atria of adult and aged rats. Data 
(mean ± standard error) represent CarbE activity in terms of percent of control. Asterisks 
represent values that are significantly different from control.  
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Figure 139: The effects of PS on muscarinic agonist binding in atria from adult and aged 
rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to determine 
specific binding). The high dose of PS produced a significant downregulation of 
muscarinic receptors in adult and aged rats. Data (mean ± standard error) represent 
specific binding in terms of percent of control. The asterisk and pound signs represent 
values that are significantly different from the control and low (adult: 9 mg/kg; aged: 3 
mg/kg) dose groups, respectively. 
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Figure 140: The effects of PS on muscarinic antagonist binding in atria from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Atrial membranes were incubated at 21ºC for 90 minutes in the 
presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM atropine (to 
determine specific binding). PS produced a slight upregulation of mucarinic receptors in 
the medium and high dose groups of aged, but not adult rats. Data (mean ± standard 
error) represent specific binding in terms of percent of control. The pound sign represent 
values that are significantly different from the low (adult: 9 mg/kg; aged: 3 mg/kg) dose 
group, while the plus sign represents values that are significantly different from the same 
dose group in adults.  
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Figure 141: The effects of PS on acetylcholinesterase activity in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were pre-incubated with 10 µM 
iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of AChE activity in the 
cortex of adult and aged rats. Data (mean ± standard error) represent AChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from the control and low (adult: 9 mg/kg; aged: 3 mg/kg) dose 
groups, respectively. 
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Figure 142: The effects of PS on butyrylcholinesterase activity in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of BChE activity in the 
cortex of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk, pound and dollar signs represent values that are 
significantly different from control, low (adult: 9 mg/kg; aged: 3 mg/kg) and medium 
(adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively.  
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Figure 143: The effects of PS on carboxylesterase activity in cortex from adult and aged 
rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical tissue homogenates were incubated at 37°C in the 
presence of the substrate p-nitrophenyl acetate to assess CarbE activity. PS produced a 
dose-dependent inhibition of CarbE activity in the cortex of adult and aged rats. Data 
(mean ± standard error) represent CarbE activity in terms of percent of control. The 
asterisk and pound signs represent values that are significantly different from the control 
and low (adult: 9 mg/kg; aged: 3 mg/kg) dose groups, respectively. 
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Figure 144: The effects of PS on muscarinic agonist binding in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical membranes were incubated at 21ºC for 90 minutes in 
the presence of 1 nM [3H]Oxotremorine-M, with or without 10 µM atropine (to 
determine specific binding). The high dose of PS produced a significant downregulation 
of muscarinic receptors in aged, but not adult rats. Data (mean ± standard error) represent 
specific binding in terms of percent of control. The asterisk, pound and dollar signs 
represent values that are significantly different from control, low (adult: 9 mg/kg; aged: 3 
mg/kg) and medium (adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively.  
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Figure 145: The effects of PS on muscarinic antagonist binding in cortex from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Cortical membranes were incubated at 21ºC for 90 minutes in 
the presence of 1 nM [3H]Quinuclidinyl benzilate, with or without 10 µM atropine (to 
determine specific binding). PS produced a significant downregulation of muscarinic 
receptors in the high dose-group of aged, but not adult rats. Data (mean ± standard error) 
represent specific binding in terms of percent of control. Asterisk represents values that 
are significantly different from control.  
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Figure 146: The effects of PS on acetylcholinesterase activity in plasma from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Diluted plasma samples were pre-incubated with 10 µM iso-
OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as described 
previously. PS produced a dose-dependent inhibition of AChE activity in the plasma of 
adult and aged rats. Data (mean ± standard error) represent AChE activity in terms of 
percent of control. The asterisk and pound signs represent values that are significantly 
different from control and low (adult: 9 mg/kg; aged: 3 mg/kg) dose groups, respectively.  
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Figure 147: The effects of PS on butyrylcholinesterase activity in plasma from adult and 
aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Diluted plasma samples were pre-incubated with 10 µM 
BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of BChE activity in the 
plasma of adult and aged rats. Data (mean ± standard error) represent BChE activity in 
terms of percent of control. The asterisk and pound signs represent values that are 
significantly different from control and low (adult: 9 mg/kg; aged: 3 mg/kg) dose groups, 
respectively. 
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Figure 148: The effects of PS on carboxylesterase activity in plasma from adult and aged 
rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated and 
sacrificed 96 hours later. Diluted plasma samples were incubated at 37°C in the presence 
of the substrate p-nitrophenyl acetate to assess CarbE activity. PS produced a dose-
dependent inhibition of CarbE activity in the plasma of adult and aged rats. Data (mean ± 
standard error) represent CarbE activity in terms of percent of control. The asterisk, 
pound and dollar signs represent values that are significantly different from control, low 
(adult: 9 mg/kg; aged: 3 mg/kg) and medium (adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose 
groups, respectively.  
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Figure 149: The effects of PS on acetylcholinesterase activity in diaphragm from adult 
and aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated 
and sacrificed 96 hours later. Diaphragm tissue homogenates were pre-incubated with 10 
µM iso-OMPA at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of AChE activity in the 
diaphragm of adult and aged rats. Data (mean ± standard error) represent AChE activity 
in terms of percent of control. The asterisk, pound and dollar signs represent values that 
are significantly different from control, low (adult: 9 mg/kg; aged: 3 mg/kg) and medium 
(adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively. 
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Figure 150: The effects of PS on butyrylcholinesterase activity in diaphragm from adult 
and aged rats. Rats (n=4-5/dose group) were treated with PS (sc) at the doses indicated 
and sacrificed 96 hours later. Diaphragm tissue homogenates were pre-incubated with 10 
µM BW284C51 at 37°C for 15 minutes prior to measuring the residual ChE activity as 
described previously. PS produced a dose-dependent inhibition of BChE activity in the 
diaphragm of adult and aged rats. Data (mean ± standard error) represent BChE activity 
in terms of percent of control. The asterisk, pound and dollar signs represent values that 
are significantly different from control, low (adult: 9 mg/kg; aged: 3 mg/kg) and medium 
(adult: 13.5 mg/kg; aged: 4.5 mg/kg) dose groups, respectively. 
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CHAPTER 4 
DISCUSSION 
 
Distribution of Acetylcholinesterase, Butyrylcholinesterase and Carboxylesterase 
Activities in Atria, Ventricles, Cortex and Plasma of Adult and Aged Rats 
The distributions of acetylcholinesterase (AChE) and butyrylcholinesterase 
(BChE) were found to vary depending on the tissue examined (Tables 1 and 5). The total 
cholinesterase activity in the cortex of both adult and aged rats is comprised of ~90-95% 
AChE and 5-10% BChE. In both age-groups, the total ChE in the ventricles is made up of 
~90% BChE and 10% AChE, while in the atria, ~80% BChE and 20% AChE make up 
the total ChE. In general, the atria contain ~2.5-fold more cholinesterase activity (4 times 
more AChE activity and 2 times more BChE activity), and 1.5-fold more 
carboxylesterase activity than the ventricles. In both adult and aged rats, plasma was 
comprised of ~70% AChE and ~30% BChE.  
These findings generally agreed with work done by others in the field. Jbilo et al 
(1994a) reported that the liver and heart generally contain a high concentration of BChE, 
while the brain and skeletal muscles predominantly express AChE. Previous reports 
indicate that the adult rat brain contains ~80% AChE and 20% BChE, whereas in 
humans, ~95% of the total ChE in the brain is AChE, with only 5% BChE (Ballard et al, 
2005; Giacobini, 2004). Chatonnet and Lockridge (1989) reported that the total ChE of 
adult
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hearts of higher vertebrates is made up of around 85% BChE and around 15% AChE. Li 
et al (2000) estimated the AChE and BChE levels in various tissues from adult rats and 
found that AChE  levels were higher than BChE in the brain, diaphragm and serum, 
whereas BChE predominated in the heart, liver, intestine and lung. In general, the ratios 
of AChE to BChE in the brain, heart, serum and diaphragm were very similar to the 
values obtained in the current studies.  
Levels of AChE, BChE and CarbE were evaluated in aged rats to determine the 
effect of aging on the activity of these enzymes (Figures 106-110). While the levels of all 
three enzymes seemed to decrease slightly in aged (compared to adult) ventricles and 
cortex, this difference was not significant. However, in the plasma, AChE and BChE 
levels were significantly higher, while CarbE activity was significantly lower (~35%) in 
aged compared to adult rats. As both AChE and BChE increased proportionately in aged 
rats, their ratio in the plasma remained the same in aged and adult rats.   
Atterberry and coworkers (1997) investigated the developmental changes in brain 
acetylcholinesterase and liver aliesterase (CarbE) in male Sprague-Dawley rats of 
different ages (1, 3, 12, 33 and 80 days). The specific activities of acetylcholinesterase in 
the cerebral cortex (but not in the medulla oblongata) and liver CarbE increased with 
maturation. This indicated that adult rats had higher levels of both target enzyme (AChE) 
as well as protective enzyme (CarbE) compared to juvenile rats. Similar results were 
obtained by Moser et al (1998), who measured the CarbE activity in the plasma and liver 
of pre-weanling (1, 4, 7, 12, 17 and 21 days old) and adult (82-92 days old) rats of both 
sexes. Pre-weanling rats were found to have considerably less CarbE than adults, and 
adult females had less liver CarbE than adult males. Pope and colleagues (2005b) 
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evaluated the human liver carboxylesterase activities in tissues from human infants (2-24 
months) and adults (20-36 years). There was no significant difference between mean 
infant and adult CarbE activities, and the authors concluded that in contrast to rodents, 
human liver CarbE activity did not change extensively during postnatal maturation.  
 Karanth and Pope (2000) evaluated the activity of CarbE in the liver, plasma and 
lung of neonatal (7 days), juvenile (21 days), adult (3 months) and aged (24 months) male 
Sprague-Dawley rats. Neonatal and juvenile rats had significantly lower levels of CarbE 
than adults in all tissues examined. While CarbE levels were similar between adult and 
aged rats in the liver and lung, plasma CarbE levels in aged rats were 50% lower than in 
adults. In our current study, we found that plasma CarbE was 35%, (but not 50%) lower 
in aged rats than in adults. However, the aged rats used in these studies were 18 months-
old as opposed to the 24 months-old rats used by Karanth and Pope (2000). Thus, plasma 
CarbE may decrease further with advanced aging in this strain of rat, potentially 
contributing to higher sensitivity to some organophosphorus insecticides.  
Several researchers have reported an age-related decrease in cholinesterase in the 
whole brain (Sastry et al, 1983), as well as in different brain regions (Michalek et al, 
1989; Sirvio et al, 1989; Pintor et al, 1990; Meneguz et al, 1992). This age-related change 
was suggested to be due to a selective loss of enzymatic activity of the G4 globular 
tetrameric isoform, but not the G1 isoform of AChE (Meneguz et al, 1992). Kosasa et al 
(1999) reported a decrease in cholinesterase activity in the heart, small intestine and 
pectoral muscle, and an increased cholinesterase activity in the liver and plasma of aged 
as compared to adult rats. The increased cholinesterase activity in the plasma of aged rats 
agreed with our findings. 
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Age-related differences in acetylcholinesterase and butyrylcholinesterase 
activities have been reported in a variety of species. Several reports indicate that basal 
parasympathetic tone decreases during aging. Meyer et al (1985), using a rat atrial mince 
preparation, reported that choline uptake, acetylcholine synthesis and acetylcholine 
release were all decreased in aged rats. Kelliher and Conahan (1980) found that the 
positive inotropic response that is normally observed following vagotomy in adult rats 
was abolished in aged rats. These authors also reported that the heart rate response to the 
muscarinic agonist methacholine was reduced in aged compared to adult rats. Kennedy 
and Seifen (1990) reported that right atrial preparations from aged rats were more 
sensitive to the negative chronotropic action of acetylcholine compared to adult rats. 
However, no age-related difference in sensitivity was observed with carbachol, a 
muscarinic agonist that is resistant to degradation by cholinesterases. When the right 
atrial preparations were pre-treated with diisopropylfluorophosphate (DFP), an 
irreversible OP cholinesterase inhibitor, age-related differences in responsiveness to 
acetylcholine were abolished. The authors concluded that the increased sensitivity of atria 
from aged rats to acetylcholine as compared to adults occurred as a result of decreased 
acetylcholinesterase activity. Su and Narayanan (1992), using isolated, perfused, 
spontaneously-beating rat hearts, arrived at a similar conclusion. They found that the 
greater sensitivity of aged rats to the negative chronotropic effects of acetylcholine as 
compared to adults, was diminished in the presence of a maximally effective 
concentration of eserine, a cholinesterase inhibitor. The negative chronotropic and 
inotropic response to carbachol was also greater in aged than in adult rats. Moreover, 
acetylcholinesterase activities were found to be decreased by 50-60% in aged atria and 
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ventricles; however, no age-related differences were observed in binding of the 
muscarinic antagonist [3H]QNB in either the atria or ventricles. These authors concluded 
that the enhanced responsiveness of the aging heart to cholinergic agonists was at least 
partly due to an age-related reduction in cardiac acetylcholinesterase activity.  
 Age-related changes in AChE and/or BChE activities and molecular isoforms 
have been reported in brain of several species including man. Skau and Triplett (1998) 
reported a significant reduction (20-50%) of AChE activity in different brain regions of 
aged (24 months) as compared to adult (6 months) Fischer 344 rats. When the ratio of 
G4/G1 isoforms was evaluated in different brain regions, it was found to be unaltered in 
aged rats, thus indicating that although aged rats exhibit decreased brain AChE levels, 
there did not appear to be any selective reduction of a particular isoform. In contrast, Das 
et al (2001) evaluating AChE activity in different brain regions of adult (3 months) and 
aged (18-22 months) male and female Sprague-Dawley rats found a significant decrease 
(40-55%) in G4 but not G1 AChE in brain regions of aged male rats. Relatively similar 
differences were observed in adult and aged female rats. Interestingly, higher levels of 
the G4 isoform were observed in female compared to male rats in both age-groups. From 
these studies, the authors concluded that age-related differences in AChE were 
predominantly due to changes in the G4 isoform, and gender-dependent differences 
occur. Atack et al (1986) compared the activities and molecular forms of AChE and 
BChE in different regions of the aged human CNS. AChE activity varied extensively 
(~50-fold) while BChE activity varied only slightly (3-fold) among the different regions 
studied. Although G4 was the predominant isoform, G1 and G2 isoforms were also 
detected in various brain regions. In contrast, the only molecular forms of BChE were G4 
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and G1, and both isoforms were evenly distributed between membrane bound and soluble 
types. The ratio of G4 to G1 isoforms of AChE varied widely between different regions, 
while the G4 to G1 ratio of BChE showed considerably less variation.  
 
 
Sensitivity of Adult and Aged Cardiac and Cortical Acetylcholinesterase and 
Butyrylcholinesterase to Chlorpyrifos Oxon and Paraoxon 
The in vitro potencies of chlorpyrifos oxon (CPO) (Figures 16-19) and paraoxon 
(PO) (Figures 20-23) on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) 
were evaluated in adult and aged heart and cortex. BChE in the cortex and heart was 
significantly more sensitive (4 to 11-fold) than AChE in vitro to inhibition by 
chlorpyrifos oxon. Furthermore, while there was no age-related difference in sensitivity 
of AChE to CPO, BChE in the heart from aged rats was significantly more sensitive to 
CPO than BChE in heart of adult rats (~ 2.5 fold). Although BChE in the cortex of aged 
rats was 2-fold more sensitive to the effect of CPO than BChE in the cortex of adult rats, 
this difference was not statistically significant. In contrast, AChE was more sensitive than 
BChE to paraoxon in both heart and brain, but no age-related difference was noted for 
either enzyme in either the cortex or the heart. The IC50 values obtained for CPO (Table 
2) ranged from 6-35 nm for AChE and 0.6-8 nm for BChE. On the other hand, the IC50 
values of PO (Table 3) ranged between 18-25 nm for AChE and 28-43 nm for BChE.  
 Amitai and coworkers (1998) examined the kinetics of inhibition of AChE and 
BChE by PO and CPO using various mammalian sources of AChE and BChE. The 
bimolecular rate constants (ki) for the inhibition by PO of recombinant human (rH) 
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AChE, recombinant mouse (rM) AChE and fetal bovine serum (FBS) AChE were ~10-
fold smaller than that obtained for the inhibition of these enzymes using CPO, even 
though both compounds form the same diethylphosphoryl-AChE conjugate. The ki values 
obtained for inhibition of rM BChE, human serum BChE and rH BChE by PO were ~10-
fold larger than those of AChE by PO in the same species. Significantly, the ki values 
obtained for BChE from various species were 160-750-fold larger than those obtained by 
CPO for AChE from the same species. These results suggest that BChE is preferentially 
inhibited by CPO as compared to AChE, which is similar to the findings from our current 
study. 
Most of the studies evaluating age-related differences in sensitivity to OP 
insecticides have focused on maturational differences, and less is known regarding 
possible sensitivity differences with aging. Benke and Murphy (1975) evaluated the 
effects of parathion and methyl parathion in male and female rats of different ages 
(ranging from newborn to adult). Cholinesterase sensitivity in vitro to inhibition by 
methyl paraoxon or paraoxon did not change with age, suggesting that differences in 
target enzyme sensitivity did not explain the increase in LD50 values with increasing age. 
Further investigation of various metabolic pathways revealed high correlations between 
cytochrome P450-mediated dearylation, A-esterase-mediated hydrolysis and CarbE-
mediated hydrolysis, and LD50 changes. The authors concluded that these detoxification 
pathways were important in conferring differential sensitivity to methyl parathion and 
parathion with age. Similar results were obtained by Mortensen et al (1998), who found 
that the in vitro IC50 of CPO (along with other OP and carbamate compounds) for brain 
AChE remained the same (4.9 nM) in neonatal (postnatal day 4) and adult rats, thereby 
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supporting the hypothesis that the greater sensitivity of young animals is not due to 
greater sensitivity of target enzyme. 
 Atterberry and colleagues (1997) investigated age-related changes in the 
sensitivity of target and non-target esterase activities and bioactivation enzymes towards 
parathion and chlorpyrifos. Using several ages of rats ranging from 1-80 days of age, the 
authors measured the developmental patterns of AChE in the cortex and pons/medulla, 
and aliesterase (CarbE) activity in liver. The IC50 values towards the target enzyme AChE 
remained constant irrespective of age, for both PO and CPO. However, there were 
striking differences noted for IC50 values of PO and CPO towards aliesterases between 
young (≤ 12 days old) and adult rats (80 days old). Moreover, no age-related changes 
were noted in the bioactivation of either PS or CPF. From this study, the authors 
concluded that neither the target enzyme inhibition, nor bioactivation of these two OPs 
were important in age-related differences in sensitivity to these compounds. Rather, the 
detoxification pathway via aliesterase in the liver appeared the most likely contributor to 
the higher sensitivity of the younger rats to these OPs.  Padilla et al (2000) arrived at a 
similar conclusion when they observed that chlorpyrifos elicited a toxic response at a 5-
fold lower dose in the pre-weanling rat than in the adult rat, whereas methamidophos had 
the same toxicity (oral maximum tolerated dose) in both age-groups of rats. Since CPF is 
detoxified by both CarbE and AE, while methamidophos is not significantly detoxified 
by either enzyme, the authors hypothesized that OP pesticides like CPF, which require 
CarbE or AE for detoxification, are more likely to exhibit age-related differences in 
toxicity than OPs that are not detoxified by these routes.    
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All of these studies have reported that the in vitro sensitivity of AChE to OPs 
does not change markedly during maturation. However, we found no studies evaluating 
the in vitro sensitivity of AChE and BChE to OPs during aging. Our studies indicate that 
BChE in the aged rat heart was about 2.5-fold more sensitive than adult heart BChE to 
inhibition by CPO. While AChE appeared to be ~ 1.5-fold more sensitive to the effect of 
PO as compared to BChE, no age-related difference in sensitivity was noted with this 
inhibitor for either enzyme. A possible explanation for the greater in vitro sensitivity of 
aged heart BChE than adult heart BChE to CPO could be that the molecular isoform of 
the enzyme changes during aging. However, in this study, in vitro sensitivity was 
assessed in a crude tissue homogenate (rather than by using the purified enzyme). Due to 
this, it was not known whether the difference in IC50’s observed was due to expression of 
different isoforms during aging. 
As mentioned above, age-related differences in sensitivity to OPs could arise from 
differences in CarbE and A-esterase enzymes in the different age-groups. 
Carboxylesterase and A-esterases are important enzymes that play a role in the 
detoxification of many OPs. Karanth and Pope (2000) found that while aged (24-month) 
Sprague Dawley rats exhibited relatively similar acute sensitivity to CPF as compared to 
adults (3-month) based on lethality, they were about 3-fold more sensitive to the acute 
effects of parathion. In the same study, they also evaluated the activity of 
carboxylesterases (CarbE) and A-esterases (AE) in the liver, plasma and lung, as well as 
the in vitro sensitivity of CarbE to CPO and PO. While aged rats demonstrated similar 
levels of AE in all tissues examined compared to adults, CarbE levels were similar 
between adult and aged rats in the liver and lung; however, plasma CarbE levels in aged 
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rats were 50% lower than in adults. Moreover, no significant age-related differences were 
observed in the in vitro sensitivity of CarbE to either CPO or PO in any tissue. The acute 
sensitivity with CPF was highly correlated with age-related differences in CarbE and AE 
activities across all three tissues, whereas, only plasma CarbE activity was highly 
correlated with acute sensitivity to PS. Thus, the authors concluded that although both 
CarbE and AE activities were correlated with acute sensitivity to CPF and PS, age-related 
differences in CarbE activity were likely more important in differential toxicity, and that 
plasma CarbE played a crucial role in differential sensitivity to PS between adult and 
aged rats. In the present study, we found relatively similar reductions in plasma CarbE in 
the aged rats, but found no difference in the levels of carboxylesterase in the cerebral 
cortex or heart of adult and aged rats (Figures 106-108). Moreover, the former study 
suggests that there are very few tissue-related differences between amounts of A-
esterases in adult and aged rats.  
 
 
In Vitro Effects of Chlorpyrifos oxon and Paraoxon on Cardiac and Cortical 
Muscarinic Receptor Binding in Adult and Aged Rats 
Some organophosphorus anticholinesterases have been previously reported to 
displace agonists from binding to cardiac muscarinic receptors (Silveira et al., 1990; 
Howard and Pope, 2002), and these direct OP-receptor interactions may be important in 
selective toxicity. The relative potencies of chlorpyrifos oxon (CPO) and paraoxon to 
displace the agonist [3H]Oxotremorine-M ([3H]OXO) binding to muscarinic receptors 
were compared in adult and aged cardiac and cortical membranes. Both CPO and PO 
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displaced [3H]OXO binding in a concentration-dependent manner in the heart and cortex 
of adult and aged rats. Of the two oxons, CPO was the more potent displacer of [3H]OXO 
in the heart and cortex of both age-groups (Figures 24 and 25). Similarly, PO also 
displaced [3H]OXO from adult and aged cardiac and cortical membranes (Figures 26 and 
27). Both OPs appeared to have similar efficacies in displacing [3H]OXO binding in heart 
and cortex of the two age-groups. However, no age-related difference was observed in 
displacement of [3H]OXO binding in either tissue (Table 4). 
 As noted above, several studies have evaluated the ability of OP compounds 
(mainly oxons) to alter radioligand binding in muscarinic receptors. Howard and Pope 
(2002) evaluated the in vitro effects of certain OPs (chlorpyrifos, parathion and methyl 
parathion, as well as their oxons) on cardiac muscarinic receptor binding in neonatal and 
adult rats. Although all three oxons displaced [3H]OXO binding from neonatal and adult 
cardiac muscarinic receptors in a concentration dependent manner, CPO was found to be 
the most potent and efficacious of the three. Surprisingly, methyl parathion (MePS) 
displaced [3H]OXO from adult but not neonatal cardiac muscarinic receptors. While the 
interaction between CPO and cardiac muscarinic receptors appeared to be irreversible, 
that between MePS and adult cardiac muscarinic receptors appeared reversible. This 
finding was similar to the studies by Bomser and Casida, who found that CPO bound 
covalently and irreversibly to the rat cardiac M2 receptor, as evidenced by the 
diethylphosphorylation of the receptors in vitro. Chlopyrifos oxon was a potent displacer 
of tritiated cis-dioxolane (CD, a high affinity M2-selective agonist) binding and inhibited 
adenylyl cyclase in the rat striatum (Huff et al, 1994). The abilities of paraoxon, 
malaoxon and chlorpyrifos oxon to alter muscarinic receptor-mediated phosphoinositide 
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turnover and cAMP formation in rat cortex were examined by Ward and Mundy (1996). 
All three oxons displaced CD binding and inhibited cAMP formation in a concentration-
dependent manner, with chlorpyrifos oxon and malaoxon being most and least potent, 
respectively. All of the above studies suggest that CPO binds covalently and irreversibly 
to muscarinic receptors in a relatively potent manner.  
 Some studies have also investigated the in vitro effects of PO on muscarinic 
receptor binding. Volpe et al (1985) found that paraoxon, dichlorvos and 
tetraethylpyrophosphate inhibited QNB binding in bovine caudate membranes at low 
nanomolar concentrations. Subsequently, Katz and Marquis (1989) reported that 
paraoxon, at concentrations as low as 10-15 M, was capable of blocking radioligand 
binding to M2 and M3 receptors. As noted above, Silveira et al (1990) reported that 
paraoxon, echothiophate and the nerve agents VX, soman and tabun blocked the in vitro 
binding of CD to rat cardiac tissues at high nanomolar concentrations. Jett and colleagues 
(1991) reported that in rat striatal cells, paraoxon displaced CD binding and inhibited the 
formation of cAMP in an atropine-sensitive manner, while the parent insecticide 
parathion was 180-fold less potent. Ward et al (1993) reported that paraoxon and 
malaoxon were more potent at blocking CD binding to rat hippocampal and cortical 
membranes that their parent compounds, parathion and malathion.  
All these studies, including the results from our studies, indicate that certain OPs 
are capable of binding directly to muscarinic M2 receptors, and in some cases, acting as 
agonists (Silveira et al, 1990; Huff et al, 1994; Ward and Mundy, 1996). M2 receptors are 
linked to the cAMP second messenger system via G proteins. If CPO competes directly 
for the agonist binding site and acts as an agonist, second messenger signaling could be 
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affected. Any alterations in the levels of cAMP could potentially induce changes in the 
long-term regulation of cardiac function or could affect neuronal function, separately 
from AChE inhibition.  
Since the in vitro potencies of CPO and PO at displacing agonist binding (IC50: 
CPO = 6-17 nm; PO = 18-44 nm) are very similar to their potencies towards AChE (IC50: 
CPO = 6-35 nm; PO = 18-25 nm) and BChE (IC50: CPO = 0.6-8 nm; PO = 28-43 nm) in 
the brain and heart of adult and aged rats, direct interaction with muscarinic receptors in 
these tissues could occur at toxicologically-relevant exposure levels and contribute to the 
expression of toxicity.  
 
 
Effects of iso-OMPA on Heart Rate, Body Temperature and Physical Activity in 
Adult Male Sprague-Dawley Rats 
The effects of iso-OMPA on heart rate, body temperature and physical activity 
were evaluated up to 96 hours post-treatment. From the dose-determination studies, 1.25 
and 5 mg/kg were selected as the low and high dose groups, respectively. These doses 
were selected since they produced a dose-related inhibition of BChE, with no AChE 
inhibition, thus ensuring only cardiac ChE inhibition occurred in the absence of central 
ChE inhibition. Since there was no cholinesterase inhibition in the CNS, neither of the 
two doses of iso-OMPA produced any effect on body weight or functional signs of 
toxicity (data not shown).  
As the heart contains a high density of BChE relative to AChE, and iso-OMPA is 
a BChE-selective inhibitor, we hypothesized that iso-OMPA could affect heart rate in the 
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absence of other physiological effects related to AChE inhibition. The low and high doses 
of iso-OMPA produced a decrease in heart rate (Figures 37, 38, 39 and 40) at 24 hours 
post-treatment, with subsequent recovery. Surprisingly, the magnitude of heart rate 
reduction was greater in the low-dose than in the high-dose group. Since most of the 
effects of iso-OMPA on heart rate seemed to occur up to 48 hours post-treatment, heart 
rate was grouped into 4 hourly intervals and viewed up to 48 hours post-treatment (Figure 
40). The low and high doses of iso-OMPA produced a decrease in heart rate 16-20 hours 
post-treatment, with recovery occuring thereafter. Although there was a trend towards 
reduced heart rate at 36-40 hours post-treatment in both iso-OMPA dosing groups, it was 
not statistically significant.  
Neither dose of iso-OMPA produced any effect on body temperature (Figures 41, 
42 and 43) at any of the time points examined. Physical activity (Figures 44, 45 and 46) 
was only significantly reduced in the low-dose group 72 hours post-treatment (in the 
nocturnal phase), with subsequent recovery occurring to pre-treatment values.  
 As mentioned previously, the total ChE of adult hearts of higher vertebrates 
consists of around 85% BChE and 15% AChE (Chatonnet and Lockridge, 1989). 
Although present in small amounts, AChE is concentrated in the conducting system of 
the heart (sinus node, atrio-ventricular node and the ventricular conduction tissues), while 
BChE is concentrated in the contractile portions of the atria and ventricles (Chow et al, 
2001). Moreover, the relative proportions of cardiac AChE and BChE vary during post-
natal development. Slavikova and Tucek reported that the ratio of AChE in the rat heart 
atrium increased from 6% on postnatal day 1 to 12-15 % in the adult (Slavikova and 
Tucek, 1986). Additionally, it has been observed that in the human heart, the cardiac 
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conduction system predominantly contained BChE in the infant, and mainly AChE in the 
adult (Chow et al, 2001).  
Chemnitius et al (1999), used the OP inhibitor mipafox to characterize the 
cholinesterases of human cardiac muscle with respect to substrate specificity and kinetics 
of enzyme inhibition. Cardiac cholinesterases were characterized as acetylcholinesterase, 
butyrylcholinesterase and an enzyme they classified as atypical cholinesterase, since it 
demonstrated some amount of ChE substrate specificity as well as minimal sensitivity to 
inhibition by mipafox. 
Butyrylcholinesterase has long been considered to be a vestigial enzyme with no 
known physiological function, and until recently, has commonly been referred to as 
“pseudocholinesterase”. More recently, however, it was found that BChE may, in fact, 
play a role in the hydrolysis of ACh. Perfusion of a selective BChE inhibitor into the rat 
brain was found to increase extracellular ACh by around 15-fold (Giacobini, 2004). Norel 
et al (1993) reported that BChE was present in human bronchial muscle, and possibly co-
regulated the degradation of ACh in that tissue. 
The role of BChE was evaluated by Oksana Lockridge and coworkers through the 
generation of the AChE-knockout (-/-, -/+) mouse model. AChE-knockout (-/-) mice 
expressing normal levels of BChE were found to live to adulthood, even though they had 
weak muscles, could not eat solid food and died prematurely from seizures. Three 
mechanisms were indentified that ensured the survival of AChE-knockouts, including a 
reduction in muscarinic and nicotinic receptors, morphological remodeling of the motor 
endplate, and hydrolysis of ACh by BChE (Li et al, 2003; Adler et al, 2004). These mice 
demonstrated a heightened sensitivity to BChE-specific inhibitors such as iso-OMPA and 
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bambuterol, suggesting that it was the BChE activity in the knockout mice that facilitated 
their survival, and that the role of BChE was to compensate for the function of AChE 
(i.e., hydrolysis of ACh) (Xie et al, 2000; Li et al, 2000). BChE was present in all parts of 
the brain receiving cholinergic signaling in wild types and knockouts. Moreover, it was 
suggested that BChE plays a constitutive rather than a back-up role in the hydrolysis of 
acetylcholine in the normal brain (Mesulam et al, 2002a). Further support for this 
hypothesis came from the fact that in the absence of AChE, BChE controls the levels of 
extracellular ACh, as evidenced by the fact that excessive hippocampal ACh levels in 
AChE-knock-out mice were regulated by BChE (Hartmann et al, 2007a).   
Measurements of contractility on phrenic nerve-hemidiaphragm preparations from 
AChE (-/-) mice further support the conclusion that BChE functions to hydrolyze 
acetylcholine in these mice (Adler et al, 2004). In a separate study evaluating evoked 
quantal transmitter release in a nerve-muscle preparation from the AChE-knockout (-/-) 
mouse, however, researchers found that BChE was not involved in hydrolysis of ACh in 
the AChE-knockout (-/-) mice, since BChE inhibitors did not affect the time course of 
synaptic potentials (Minic et al, 2003). These inhibitors did however, decrease evoked-
quantal transmitter release, suggesting that BChE might be involved in a presynaptic 
modulation of synaptic transmission at mature neuromuscular junctions (Minic et al, 
2003). These investigators hypothesized that BChE inhibition leads to diminished rather 
than excessive acetylcholine in the neuromuscular junction (Girard et al, 2005; Girard et 
al, 2007), and measurements of respiratory activity in AChE (-/-) mice agreed with this 
hypothesis (Chatonnet et al, 2003).  
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Recently, BChE homozygous (-/-) and heterozygous (-/+) knockout mice have 
been generated (Li et al, 2006a). BChE (-/-, -/+) knockout, AChE (-/-) knockout and wild 
type mice were treated with the AChE-specific inihibitors huperzine A and donepezil, as 
well as with organophosphorus inhibitors, ecothiophate and chlorpyrifos oxon. After 
treatment with huperzine A and donepezil, the BChE homozygous knockout mice 
exhibited severe signs of toxicity and subsequently died. The BChE heterozygous 
knockouts exhibited intermediate signs of toxicity and survived for a longer time, while 
the wild type mice showed very minor signs of toxicity and recovered after 24 hours. 
Plasma AChE activity was inhibited to the same extent in all three groups, whereas 
plasma BChE activity was unaffected. This confirmed that the protective effect of BChE 
was not a result of inhibitor “scavenging”. AChE (-/-) mice were unaffected by huperzine 
A and donepezil, thereby confirming their specificity for this enzyme. When AChE (-/-) 
mice were treated with chlorpryifos oxon, they lost all BChE activity, developed severe 
signs of cholinergic toxicity and died of seizures/convulsions, thus demonstrating again 
that BChE activity was essential for the survival of the AChE (-/-) mouse. From this 
study, Duysen et al (2007) concluded that BChE exerted its protective effect by 
hydrolyzing excess ACh in physiologically relevant regions such as the diaphragm, 
cardiac muscle and the brain, and that BChE normally participates in cholinergic 
neurotransmission. All of the above studies suggest a physiological role for 
butyrylcholinesterase in cholinergic neurotransmission.  
Previous studies suggest discreet association of acetylcholinesterase and 
butyrylcholinesterase with separate populations of intrinsic cardiac neurons, and their 
possible selective involvement in neurotransmission in the intrinsic cardiac ganglia 
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(Darvesh et al, 1998). In the canine right atrial neurons, four neuronal populations were 
present: those containing a) only AChE, b) only BChE, c) both AChE and BChE and d) 
those containing neither enzyme. The local application of acetylcholine was found to 
increase the activity of intrinsic cardiac neurons, with an even greater increase being 
observed by local application of butyrylcholine. These two enzyme substrates were found 
to preferentially affect different populations of intrinsic cardiac neurons, which agreed 
with enzyme kinetic studies showing that canine AChE preferentially hydrolyzed ACh, 
while canine BChE preferentially hydrolyzed BCh. Using AChE-specific and BChE-
specific inhibitors, as well as inhibitors targeting both enzymes, the activity of neurons in 
the intrinsic cardiac ganglia were only affected when both cholinesterases were inhibited, 
leading to the conclusion that AChE- and BChE-containing intrinsic cardiac neurons act 
synergistically to influence the overall tonic activity of the intrinsic cardiac ganglia. In a 
subsequent study using porcine intrinsic cardiac neurons, which contained AChE and/or 
BChE, acetylcholine and butyrylcholine increased or decreased the spontaneous activity 
of the intrinsic cardiac neurons. It was concluded from these studies that inhibition of 
AChE and BChE by cholinesterase inhibitors directly affects the porcine intrinsic cardiac 
nervous system (Darvesh et al, 2004). 
In an earlier study, Burn and Walker (1954) reported that the BChE-specific 
inhibitor Nu 683 reduced heart rate while the AChE-specific inhibitor BW 284C51 had 
no effect using the Starling heart-lung preparation of the dog. They concluded BChE 
regulated parasympathetic control of heart rate. This finding agreed with results from our 
studies wherein, iso-OMPA-induced cardiac BChE inhibition decreased heart rate. The 
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lack of other physiological effects (such as effects on body temperature or motor activity) 
may be due to lack of AChE inhibition in the central and/or peripheral nervous system.   
In the present study, both doses of iso-OMPA decreased heart rate. This was in direct 
contrast to Knuepfer and Gan (1999), who did not observe any difference in heart rate 
after treatment of rats with this compound. The authors reported that ten minutes after 
intravenous treatment of rats with 0.5 mg/kg iso-OMPA, no difference was observed in 
heart rate compared to baseline values. The experimental design of Knuepfer and Gan 
(1999) was very different from ours (intravenous vs. subcutaneous administration, 0.5 vs. 
1.25 and 5 mg/kg doses, measurement of heart rate until 10 minutes post-treatment vs. 
until 96 hours post-treatment), which could possibly explain the differences in the 
observed outcome.  
In the current study, a decrease in heart rate by iso-OMPA was observed between 
16-20 hours post-treatment. Subsequent to that, heart rate in both dose-groups appeared 
to recover. This might be explained by the fact that iso-OMPA-induced BChE inhibition 
recovered between 24 and 96 hours post-treatment in the heart (Figures 48 and 52). 
Interestingly, the magnitude of heart rate decrease was greater in the low dose than the 
high dose group. Since the inhibition of BChE in the atria and ventricles was greater with 
the high dose than the low dose, we were surprised by this inverse dose-related  effect. 
One possible explanation for this could be that iso-OMPA, in addition to inhibiting 
cardiac BChE, also bound directly to cardiac muscarinic receptors. If this were the case, 
iso-OMPA could antagonistically block the effects of accumulated ACh (which would 
presumably result from iso-OMPA-induced BChE inhibition) and thereby prevent ACh-
induced slowing of heart rate. As mentioned previously, several OP compounds have 
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been shown to bind directly to muscarinic receptors. However, no studies have reported 
the effects of iso-OMPA binding on to muscarinic receptors. To test this hypothesis, we 
evaluated the relative in vitro inhibition of [3H]OXO binding and BChE activity by iso-
OMPA in heart (Figure 47). These data suggested that in addition to inhibiting BChE, 
iso-OMPA can directly bind to [3H]OXO binding sites in the heart. Iso-OMPA was 
approximately three orders of magnitude more potent at inhibiting BChE (IC50: 188 nM), 
however, than at displacing [3H]OXO binding (IC50: 116 µM).  At low concentrations, 
iso-OMPA may inhibit BChE with less effect on muscarinic receptors, and as the 
concentration of iso-OMPA increases, direct effects on muscarinic receptors may become 
more relevant. If so, this could explain the greater effect of the low dose of iso-OMPA in 
reducing heart rate than the high dose.  
 
 
Effects of iso-OMPA on Acetylcholinesterase, Butyrylcholinesterase, 
Carboxylesterase and Muscarinic Receptor Binding in Ventricles, Atria, Cortex and 
Plasma 24 and 96 Hours Post-Treatment 
The effects of iso-OMPA on AChE, BChE, CarbE and muscarinic receptor 
binding were evaluated 24 and 96 hours post-treatment.  Iso-OMPA produced a dose-
related inhibition of BChE (Figures 48, 52, 56 and 59) and CarbE (Figures 50, 54, 58 and 
61) in all of the tissues investigated. Iso-OMPA inhibited ~60% (low dose) to 80% (high 
dose) BChE activity in the atria, ventricles and plasma at the 24 hour time point, with 
enzyme recovery occurring by the 96 hour time point. In the cortex, only the high dose 
produced a significant inhibition of BChE at the 24 hour time point, with enzyme 
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recovery occuring by the 96 hour time point. The amount of CarbE inhibited by iso-
OMPA at the 24 hour time point ranged from ~10-30% for the low dose, and 10-40% for 
the high dose. The amount of CarbE inhibited remained approximately the same by 96 
hours post-treatment for all tissues, except in the ventricles, wherein the high dose of iso-
OMPA caused further inhibition of CarbE. Neither of the two doses of iso-OMPA used in 
the study produced any inhibition of AChE (Figures 49, 53, 57 and 60) at the 24 and 96 
hour time points, thereby confirming their selectivity for BChE. Interestingly, 
significantly higher levels of AChE were noted in some tissues following treatment with 
iso-OMPA.  
 Muscarinic receptor binding (Figures 51 and 55) was evaluated using the agonist 
[3H]oxotremorine-M. Muscarinic receptor binding was significantly reduced  (~25%) by 
the high dose of iso-OMPA in the ventricles at 24 hours, with recovery occurring by 96 
hours post-treatment. Approximately 20% down-regulation of muscarinic receptors 
occurred in the low and high dose groups of iso-OMPA in the atria at 24 hours post-
treatment, which persisted until 96 hours. Thus, these data argue against a selective effect 
of high-dose iso-OMPA on cardiac muscarinic receptors as suggested above for dose-
related differences in heart rate.  
 Iso-OMPA is an organophosphorus compound that has mainly been used for 
experimental purposes due to its highly selective inhibition of BChE relative to AChE 
(Girard et al, 2005; Minic et al, 2003). Iso-OMPA is a direct-acting esterase inhibitor, 
i.e., it does not require metabolic activation, and hence can elicit rapid cholinesterase 
inhibition. In addition to inhibiting BChE, the carboxylesterase inhibiting properties of 
iso-OMPA have also been recognized (Gupta et al, 1985; Gupta and Dettbarn, 1987; 
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Gupta and Kadel, 1989). Due to this fact, in addition to evaluating the effects of iso-
OMPA on BChE and AChE, CarbE activity was also evaluated after treatment with this 
compound.  
 Gupta et al (1985) evaluated the effects of iso-OMPA (3 mg/kg, administered 
subcutaneously for 5 consecutive days) on acetylcholinesterase and butyrylcholinesterase 
activities in the diaphragm and cortex of adult rats. At this dose, iso-OMPA inhibited 
~18% AChE in the cortex and 96% and 70% BChE in the diaphragm and cortex, 
respectively. In a subsequent study, iso-OMPA (1 mg/kg, sc) inhibited ~78% and 73% 
BChE activity in the plasma and liver, respectively 1 hour after treatment (Gupta and 
Dettbarn, 1987). Twenty-four hours after treatment (1 mg/kg), BChE was inhibited by 
20% and 0% in the cortex and hemi-diaphragm, respectively.  
Gupta and Kadel (1989) reported that 1 mg/kg iso-OMPA (sc) inhibited ~85%, 
50% and 25% CarbE activity in the plasma, liver and cortex, respectively. In our study, 
we did not observe any CarbE inhibition in the cortex with the 1.25 mg/kg dose group 
and ~30% CarbE inhibition in the plasma with this dose. The discrepancy obtained 
between these studies may be explained by the different times of sacrifice and tissue 
collection. Gupta and Kadel (1989) reported that iso-OMPA produced maximal CarbE 
inhibition within 1 hour after treatment, whereas the earliest sacrifice time point we used 
was 24 hours post-treatment. Another explanation might be experiment to experiment 
variation, since, in a separate study, Gupta and Dettbarn (1987) reported that the same 
dose of iso-OMPA (1 mg/kg, sc) inhibited 100%, 70% and 30% CarbE activity in the 
plasma, liver and cerebral cortex 1 hour after treatment, which differed from the CarbE 
inhibition obtained in their previous study (Gupta and Kadel, 1989).  
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In our study, iso-OMPA exposure was associated with significantly higher AChE 
activity (compared to control) in the atria and cortex. Although increased levels of AChE 
might seem surprising following exposure to a BChE inhibitor, similar findings have 
been previously reported. Friedman et al (1996) reported that mice that were stressed (by 
forced swimming) and treated with pyridostigmine (which is a peripherally-acting 
cholinesterase inhibitor) had early and immediate increased levels of c-fos oncogene and 
AChE mRNAs in the brain. Further, they suggested that under conditions of stress, 
peripherally-acting drugs could reach the brain and affect centrally controlled functions. 
A subsequent study from the same laboratory (Kaufer et al, 1998) found that following 
stress exposure, there was a transient increase in acetylcholine release, accompanied by a 
phase of enhanced electrical brain activity. These authors found that this led to a similar 
bi-directional modulation of genes that regulated the availability of acetylcholine by 
either stress or AChE inhibition. Excessive cholinergic stimulation triggered rapid 
induction of the gene encoding the transcription factor c-Fos. Since c-Fos binding sites 
are present in the promoter regions of the genes encoding AChE, ChAT and VAChT, 
elevated c-Fos levels could lead to long-lasting changes in cholinergic gene expression 
via increased AChE mRNA levels and decreased ChAT and VAChT mRNA levels. 
Kaufer and colleagues (1999), using perfused mouse sagittal brain slices that were 
exposed to either an organophosphate (DFP) or carbamate (pyridostigmine) 
anticholinesterase reported overexpression of the mRNA encoding the immediate early 
response transcription factor, c-Fos within 10 minutes. Twenty minutes later, an 8-fold 
increase in AChE mRNA and a 3-fold decrease in ChAT mRNA and VAChT mRNA 
were noted. They concluded that low-level exposures to anticholinesterases could lead to 
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elevated levels of brain AChE via feedback induction, leading to possible long-term 
deleterious changes in cholinergic signaling and functions such as cognition. All of these 
studies suggest that in the presence of stress or an anticholinesterase, there may be rapid 
induction of AChE mRNA. These findings agree with our studies wherein we observed 
elevated levels of AChE in the atria and cortex of iso-OMPA treated rats as early as 24 
hours post-treatment. Further studies should evaluate these possible changes in AChE 
gene induction by iso-OMPA. 
Muscarinic receptors in the atria were down-regulated by ~20% in both iso-
OMPA dose groups at both time points, in spite of the significant difference in BChE 
inhibition. BChE activity appeared to recover from 45% and 20% (low and high dose 
groups) at 24 hours to 75% and 80% (low and high dose groups) at 96 hours. Yet, 
muscarinic receptors remained down-regulated to the same extent at both time points 
with the two doses. Down-regulation of muscarinic receptors is typically regarded a 
tolerance mechanism in reponse to the effects of synaptic ACh accumulation and 
activation of the muscarinic receptors, and has been described by a number of researchers 
(Cioffi and El-Fakahany, 1988; Zhu et al, 1991; Howard et al, 2007; Karanth et al, 2007). 
It may be that after a degree of cholinesterase inhibition and resulting ACh accumulation, 
muscarinic receptors on the cell surface are reduced by approximately the same level. 
Similar results were observed with Howard et al (2007), when adult rats gavaged with 68 
and 136 mg/kg CPF produced ~70% and ~90% cardiac cholinesterase inhibition at 4 and 
24 hours post-treatment, respectively, along with ~25% down-regulation of cardiac 
muscarinic receptors at both time points.  
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Effects of Acute Chlorpryifos or Parathion Exposure on Heart Rate, Body 
Temperature and Physical Activity in Adult and Aged Rats 
The effects of acute equitoxic doses of chlorpyrifos and parathion on heart rate, 
body temperature and motor (physical) activity were evaluated in adult and aged rats 
using radiotelemetry. Radiotelemetry is considered to be a humane and efficient method 
for observing physiological parameters in conscious, unrestrained animals (Kramer et al, 
2001; Kramer et al, 2003). By using radiotelemetric devices, it is possible to monitor 
several physiological parameters in conscious, freely moving animals. Since no restraints 
are required, there is reduced handling stress to the animal. Moreover, it is possible to 
obtain data almost continuously from the animal, with minimal handling, which can also 
reduce variability among animals (Kramer et al, 2003). Continuous monitoring of data 
reduces the possibility of missing subtle changes that might otherwise be overlooked. 
Both chlorpyrifos and parathion produced a dose-related decrease in heart rate in 
the medium and high dose groups of adult and aged rats. Both OPs caused a dose-related 
decrease in heart rate which persisted throughout the study. In general, the bradycardia 
induced by CPF and PS was preceded by a brief elevation in heart rate in the diurnal 
phase.  Heart rate responded differently in aged rats (compared to adults) treated with PS 
(Figures 91-93). A brief period of tachycardia in the medium-dose group was followed by 
a decrease and a subsequent trend towards recovery by the end of the study. In the high-
dose group, an initial decrease in heart rate was followed by a brief period of increase, 
after which the heart rate continued to decrease significantly until the end of the study.  
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Chlorpryifos and parathion produced a dose-related decrease in body temperature 
in the medium- and high dose-groups of both adult and aged rats. The decrease in body 
temperature in the medium- and high dose-groups of both OPs predominantly occurred 
during the nocturnal phase and peaked ~24 hours post-treatment. In general, body 
temperature either recovered to pre-treatment levels or remained suppressed until the end 
of the observation period in both adult and aged rats. 
CPF and PS both produced a dose-dependent decrease in motor activity which 
peaked 24 hours after treatment in adult rats. Subsequently, CPF produced a diurnal 
increase in motor activity in the medium- and high-dose groups, which recovered to 
baseline values by the end of the study. With PS,  motor activity remained depressed in 
the medium- and high dose-groups. In aged rats, both CPF and PS produced a dose-
dependent decrease in motor activity that peaked by 24 hours following exposure. 
Thereafter, both OPs induced a diurnal increase in physical activity in the aged rats, 
which persisted until the end of the study. The basis for these directional changes in 
motor activity are unclear.  
Numerous investigators have reported varying degrees of cardiotoxicity following 
exposure to organophosphorus insecticides. Electrocardiographical (ECG) abnormalities 
have been found to occur in humans with severe OP intoxication, the most common of 
which are prolongation of the Q-Tc interval and ST/T changes (elevated ST segment and 
inverted T waves) (Karki et al, 2004). Another common ECG abnormality that occurs in 
OP poisoning is the torsade de pointes type of polymorphic ventricular tachycardia, 
which has been attributed to the prolonged Q-Tc interval (Saadeh et al, 1997; 
Ludomirsky et al, 1982). In a 2007 review, Bar-Meir and coworkers proposed several 
 266 
hypotheses to explain the phenomenon of OP-induced QT prolongation (considered an 
unfavorable prognostic indicator of survival): 1) vagal overstimulation 2) muscarinic 
receptor involvement leading to an abnormal regulation of potassium channels 3) effect 
on central or peripheral nervous system 4) direct effect on cardiac autonomic innervation, 
and 5) excessive cholinergic stimulation. Although the exact mechanism of cardiotoxicity 
is still unknown, there have been some proposed mechanisms. Saadeh et al (1997) 
suggested possible mechanisms of cadiotoxicity included sympathetic and 
parasympathetic over-activity, hypoxemia, acidosis, electrolyte imbalance and a direct 
toxic effect of the OP compounds on the myocardium. Peter and Cherian (2000) 
suggested that OP-induced cardiotoxicity may be due to 1) a direct toxic effect on the 
myocardium, 2) overactivity of muscarinic or nicotinic receptors leading to 
haemodynamic alterations, and/or 3) complications that might arise as a result of high 
dose atropine therapy. Abraham et al (2001) implicated several factors in OP-induced 
cardiotoxicity, including catecholamine overflow, neurogenic effects and direct 
myocardial damage. Allon et al (2005) reported a decrease in the threshold for 
epinephrine-induced arrhythmias in rats exposed to sarin vapors, which lasted up to 6 
months after exposure. The authors concluded that this increase in vulnerability to 
developing arrhythmias long after OP exposure, especially under conditions like stress or 
physical exercise, may explain delayed mortality associated with severe OP intoxications. 
In the present study, most doses of CPF and PS elicited a brief diurnal period of 
tachycardia, which was followed by prolonged bradycardia. While the initial elevation in 
heart rate might seem surprising, there have been reports of OP-induced tachycardia. 
Petroianu and Rufer (1992) found that high-dose intravenous administration of paraoxon 
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in mini pigs led to extreme hypertension, tachycardia and a hematocrit increase, with 
death occurring as a result of sympathetic overstimulation and hypovolemia. Petroianu 
and coworkers (1998) recommended antihypertensive therapy in such cases, due to what 
they called a “phaeochromocytoma-like pattern” which is caused by an excessive release 
of catecholamines from the adrenal medulla after activation by acetylcholine. 
Ludomirsky et al (1982) described three phases of organophosphate-induced 
cardiotoxicity: 1) a brief period of sympathetic tone, characterized by sinus tachycardia 
and hypertension 2) a prolonged period of parasympathetic tone characterized by sinus 
bradycardia and hypotension, ST-T wave abnormalities and AV conduction disturbances 
of varying degrees and 3) a prolonged Q-T interval with torsades de pointes, and sudden 
cardiac death. Hence, the current study agreed with the observations of Ludomirsky and 
coworkers, wherein bradycardia was generally preceded by a brief phase of tachycardia.  
Several investigators have reported a decrease in heart rate following exposure to 
various OP insecticides in different animal models. Naidu et al (1986) reported that 
dichlorvos induced ECG abnormalities, bradycardia and cardiac arrest in Wistar rats. The 
degree of bradycardia was correlated with the degree of cholinesterase inhibition in the 
heart and brain. Bataillard and colleagues (1990) reported a marked, sustained increase in 
blood pressure accompanied by bradycardia following an intravenous administration of 
paraoxon and soman. Cetin et al (2007) observed chlorpyrifos-induced cardiac 
dysfunction in rabbits, which was manifested by significant decreases in heart rate, 
cardiac output, left ventricular fractional shortening, left ventricular ejection fraction, 
thickening of left ventricle posterior wall, and significant increases in left atrial diameter, 
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left ventricular internal diameter in end diastole, left ventricular end diastolic volume and 
end systolic volume.  
Radiotelemetry has been previously used by Dr. Chris Gordon’s laboratory to 
evaluate the effects of various OP insecticides on physiological parameters such as heart 
rate, body temperature and motor activity in the rat model. Gordon (1993) evaluated the 
acute and delayed effects of diisopropylfluorophosphate (DFP) on the above-mentioned 
parameters using radiotelemetry. In this study, physiological parameters were 
continuously monitored for 96 hour after subcutaneous treatment of Long-Evans rats with 
DFP (0, 0.1 or 1 mg/kg). The reduction in core body temperature in rats treated with 1 
mg/kg DFP peaked by 5 hours post-treatment and recovered to control values by 17 hours 
after treatment. Although motor activity and heart rate were affected during the first 24 
hours (motor activity decreased; heart rate initially increased, then decreased), core body 
temperature was significantly elevated during the 24-96 hour recovery phase. The 0.1 
mg/kg DFP group displayed a hyperthermic response throughout. It has long been known 
that OP toxicity is associated with hypothermia in rats. However, this was the first report 
of a delayed hyperthermic response (preceded by hypothermia) following OP exposure. 
Rapid blockade of this hyperthermic response was achieved by administration of sodium 
salicylate, an antipyretic drug that acts through inhibition of cyclooxygenase activity 
(Gordon, 1996). This finding corroborated many observations of fever in humans acutely 
exposed to OP pesticides (Namba et al, 1971; Hirshberg and Lerman, 1984; Hantson et 
al, 1996).  
Gordon and Padnos (2000b) assessed systolic, diastolic and mean blood pressure, 
pulse pressure (systolic-diastolic), heart rate, core body temperature and motor activity in 
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rats treated with various doses of orally administered chlorpyrifos (CPF). The highest 
dose of CPF increased blood pressure within 2 hours of treatment, which persisted 
throughout the night and into the next day, slightly decreased heart rate, and led to 
hypothermia followed by hyperthermia, elevated pulse pressure and decreased motor 
activity. The authors concluded that the increase in blood pressure without a 
corresponding increase in heart rate could be due to a CPF-induced increase in total 
peripheral resistance and an alteration of the baroreflex control of blood pressure. They 
concluded that although the initial effects of CPF on blood pressure could be explained 
by cholinergic stimulation of the central nervous system, the persistent pressor response 
probably involved neurohumoral pathways.  
In the current study, the medium and high doses of CPF and PS elicited a decrease 
in body temperature, which either recovered to pre-treatment levels or remained 
suppressed until the end of the observation period. However, in most studies by Gordon 
and colleagues, CPF initially elicited a hypothermic response followed by a delayed 
fever. Gordon et al (1997b) evaluated the thermoregulatory effects of orally administered 
chlorpyrifos (0, 10, 50 or 80 mg/kg) in male and female Long-Evans rats using 
radiotelemetry. Following treatment with CPF, both male and female rats exhibited a 
significant hypothermic response that lasted ~16 hours and a delayed hyperthermia which 
persisted during the diurnal phase for 1-2 days after CPF exposure. Female rats were 
significantly more sensitive to CPF, exhibiting a significant hypothermic response at 
doses which did not produce hypothermia in male rats. Similar to DFP, the CPF-induced 
hyperthermia was blocked by administration of sodium salicylate. Castrated male rats 
were significantly more sensitive to the hypothermic and hyperthermic effects of CPF 
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compared to sham operated controls, whereas, ovariectomized female rats displayed 
similar sensitivity to CPF compared to sham operated controls. Hence, the authors 
concluded that testicular function plays an important role in gender-dependent differences 
in sensitivity to CPF. In a subsequent study, Gordon and Yang (2000a) reported that 
vasodilatation of the tail skin is an important mechanism by which core body temperature 
decreases during the acute hypothermic stage of CPF exposure, and that these 
hypothermic and vasodilatory responses to CPF are mediated via a cholinergic 
muscarinic pathway in the CNS. A radiotelemetric probe was used to non-invasively 
monitor the tail skin temperature of rats (Gordon et al, 2002).  
Using the peripheral and central muscarinic antagonists methyl scopolamine and 
scopolamine, respectively, Gordon and Grantham (1999) concluded that cholinergic 
stimulation of heat loss pathways in the thermoregulatory centers of the CNS were 
responsible for CPF-induced hypothermia. While peripheral cholinergic pathways did not 
appear to play a role in CPF-induced hypothermia, they appeared to participate in CPF-
induced fever. Gordon and Mack (2001) assessed the effect of time of exposure on the 
ability of CPF to alter core body temperature and motor activity in rats, by dosing at 
either 0900 or 1500 hours. While the maximum decrease in core temperature (Tc) was 
found to be similar with both dosing times, the temperature index (area under curve of 
∆Tc with time) was significantly greater when CPF was administered in the afternoon as 
compared to the morning. Motor activity was depressed to a similar extent by CPF 
administered at both times. Hence, the authors concluded that time of day affected the 
thermoregulatory effects of CPF. Rowsey and Gordon (1999) reported the involvement of 
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endogenously produced tumor necrosis factor in the etiology of CPF-induced 
hypothermia and fever.  
Gordon (1997a) studied the link between CPF-induced hypothermia and delayed 
hyperthermia to ascertain whether these two thermic responses were regulated by the 
thermoregulatory centers of the CNS. Core temperature and motor activity were 
monitored in rats housed in a temperature gradient. While non-heated rats underwent 
hypothermia followed by hyperthermia 48 hours after CPF exposure, rats maintained at 
high temperatures did not show a hypothermic response, but did demonstrate a 
hyperthermic response 48 hours after treatment with CPF. Motor activity was suppressed 
during the first nocturnal period post-treatment with CPF in both groups of rats. Hence, 
Gordon concluded that the delayed fever associated with CPF was not dependent on the 
development of hypothermia, and that both of these responses were regulated by the 
thermoregulatory centers in the CNS.  
Ahdaya and coworkers (1976) examined the ability of mice held at 1°C, 27°C 
(room temperature) and 38°C to thermoregulate subsequent to treatment with parathion. 
While mice maintained at 1°C showed a slight decrease in rectal temperature, those kept 
at 27°C and 38°C did not vary from controls. Moreover, mice that were held at 1°C and 
38°C showed greater mortality than those held at room temperature (27°C). 
In general, work from Gordon’s lab found that CPF leads to an initial period of 
hypothermia lasting for ~24 hours, followed by an elevation  in diurnal core body 
temperature (delayed fever) lasting for 48-72 hours. While we observed a decrease in 
body temperature following exposure to both CPF and PS in adult and aged rats, we did 
not find any evidence of a hyperthermic response. Several factors could be responsible 
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for the differential responses noted between the two laboratories, such as strain 
differences of rats (Sprague-Dawley vs. Long-Evans), route of administration of OP 
insecticide (subcutaneous vs. oral), and (more likely) the relative site of placement of the  
transmitter within the rat (subcutaneous vs. intraperitoneal). It seems plausible that while 
subcutaneous placement of the transmitter can detect changes in body temperature, it 
might not be as accurate as intraperitoneal implantation. With subcutaneous implantation, 
changes in ambient temperature are more likely to influence the temperature sensor, 
whereas intraperitoneal implantation would be better at detecting core body temperature 
changes.  
Gordon and Watkinson (1995) evaluated the intraspecies variation in the 
responses of heart rate, core body temperature and motor activity to DFP using Sprague-
Dawley, Long-Evans, Fischer 344 and Wistar rats. The Fischer 344 rats, which had the 
lowest degree of brain and serum cholinesterase inhibition (as compared to the other 
strains) showed the least susceptibility to the hypothermic response to DFP. Sprague-
Dawley rats differed from the other strains in that heart rate was elevated after DFP, in 
spite of a significant decrease in core body temperature and motor activity. Of all four 
strains, Long-Evans rats demonstrated the largest decrease in core body temperature and 
heart rate following DFP exposure.  
Most of the studies involving CPF by Gordon’s lab involved CPF administered 
via the oral route. In 1994, however, Gordon evaluated the effects of subcutaneously 
administered CPF (280 mg/kg) on core temperature, heart rate and motor activity. In 
contrast to the other reports from this laboratory, other than a significant reduction in 
nocturnal body temperature within the first 24 hours no other effects were observed on 
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core temperature. While motor activity was unaffected by CPF, heart rate was 
significantly elevated for up to 72 hours following treatment. Therefore, it appears that 
the route of administration of OPs can markedly influence the qualitiative outcome and 
the time course of effects on these physiological parameters.  
In our studies, motor activity was initially reduced by both CPF and PS in adult 
and aged rats. However, towards the end of the observation period, there was a diurnal 
increase in activity with both OPs. A number of studies have reported changes in motor 
activity (predominantly a decrease) following exposure to common OP 
anticholinesterases including CPF, PS and DFP (Pope et al, 1992b; Gordon 1993; Gordon 
and Mack, 2001; Karanth et al, 2006, 2007). Pope et al (1992b) observed a reduction in 
motor activity for 2 days following exposure to 279 mg/kg CPF, administered 
subcutaneously. Subsequently, motor activity recovered to control levels. Karanth et al 
(2006) evaluated the effects of various doses of CPF on motor activity in adult, male 
Sprague-Dawley rats. While diurnal motor activity was unaffected by all doses of CPF, 
nocturnal motor activity (in particular, rearing) was significantly reduced in all CPF-
treated rats from one to four days after exposure. Gordon and Mack (2001) also reported 
that CPF decreased nocturnal motor activity, with no significant effect on diurnal activity. 
Timofeeva and Gordon (2001, 2002) evaluated changes in EEG power spectra and 
behavioral states in rats exposed to CPF. Changes in EEG and behavior following CPF 
included cortical arousal, increased quiet waking and decreased sleep, occurring 
independently from a decrease in motor activity. These responses were concluded to be 
due to CPF-induced hyperactivity in brain cholinergic neuronal networks.  
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Karanth et al (2007) evaluated the effects of equitoxic doses of parathion on 
motor activity in adult (3 months, 27 mg/kg, sc) and aged (18 months, 9 mg/kg, sc) rats. 
Nocturnal motor activity (both ambulation and rearing) was reduced in both age-groups. 
In spite of similar reductions in striatal and diaphragm cholinesterase activities in the two 
age-groups, more prominent effects were observed (especially in nocturnal rearing) in 
adults. The highest dose of PS led to a significant reduction in rearing activity in adults 
until 7 days post-treatment, and only at 2 days following exposure in aged rats.  
Lopez-Crespo and coworkers (2007) evaluated the time-course of effects of a 
single high dose (250 mg/kg, sc) of CPF on rat locomotor activity for 30 days after 
exposure. AChE inhibition in the whole brain recovered partially from 72% inhibition on 
day 2 to 55% inhibition on day 30. CPF had a biphasic effect on motor activity (similar to 
the results from the present study), wherein there was a reduction on day 2 followed by 
an increase over control by day 30. To explain this delayed increase in motor activity, the 
authors concluded that adaptive changes occurred in the cholinergic system to balance the 
effects of excessive acetylcholine accumulation, leading to this long-term alteration. 
Subsequently, due to the possibility of interactions with the dopaminergic system, the 
authors tested motor activity following challenge with amphetamine at 11 and 30 days 
following CPF exposure. Whereas amphetamine increased motor activity at both time 
points in the vehicle and CPF groups, rats treated with CPF exhibited less of an increase 
(relative to the vehicle-treated control). From these findings, the authors concluded that 
CPF affects the dopaminergic system, leading to subtle, long-lasting effects that are 
independent of its cholinergic effects.  
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Other studies have reported an interaction between CPF and the dopaminergic 
system. Karen et al (2001) examined the effects of CPF on striatal dopaminergic 
pathways in mice. CPF decreased dopamine uptake and increased dopamine turnover in 
striatal synaptosomes. Moreover, the highest dose of CPF also decreased open field 
behavior, providing additional information that dopaminergic neurotransmission is 
disrupted by exposure to CPF. Bloomquist et al (2002) evaluated the effects of CPF on 
the nigrostriatal dopaminergic nerve pathways in mice. They observed that CPF 
decreased dopamine uptake in striatal synaptosomes.  
Moreno and colleagues (2008) investigated the time-course (up to 30 days post-
treatment) of acute CPF (250 mg/kg, sc) on monoamine and cholinergic systems in the 
striatum and nucleus accumbens of adult rats. CPF elicited long-term inhibition of AChE 
in the striatum and nucleus accumbens, and significant decreases in dopamine, 
norepinephrine and serotonin content (along with their metabolites) in the nucleus 
accumbens for 30 days after exposure. Moreover, changes in dopamine metabolism and 
serotonin turnover were also observed in the striatum at various time-points following 
intoxication by CPF. The authors concluded that acute exposure to CPF leads to long-
term changes in the monoamine systems (norepinephrine, dopamine and serotonin), that 
are independent of cholinergic dysfunction . All of the above studies suggest that the 
interaction of CPF and other organophosphorus insecticides with the dopaminergic 
system could elicit motor effects which are independent of OP-induced cholinergic 
dysfunction. Subsequent changes in dopaminergic neurotransmission may form the basis 
of expression of increased motor activity at later time points noted in our studies.  
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Effects of Acute Chlorpryifos or Parathion Exposure on Functional Signs of 
Toxicity, Acetylcholinesterase, Butyrlcholinesterase, Carboxylesterase and 
Muscarinic Receptor Binding in Adult and Aged Rats 
In this study, equitoxic doses of CPF and PS were administered to adult and aged 
rats. Maximum tolerated doses or fractions thereof, of these two OPs were administered 
subcutaneously to adult and aged rats. Rats were sacrificed at 96 hours following CPF or 
PS exposure since previous studies had shown peak cholinesterase inhibition at this time 
point in adult rats (Pope et al, 1991; Karanth and Pope, 2003; Karanth et al, 2006). The 
effects of acute equitoxic doses of CPF and PS exposure on body weight and functional 
signs of toxicity [involuntary movements and SLUD (i.e., salivation, lacrimation, 
urination and defecation)] were evaluated in adult and aged rats. For CPF, adult and aged 
rats were treated with vehicle (peanut oil), 0.1 x MTD (low dose: 28 mg/kg), 0.5 x MTD 
(medium dose: 140 mg/kg) and 1 x MTD (high dose: 280 mg/kg), while for PS, rats of 
the two age-groups were treated with vehicle (peanut oil), 0.5 x MTD (low dose: adult = 
9 mg/kg; aged = 3 mg/kg), 0.75 x MTD (medium dose: adult = 13.5 mg/kg; aged = 4.5 
mg/kg) and 1 x MTD (high dose: adult = 18 mg/kg; aged = 6 mg/kg).  
CPF (Figure 62 and 63) and PS (Figure 64 and 65) elicited a dose-related decrease 
in body weight, which persisted until the end of the study in the medium and high dose 
groups of adult and aged rats. The reduction in body weight peaked earlier in adult rats 
(48 hours post-treatment) than in aged rats (72 hours post-treatment) with both CPF and 
PS. In terms of percent body weight lost, the body weight decrease appeared to be greater 
in adults than in aged rats. The implication for this relative “toxicity”, considering that 
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the aged rats were markedly higher in body weight to at the start of the study, is unclear.. 
Although CPF produced some evidence of toxicity (mainly IM) in the high dose group of 
adult and aged rats (Tables 6, 7, 8 and 9), these changes were not significantly different. 
Figures 66, 67, 68 and 69 show the functional signs of toxicity (IM and SLUD) in adult 
and aged rats after acute exposure to PS. In adult rats, the high dose of PS produced IM 
and SLUD signs 24 hours after treatment, which peaked by 72 hours, and these effects 
persisted until the end of the study. Involuntary movements had a slightly delayed onset 
(48 hours post-treatment) in the high dose group of aged rats, after which it peaked by 72 
hours. SLUD signs were observed in the high dose group of adult rats 24 hours after 
treatment, and these effects diminished by 72 hours post-treatment. Karanth et al (2006) 
using various doses of (84, 156 and 279 mg/kg) CPF in adult male Sprague-Dawley rats, 
observed a significant reduction in body weight gain in the high dose group (as compared 
to the control). Similar to results from the present study, very few functional signs of 
cholinergic toxicity were observed in any of the treatment groups. This phenomenon of 
minimal signs of cholinergic toxicity following doses of CPF that produce extensive 
AChE inhibition in the brain has been observed in the past (Won et al, 2001; Zhang et al, 
2002; Karanth and Pope, 2003a). In a subsequent study, Karanth and colleagues (2007) 
evaluated the effects of a range of doses of parathion in adult and aged rats. In both age-
groups, the highest dose of PS (adult: 27 mg/kg; aged: 9 mg/kg) led to a time-dependent 
decrease in body weight, and marked signs of cholinergic toxicity, manifested as 
involuntary movements and SLUD signs peaking 3-4 days following exposure, similar to 
results reported herein. 
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The effects of CPF and PS on AChE, BChE, CarbE, and muscarinic receptor 
agonist and antagonist binding were evaluated in adult and aged rats. CPF and PS 
inhibited AChE and BChE in all of the tissues examined in a dose-related manner, in both 
adult and aged rats. In general, the same dose of CPF inhibited BChE (Figures 112, 117, 
122, 127 and 130) to a greater extent (~2 to 2.5 fold) than AChE (Figures 111, 116, 121, 
126 and 129), while the same dose of PS inhibited AChE (Figures 131, 136, 141, 146 and 
149) to a greater extent (~1.5 fold) than BChE (Figures 132, 137, 142, 147 and 150). This 
was especially apparent in the low and medium dose groups. In vitro, there was greater 
selectivity of CPO for BChE, while PO was a more selective AChE inhibitor. In this 
respect, these in vivo results seem to agree with the in vitro studies. AChE and BChE in 
the ventricles were inhibited to a greater extent than in the atria, with all doses of CPF 
and PS. In the atria, the low dose of CPF and PS elicted a significantly greater inhibition 
of both AChE and BChE in aged than in adult rats. Similarly, AChE and BChE in the 
plasma and diaphragm of aged rats showed a trend towards greater inhibition in aged 
compared to adult rats. Although not significant, BChE in the plasma of aged rats 
appeared to be inhibited to a greater degree than in adult rats by the same dose of PS; 
however, no such age-related difference was observed for plasma AChE activity.  
In general, very few studies have assessed the effects of acute exposure to 
anticholinesterases including OPs on cholinesterase activity in aged rats (Overstreet, 
2000). Scali and coworkers (1997) evaluated the effects of the Alzheimer’s drug 
metrifonate (which is an organophosphate AChE inhibitor), in adult and aged rats. 
Although the same doses of metrifonate produced slightly greater levels of brain regional 
cholinesterase inhibition in aged rats compared to adults, these differences were not 
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statistically significant. Kosasa et al (1999) evaluated the effects of donepezil and tacrine 
on cholinesterase activity in the brain and peripheral tissues (brain, plasma, erythrocytes, 
heart, small intestine, liver and pectoral muscle) of adult and aged rats. Tacrine, which is 
a non-selective cholinesterase inhibitor, produced more extensive cholinesterase 
inhibition in all tissues examined in aged as compared to adult rats. On the other hand, 
donepezil, which displays more selectivity towards AChE, elicited greater cholinesterase 
inhibition in the brain, erythrocyte and pectoral muscle of aged rats, relative to adults. 
The brain and plasma concentrations of the parent compound were higher in aged than in 
adult rats, due to which, the authors concluded that toxicokinetic factors could be 
responsible for the greater cholinesterase inhibition observed in aged rats. Similarly, 
Karanth and Pope (2000) reported significantly lower levels of plasma carboxylesterase 
in aged compared to adult rats. Moreover, age-related reductions in the levels of certain 
isoforms of cytochrome P450 have been reported (Warringtom et al, 2004; Wauthier et 
al, 2006). In the Karanth et al (2006) study, cholinesterase activities in the diaphragm and 
striatum were extensively inhibited in a time-dependent, but not dose-dependent manner. 
Peak cholinesterase inhibition occurred by day 4 in both tissues, with apparent recovery 
occurring by day 7 only in the diaphragm. The cholinesterase inhibition obtained by the 
highest dose (280 mg/kg) at 4 days in the diaphragm and striatum agreed closely with the 
data we obtained in adult rats. In a subsequent study, Karanth and colleagues (2007) 
evaluated the effects of a range of doses of parathion in adult and aged rats. 
Cholinesterase activities in the diaphragm and striatum were inhibited in a dose and time-
dependent manner, with significantly greater inhibition in aged animals treated with the 
same dose of PS.  
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The atria of aged rats showed greater inhibition of both AChE and BChE by CPF 
and PS. In our in vitro studies, we BChE (but not AChE) in the heart from aged rats was 
significantly more sensitive to the effect of CPO than BChE from adult rat heart. In 
contrast, neither enzyme displayed an age-related difference in sensitivity to the effects of 
PO. We observed that both CPF and PS produced significantly greater inhibition of both 
cholinesterases in the atria from aged compared to adult rats. One reason for higher 
sensitivity in aged rats could be less detoxifying enzyme, carboxylesterase, in the plasma 
of this age-group. However, if this were the case, this age-related difference in enzyme 
inhibition should extend to other tissues as well. This was not the case, however, since 
similar levels of both enzymes were inhibited in all other tissues. Another reason for 
greater cholinesterase inhibition in the atria of aged rats compared to adults could be that 
lower levels of both enzymes exist in the atria of aged rats as compared to adults. In this 
case, the same dose of OP would lead to a more extensive inhibition in this age-group. 
We did not, however, observe any age-related decrease in atrial AChE or BChE. It is 
possible that the isoforms of the two enzymes might change during aging, such that the 
total cholinesterase activity remains the same. As noted previously, the molecular 
isoforms of AChE and BChE in the brain change as a function of age. Hence, it is 
possible that such changes might occur in the atria as well, which might account for the 
differential sensitivity.  
Carboxylesterase was also inhibited in a dose-related manner by CPF (Figures 
113, 118, 123 and 128) and PS (Figures 133, 138, 143 and 148) in adult and aged rats. 
Other than the ventricles (for CPF), there did not appear to be any age-related difference 
in the degree of CarbE inhibition by any dose of CPF or PS. The highest dose of CPF and 
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PS inhibited a maximum of ~80% and ~70%, respectively, of the total CarbE activity in a 
tissue, with the exception of the cortex, which had ~40-50% residual enzyme after 
treatment with the highest dose of CPF or PS.  
Age-related differences in sensitivity to OPs could arise from tissue differences in 
carboxylesterase and A-esterase enzymes in the different age-groups. As noted above, 
our laboratory evaluated carboxylesterase and A-esterase activities in the liver, lung and 
plasma of rats during maturation and aging, and compared it to the toxicity of CPF and 
PS in rats (Karanth and Pope, 2000). Plasma of aged rats had 50% less carboxylesterase 
compared to adult rats. In the present study, we did not find any difference in the levels 
of carboxylesterase in the cerebral cortex or heart of adult and aged rats.  
Muscarinic receptor binding was also evaluated using radioligand binding of a 
muscarinic agonist ([3H]OXO) and antagonist ([3H]QNB). In general, [3H]QNB binding 
was reduced by ~20-25% in adult and aged rats treated with medium and/or high dose 
groups of CPF (Figures 115, 120, 125 and 130) or PS (Figures 135, 140, 145 and 150), 
with the exception of aged rats treated with the high dose of PS, wherein there was ~30% 
increase in binding. Muscarinic agonist binding in cortex was reduced by ~25% in adult 
and aged rats treated with the high dose of CPF, and by ~45% in aged rats treated with 
the high dose of PS. Muscarinic agonist binding in the ventricles was unaffected by CPF, 
and was reduced by ~25% in the medium and high dose groups of adults. A more robust 
decrease in [3H]OXO binding was observed in the atria, where ~50% of the receptors 
were down-regulated in adult and aged rats treated with the high dose of CPF. Similarly, 
PS decreased [3H]OXO binding (20%) in the atria with the low dose in adult rats and 
high dose in aged rats, with a more substantial decrease being observed in the medium 
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and high dose groups of adult rats (~35-40%). In general, more extensive changes were 
noted in muscarinic agonist (OXO) binding than muscarinic antagonist (QNB) binding 
with both CPF and PS.  Karanth et al (2007) reported somewhat similar findings 
following PS exposure. Muscarinic antagonist (QNB) binding was significantly lower in 
the striatum of aged as compared to adult rats. QNB binding was significantly reduced 
(~46%) in the striatum of adult rats at the highest dose (27 mg/kg) up to 7 days after 
treatment, and in aged rats by ~33% in the two highest doses (6 and 9 mg/kg). PS 
produced an extensive (~78%) reduction in OXO binding in adult rat striatum and with 
somewhat lesser effect (54% reduction) in aged rats.  
Several studies demonstrated that prolonged and extensive AChE inhibition leads 
to an adaptive down-regulation of muscarinic receptors in rats of different ages (Costa et 
al, 1982; Russell and Overstreet, 1987; Pintor et al, 1988; Jett et al, 1993; Zhang et al, 
2002; Karanth et al, 2007). Both CPF and PS have been shown to affect different 
subtypes of muscarinic receptors in the brain (Chaudhuri et al, 1993; Chakraborti et al, 
1993; Zhang et al, 2002). Numerous studies have suggested that the ability of muscarinic 
receptors to adapt to prolonged AChE inhibition is less efficient in the senescent rather 
than adult nervous system. Pedigo and coworkers (1984) compared the effects of 
cholinergic drugs and muscarinic receptor binding in the brain of adult and aged rats. 
Although muscarinic receptor density decreased with age, no age-related changes in 
receptor affinity were observed. Aged rats were markedly more sensitive to the effects of 
the cholinergic agonist, oxotremorine, and were less sensitive to the cholinergic 
antagonist, scopolamine, than adult rats.  These researchers concluded that the observed 
age-related differences in sensitivity between adult and aged rats to the effects of 
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cholinergic drugs represented a decreased ability on the part of the aged rats to adapt to 
changes in its environment. Pintor and colleagues (1988) evaluated the plasticity of 
muscarinic receptors in the brain of adult and aged rats, by observing the response of 
these animals to repeated administration of the OP anticholinesterase, DFP. Aged rats 
were more sensitive than adults to the effects of the same dose of DFP. The authors 
concluded that increased sensitivity of aged rats resulted from a failure of adaptive 
mechanisms.  
In the present study, we did not observe significant differences between adult and 
aged rats in the apparent adaptive down-regulation of muscarinic receptors following 
exposure to either CPF or PS. We did note, however, a trend towards up-regulation 
(which was significant in some cases) in muscarinic antagonist binding in aged rats but 
not in adults following PS exposure. It is possible that age-related differences in the 
membrane composition or muscarinic receptor density could explain this differential 
response of aged rats to the effects of PS. There are several conflicting reports on aging-
related changes in the functionality and density of muscarinic receptors in rats (Dhein et 
al, 2001). Narayanan and Derby (1983) reported that while muscarinic receptor density 
was higher in the atria of aged rats compared to adults, ventricles from both age-groups 
had similar densities of muscarinic receptors. Baker et al (1985) reported that with 
increasing age, the ability of the cardiac muscarinic receptor to form a high affinity 
agonist binding state was reduced. Chevalier et al (1991) reported a reduction in cardiac 
muscarinic receptor density in aged rats.  Several investigators have reported a reduction 
in cardiac parasympathetic activity with increasing age in humans. This reduced activity 
has been ascribed to a decrease in the density (Brodde et al, 1998) as well as functionality 
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(Brodde et al, 1998; Oberhauser et al, 2001; Poller et al, 1997) of cardiac muscarinic 
receptors in the heart of older individuals. 
 A decrease in the densities of muscarinic receptors in the brain of aged as 
compared to adult animals has been reported by several investigators (Tayebati et al, 
2006; Yufu et al, 1994; Araujo et al, 1990; Kadar et al, 1990) using a variety of 
experimental approaches, including radioligand binding methods (Yufu et al, 1994; 
Araujo et al, 1990; Schwarz et al, 1990; Amenta et al, 2006; Amenta et al, 1995), in vitro 
quantitative receptor autoradiography (Tayebati et al, 2006; Kadar et al, 1990) and 
assessing subtype specific mRNA expression (Lee et al, 1994; Blake et al, 1991). Using 
the radial arm maze, Kadar et al (1990) correlated working memory deficits in 3, 12, 17 
and 24 month-old Wistar rats with an age-related decrease in muscarinic receptor density 
in various brain regions.  
The results obtained from the current study suggest that selective cardiac BChE 
inhibition by iso-OMPA (in the absence of AChE inhibition) leads to altered heart rate. 
BChE is more sensitive to inhibition by CPF than AChE, both in vitro and in vivo. The 
reverse was true for PS, wherein this compound showed greater selectivity for AChE than 
BChE in vitro and in vivo. In general, age-related differences were only noted for both 
compounds in the atria, wherein both AChE and BChE were inhibited to a greater extent 
in aged than in adult animals. However, the higher sensitivity of atrial cholinesterases to 
CPF and PS in aged rats did not appear correlated with more extensive dysregulation of 
heart rate in this age-group. Equitoxic doses of CPF and PS produced disparate functional 
signs of toxicity, with PS demonstrating greater toxicity than CPF in both adult and aged 
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rats. Yet, relatively similar changes in cardiac function and other physiological 
parameters were observed with both CPF and PS.  
According to the World Health Organization, around 3 million people worldwide 
suffer from acute pesticide poisoning each year. Organophosphates are the most 
commonly used class of insecticides. While their use is somewhat lower in the US now 
than in the recent past, they will continue to be used in substantial quantities, and their 
use worldwide is expected to increase in the future due to a variety of reasons (Walker 
and Nidiry, 2002). Recent studies reported that exposure to OP insecticides, especially 
CPF, has occurred, or is occurring in essentially everyone in the US, either in minute 
amounts through the diet, or in the home or work place (Barr et al, 2004; 2005). 
Approximately 2.5 million people, primarily agricultural workers and pesticide 
applicators, are directly exposed to pesticides, and hence, are the most predisposed to the 
ill-effects of pesticide exposure (Walker and Nidiry, 2002). Although organophosphates 
are one of the most extensively studied classes of insecticides, the main focus of research 
has been on neurotoxicity produced by AChE inhibition, and effects on cardiac function 
have received considerably less attention. This study evaluated the role of BChE in 
cardiac function, and the cardiotoxic consequences of parathion and chlorpyrifos in adult 
and aged rats.  
In elderly people suffering from Alzheimer’s disease, cholinesterase inhibitors 
with selective affinities for either AChE alone, BChE alone, or both AChE and BChE, 
are being currently used or evaluated for therapy (Giacobini, 2003b; Masuda, 2004). 
Although ChE inhibitors have been demonstrated to improve cognitive function, possibly 
by increasing ACh levels in the brain, concomitant inhibition of ChE in the heart may 
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produce selective effects in this organ, especially in compromised patients (Masuda, 
2004). Hence, a thorough understanding of the effects of ChE inhibitors on cardiac 
function is critical. Moreover, due to the continuing wide-spread use of OPs, knowledge 
of the cardiotoxic consequences of these toxicants, in particular during aging, is essential. 
In the current study we evaluated the cardiotoxic potential of the OP insecticides, CPF 
and PS during aging, which could have implications in formulating regulatory policies 
governing the usage of these pesticides, especially for the protection of the elderly 
subpopulation. 
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CHAPTER 5 
SUMMARY 
 
Acetylcholinesterase (AChE) makes up most of the cholinesterase activity in the 
cortex, diaphragm and plasma, while butyrylcholinesterase (BChE) predominates in the 
atria and ventricles. The ratio of AChE to BChE in the cortex, atria, ventricles and plasma 
of adult and aged rats is approximately 9:1, 1:9, 2:8 and 7:3, respectively. In both adult 
and aged rats, the relative amounts of both enzymes remained roughly the same for each 
tissue. In general, the atria contained ~2.5-fold more cholinesterase activity, and 1.5-fold 
more carboxylesterase activity than the ventricles (specific activity relative to protein 
content). While the levels of these enzymes decreased slightly in aged (compared to 
adult) ventricles and cortex, this difference was not statistically significant. However, in 
the plasma, AChE and BChE levels were significantly higher, while CarbE activity was 
significantly lower in aged than adult rats.  
BChE in the cortex and heart was significantly more sensitive (4- to 11-fold) than 
AChE in vitro to inhibition by chlorpyrifos oxon (CPO) in both adult and aged rats. 
Furthermore, cardiac BChE from aged rats was significantly more sensitive to CPO than 
cardiac BChE in adult rats (~ 2.5 fold). Relatively similar differences in sensitivity were 
noted in the cortex BChE. Age-related differences in potency did not appear to be due to 
differences in endogenous detoxification via CarbE or A-esterase. AChE was more 
sensitive than BChE to paraoxon (PO) in both heart and cortex. No age-related 
 288 
differences were noted for either enzyme, however. CPO and PO displaced muscarinic 
agonist ([3H]oxotremorine-M) binding in a concentration-dependent manner in the heart 
and cortex of adult and aged rats. Of the two oxons, CPO was the more potent displacer 
of [3H]oxotremorine-M binding in the heart and cortex of both age-groups. However, no 
age-related difference was observed in displacement of [3H]oxotremorine-M binding in 
either tissue with either oxon. 
The low (1.25 mg/kg) and high (5 mg/kg) doses of iso-OMPA decreased heart 
rate at 24 hours post-treatment, with recovery occuring thereafter. The magnitude of heart 
rate reduction was greater in the low-dose than in the high-dose group. Additional non-
cholinesterase actions of iso-OMPA may be important in this dose-related difference in 
response. Neither dose of iso-OMPA produced any effect on body temperature or motor 
activity at any of the time points examined. Selective reduction of heart rate by iso-
OMPA in the absence of other physiological effects appeared due to specific inhibition of 
cardiac BChE, in the absence of AChE inhibition. BChE and CarbE were inhibited by 
iso-OMPA at 24 hours, with enzyme recovery generally occuring by 96 hours. Recovery 
of cardiac BChE activity after 24 hours could be responsible for return of heart rate to 
baseline conditions at later time points. In some tissues, increased levels of AChE were 
noted at later time points following iso-OMPA exposure. Muscarinic receptors were 
significantly down-regulated in the atria and ventricles by both doses of iso-OMPA used 
in the study. 
Chlorpyrifos (CPF) and parathion (PS) generally elicited a brief period of 
tachycardia during the initial diurnal phase, which was followed by prolonged dose-
related bradycardia in both adult and aged rats. Heart rate remained depressed until the 
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end of the observation period. Heart rate responded somewhat differently in aged rats 
compared to adults following PS exposure. A brief period of tachycardia in the medium 
dose group was followed by a decrease in rate and a subsequent trend towards recovery 
by the end of the study. In the high dose group, an initial decrease in heart rate was 
followed by a brief period of increase, after which the heart rate continued to decrease 
significantly until the end of the study. The reason for this time-dependent difference in 
response to PS in aged rats is unclear. The medium and high doses of CPF and PS elicited 
a dose-related decrease in body temperature, which either recovered to pre-treatment 
levels or remained suppressed until the end of the observation period in adult and aged 
rats. Motor activity was initially reduced by both CPF and PS in adult and aged rats. 
However, towards the end of the observation period, there was an increase in activity 
during the diurnal phase, most prominently in aged rats.  
 CPF and PS decreased body weight in a dose-related manner, persisting until the 
end of the study in the medium and high dose groups of adult and aged rats. In terms of 
percent body weight lost, the body weight reduction appeared greater in adults than in 
aged rats. The relative impact of such body weight reductions needs to be considered 
based on pre-treatment body weights, however. In spite of extensive cholinesterase 
inhibition, CPF did not produce any significant signs of cholinergic toxicity in either 
adult or aged rats. PS produced signs of cholinergic toxicity (involuntary movements and 
SLUD), in both adult and aged rats, peaking at around 72 hours after exposure. Both CPF 
and PS inhibited AChE, BChE and CarbE activity in a dose-related manner in all of the 
tissues examined in adult and aged rats. In general, BChE was inhibited to a greater 
extent than AChE by CPF, while the reverse was true for PS. The only evidence of an 
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age-related biochemical difference was in the atria, wherein the low doses of CPF and PS 
elicted a significantly greater inhibition of both AChE and BChE in aged than in adult 
rats. However, the higher sensitivity of atrial cholinesterases to CPF and PS in aged rats 
did not appear to be correlated with more extensive dysregulation of heart rate in this 
age-group. In vivo, CPF and PS reduced muscarinic receptor binding (QNB and OXO 
binding) in both adult and aged rats. In general, more extensive changes were noted in 
muscarinic agonist (OXO) binding than with muscarinic antagonist (QNB) binding with 
both CPF and PS.   
These studies suggest that butyrylcholinesterase plays a role in the normal 
functioning of the heart. Thus, OP toxicants that selectively target this enzyme may have 
cardiotoxic potential. Moreover, some OP insecticides bind directly to  muscarinic 
receptors at low concentrations, indicating that direct interaction with muscarinic 
receptors in these tissues could occur at toxicologically relevant exposure levels. Both 
adult and aged rats are susceptible to the effects of CPF and PS, as evidenced by changes 
in heart rate, body temperature and motor activity.  
Equitoxic doses of CPF and PS have been found to produce very different degrees 
of functional toxicity, with PS eliciting more extensive cholinergic signs than CPF in 
both adult and aged rats. We observed similar differences in the expression of functional 
signs of toxicity between these two insecticides. Interestingly, in our studies we found 
that while PS elicited more extensive cholinergic signs, relatively similar degrees of 
cardiac dysfunction and disruption of other physiological parameters were noted 
following exposure to either CPF or PS.  
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CHAPTER 6 
CONCLUSIONS 
 
Previous studies have suggested that butyrylcholinesterase plays a role in the 
modulation of cholinergic neurotransmission. Since the heart of several species has been 
found to contain disproportionately more butyrylcholinesterase than acetylcholinesterase, 
in this study we evaluated the role of BChE in the regulation of cardiac function. The 
effects of tetraisopropylpyrophosphoramide (iso-OMPA), an OP with high selectivity 
towards BChE, on cardiac function were evaluated using radiotelemetry. We also 
compared cardiac function in adult and aged rats following exposure to the common OPs 
chlorpyrifos (CPF) and parathion (PS). Our studies also evaluated in vitro tissue- and 
age-related differences in sensitivity of cholinesterases and muscarinic receptors to 
chlorpyrifos oxon (CPO) and paraoxon (PO) in heart and brain of adult and aged rats.  
 BChE was significantly more sensitive than AChE to inhibition by CPF both in 
vitro and in vivo, in adult and aged rats. Furthermore, BChE in the heart from aged rats 
was significantly more sensitive to CPO than BChE in heart of adult rats in vitro. In 
contrast, PS preferentially targeted AChE as compared to BChE. However, no age-related 
difference in sensitivity was observed with this OP for either enzyme. Both CPO and PO 
were found to bind directly to muscarinic receptors at low concentrations, indicating that 
direct interaction with muscarinic receptors in these tissues could occur at toxicologically 
relevant exposure levels.
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Selective BChE inhibition in the heart by iso-OMPA, in the absence of AChE 
inhibition, significantly reduced heart rate, suggesting BChE does play a role in the 
regulation of cholinergic neurotransmission in the heart. Thus, OP toxicants that 
selectively target this enzyme may have cardiotoxic potential. Since CPF was observed to 
preferentially target BChE as compared to PS, the former OP was expected to have a 
differential expression of cardiotoxicity as compared to PS.  
Effective dosages of CPF and PS initially decreased heart rate, temperature and 
motor activity in both adult and aged rats. Heart rate remained depressed for four days in 
both age-groups, while temperature either recovered to pre-treatment levels or remained 
suppressed until the end of the observation period in adult and aged rats. Towards the end 
of the observation period, there was an increase in motor activity during the diurnal 
phase, most prominently in aged rats. This delayed increase in motor activity 
predominantly in aged rats, could be due to a differential effect of OPs on the 
dopaminergic system in this age-group, or an age-related difference in the interaction 
between the cholinergic and dopaminergic systems.  
Both CPF and PS elicited dose-dependent AChE and BChE inhibition in atria, 
ventricles, cortex, plasma and diaphragm in adult and aged rats. In spite of extensive 
cholinesterase inhibition, CPF did not produce any significant signs of cholinergic 
toxicity in either adult or aged rats. On the other hand, PS produced signs of cholinergic 
toxicity in both adult and aged rats. Atrial cholinesterases in aged rats appeared more 
sensitive to the low doses of both, CPF and PS as compared to adults. Toxicokinetic 
differences might be responsible for the age-related difference in sensitivity of aged 
AChE and BChE to CPF and PS in vivo, since no such difference was observed in vitro. 
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However, the higher sensitivity of atrial cholinesterases to CPF and PS in aged rats did 
not appear to be correlated with more extensive dysregulation of heart rate in this age-
group.  
It has been a common finding that equitoxic doses (operationally defined as doses 
that produce similar levels of AChE inhibition) of chlorpyrifos and parathion elicit very 
different degrees of toxicity (IM and SLUD), with PS being more toxic. We observed 
similar differences in the expression of functional signs of toxicity between these two 
insecticides. Interestingly, in our studies we found that while PS elicited more extensive 
cholinergic signs, relatively similar degrees of cardiac dysfunction and disruption of other 
physiological parameters were noted following exposure to either CPF or PS. 
 In summary, radiotelemetry was successfully optimized for obtaining 
physiological data including heart rate, electrocardiogram, body temperature and motor 
activity in both adult and aged rats. These studies suggest that BChE plays a role in the 
normal functioning of the heart. Thus, OP toxicants that selectively target this enzyme 
may have cardiotoxic potential. Moreover, some OP insecticides bind directly to 
muscarinic receptors at low concentrations, suggesting that direct interaction with 
muscarinic receptors could occur at toxicologically relevant exposure levels. Equitoxic 
doses of CPF and PS produce very different degrees of functional toxicity, with PS 
eliciting more extensive cholinergic signs than CPF in both adult and aged rats. In 
contrast, relatively similar changes in heart rate, body temperature, and motor activity 
were observed following exposure to CPF or PS.  
 Future studies should further investigate the role of CPF and PS on cardiac 
function, via assessment of the Q-T cycle length in electrocardiograms. Moreover, the 
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use of cardiac biomarkers (such as cardiac Troponin I and T) would also aid in 
assessment of the time course of possible cardiac damage. Histopathological analysis of 
the hearts of adult and aged rats could reveal possible differential effects of these OP 
insecticides on the myocardium. 
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Scope and Method of Study: Organophosphorus insecticides (OPs) elicit toxicity by 
inhibiting acetylcholinesterase (AChE). Most OPs also inhibit a related enzyme, 
butyrylcholinesterase (BChE), which is highly expressed in cardiac tissues. However, 
little is known regarding the function of BChE or its possible role in OP toxicity. While 
aging is associated with higher sensitivity to neurotoxicity of some OPs, little is known 
about age-related sensitivity of the cardiac system. The present study was undertaken to 
evaluate the in vitro and in vivo sensitivity of AChE and BChE in the heart and cortex of 
adult (3 months) and aged (18 months) rats to the common OPs, chlorpyrifos (CPF) and 
parathion (PS). Tetraisopropylpyrophosphoramide (iso-OMPA), a BChE-selective OP 
inhibitor, was used to probe the possible role of BChE in the regulation of heart rate in 
adult rats. We also compared the in vivo effects of CPF and PS on AChE and BChE 
inhibition and heart rate, temperature and physical activity in adult and aged rats. In all 
cases, we evaluated the effects of OP-induced BChE and/or AChE inhibition on heart 
rate, body temperature and physical activity using radiotelemetry. 
 
Findings and Conclusions:  BChE was significantly more sensitive than AChE to 
inhibition by CPF both in vitro and in vivo, while the reverse was true for PS. 
Furthermore, BChE in the heart from aged rats was significantly more sensitive to CPO 
than BChE in heart of adult rats in vitro. Selective BChE inhibition in the heart by iso-
OMPA, in the absence of AChE inhibition, significantly reduced heart rate, suggesting 
BChE does play a role in the regulation of cholinergic neurotransmission in the heart. 
Both CPF and PS elicited dose-dependent AChE and BChE inhibition in atria, ventricles 
and other tissues in both age-groups. Effective dosages initially decreased heart rate, 
temperature and motor activity in both adult and aged rats. Heart rate remained depressed 
for four days, while temperature recovered to baseline and activity increased above 
baseline in both age groups, with both OPs. Atrial cholinesterases in aged rats appeared 
more sensitive to both CPF and PS, but this difference was not correlated with higher 
sensitivity to cardiac dysregulation. Equitoxic doses of CPF and PS produce very 
different degrees of functional toxicity, with PS eliciting more extensive cholinergic signs 
than CPF in both adult and aged rats. In contrast, relatively similar changes in heart rate, 
body temperature, and motor activity were observed following exposure to CPF or PS.  
